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Deterministic and Stochastic Modeling of Human
Papillomavirus Gene Regulatory Network
ABSTRACT
In this thesis a novel stochastic and deterministic mathematical model
of Human papillomavirus (HPV) gene regulatory network was devel-
oped. The novelty of this project is both on methodological and biolog-
ical /clinical site. The former is in line with the current challenge in re-
cent years to have a holistic view of the basics regulatory mechanisms in-
terconnected to form a complex machinery, where complex patterns can
arise, only form the interconnection of basics modules. In fact, HPV offers
a case of study of great interest in molecular systems biology. It involves
a number of relevant regulatory mechanisms (e.g. transcription, trans-
lation, promoter modulation, polyadenylation regulation, splicing,) con-
nected together to form a complex network, albeit its genome is relatively
simple, thus suitable for an accurate deterministic and even stochastic
modeling.
HPVs cause a series of diseases of the cutaneous and mucosal epithe-
lium, ranging from minor lesions to precancerous cervical lesions and
cervical cancer, which is considered one of the most common cancer in
the women worldwide. Therefore, on the biological/clinical aspect the
development of a mathematical model of HPV gene expression, is of
great interest in order to dispose of an in silico simulator useful to achieve
a better comprehension of the complex gene regulatory network, and ca-
pable to predict different scenarios from the first stages of viral infection
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up to a cervical cancer condition. As far as we know, there is no model of
HPV gene regulation available in literature.
A new synthesis of the HPV molecular biology with especial regard
to gather/infer from literature the parameters useful for designing a dy-
namical model, and to shed light in what is still lacking in the biologi-
cal literature, was preformed. The biological knowledge was translated
into a stochastic model in terms of biochemical reactions. In particular,
we modeled the HPV early and late promoters that account for the tran-
scripts and proteins evolution during the entire viral life cycle. Even the
post-transcriptional and post-translational modifications were modeled
in order to properly capture the complex viral regulation known from lit-
erature. As far as we know, it is the first time a stochastic model accounts
for the complex post-transcriptional control, modeling the splicing and
polyadenylation sites regulation, and connect this latter to the transcrip-
tional control layer, mediated by the promoters activities, in order to ex-
plore complex patterns that can arise only from the interconnection of
different control layers.
The Master Equation (ME) of the system was considered in order to
predict and investigate its stochastic behavior. Because of the complex
system structure it wasn’t possible to solve the whole ME analytically,
hence numerical exact simulations were performed by means of the Gille-
spie’s algorithm. A quasi-equilibrium approximation of the ME was de-
veloped in order to get a deterministic approximation of the model.
The model structure together with the fixed parameters we have gath-
ered/inferred from literature was able to fit a dataset consistent of the
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early promoter activity and to qualitatively reproduce the main dynam-
ical behavior of two of the most important regulatory transcripts during
viral late phase.
Different in silico experiments were designed to opportunely explore
both the capability of the stochastic model to follows the deterministic
predictions, when in fast fluctuations regimen, and to discover complex
stochastic patterns, that can arise through the interconnection of the tran-
scriptional and post-transcriptional control layers.
In general, both the stochastic and deterministic formulation of the
model showed the capability to reproduce the HPV gene expression dy-
namics, during the entire viral life cycle, in good agreement with the cur-
rent biological knowledge.
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Modellizzazione Deterministica e Stocastica della rete
di regolazione genica dello Human papillomavirus
SOMMARIO
In questa tesi e´ stato sviluppato un nuovo modello deterministico e
stocastico della rete di regolazione genica dello Human papillomavirus
(HPV).
Gli aspetti di novita´ del modello ricadono sia sull’aspetto metodologico
che clinico /biologico. Per quanto riguarda il primo aspetto il progetto
e´ in linea con l’attuale sfida, presente in questi ultimi anni, di ottenere
una visione olistica dei meccanismi regolatori di base interconnessi a for-
mare un sistema complesso, all’interno del quale dinamiche complesse
possono scaturire solo tramite un’interconnessione di moduli base. In
linea con questo, l’HPV si pone come un caso di studio di grande in-
teresse nella systems biology molecolare. Esso comprende una serie di
importanti meccanismi regolatori (ad esempio trascrizione, traduzione,
modulazione dei promotori, regolazione della poliadenilazione, splic-
ing,...) connessi tra di loro al fine di formare una complessa rete, sebbene
il genoma virale sia relativamete semplice e quindi adatto per sviluppare
accuratamente una modellistica deterministica e persino stocastica.
L’HPV puo´ causare una serie di malattie della cute e della mucosa
epiteliale, che spaziano da lesioni minori fino a lesioni pre-cancerogene
e cancro al collo dell’utero, considerato uno dei principali tipi di can-
cro che affligge la popolazione femminile. Conseguentemente, da un
punto di vista clinico/biologico lo sviluppo di un modello matematico
v
dell’espressione genica dell’HPV, e´ di grande interesse al fine di disporre
di un simulatore in silico utile per raggiungere una migliore compren-
sione della complessa rete di regolazione genica e capace di predire sce-
nari differenti a partire dalle prime fasi dell’infezione virale fino all’evoluzione
del cancro. Da quello che sappiamo finora, non esiste alcun modello
reperibile in letterature della regolazione genica dell’HPV.
E’ stata effettuata una nuova sintesi della biologia molecolare dell’HPV
con particolare riguardo al raccogliere/inferire da letteratura i parametri
utili al fine di progettare un modello dinamico, e al fine di evidenziare le
conoscenze biologiche mancanti in letteratura. La conoscenza biologica e´
stata tradotta in un modello stocastico in termini di un sistema di reazioni
biochimiche. In particolare, sono stati modellati il primo ed il secondo
promotore per tener conto della evoluzione dei trascritti e delle proteine
durante l’intero ciclo virale. Sono state modellate anche le regolazioni
post-trascrizionali e post-traduzionali al fine di catturare appropriata-
mente la complessa regolazione virale, nota in letteratura. Da quello
che sappiamo finora, e´ la prima volta che un modello stocastico tiene
conto del complesso controllo post-trascrizionale, modellando i siti di re-
golazione dello splicing e della poliadenilazione, e connettendo questi
ultimi al modulo di controllo trascrizionale mediato dall’attivita´ dei pro-
motori, al fine di esplorare dinamiche complesse che possono scaturire
solo dal modellare l’interconnessione dei singoli stadi di controllo.
E’ stata considerata la Master Equation (ME) del sistema al fine di
predire a investigare il suo comportamento stocastico. A causa della com-
plessa struttura del sistema non e´ stato possibile risolvere analiticamente
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la ME, percio´ sono state effettuate simulazioni numeriche esatte facendo
uso dell’algoritmo di Gillespie. Un’approssimazione al quasi-equilibrio
della ME e´ stata sviluppata al fine di ottenere un modello deterministico.
Il modello sviluppato, fissando i parametri trovati/inferiti da letter-
atura, e´ stato in grado di fittare un dataset inerente l’attivita´ dell’early
promoter e riprodurre qualitativamente il principale comportamento di-
namico di due dei piu’ importanti trascritti sviluppati durante la fase ter-
minale del ciclo virale.
Differenti esperimenti in silico sono stati progettati per esplorare op-
portunamente sia la capacita´ del modello stocastico di inseguire le predi-
zioni del modello deterministico, in regime di fluttuazioni veloci, che per
scoprire dinamiche complesse che possono originarsi dall’interconnessione
dei moduli di regolazione trascrizionale e post-trascrizionale.
In generale, sia la formulazione deterministica che stocastica del mod-
ello hanno mostrato la capacita´ di riprodurre, in buon accordo con l’attuale
conoscenza biologica, la dinamica dell’espressione genical durante l’intero
ciclo virale.
vii
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Introduction
1.1 COMPLEXITY IN CELL BIOLOGY
Cellular systems can be amazingly complex and composed by a huge
variety of molecular actors, that interact each other in order to accomplish
different and articulated tasks, orchestrated in multiple layers of control.
There is increasingly interest in a deep understanding of gene expres-
sion, representing that process by which the DNA information sequence
is decoded into structure and function. As stated by the central dogma
of molecular genetics, each gene, representing the minimal information
element of DNA, is transcribed into complementary sequences, called
mRNAs, that are usually translated into proteins, representing the main
functional components of the cell as they preform work, they control
metabolism and they are responsible for the regulation of DNA transcrip-
tion. For non-protein coding genes the product is a functional RNA hav-
ing regulatory tasks inside the cell, from transcriptional to translational
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control.
Gene expression is modulated among different processes consisting of
transcriptional, translational, post-transcriptional and post-translational
regulation. Transcriptional regulation accounts for the conversion of the
genes information into mRNAs. This process is initiated by a particu-
lar DNA sequence called promoter which activity, controlling the mRNA
production, can be modulated by transcription factors (usually proteins)
that, in turn, can bind DNA upstream the promoter. In some cases, a pro-
moter accounts for the regulation of more genes simultaneously, produc-
ing a pre-mRNA codifying the complementary information of the entire
cluster of genes. This is actually very frequent in prokaryotes and viruses,
but also in eukaryotes. The pre-mRNA undergoes post-transcriptional
regulation, such as splicing and polyadenylation, in order to generate
mature mRNAs for every single gene. To complete the picture, pro-
teins can undergo to post-translational modification, during or after their
biosynthesis, in order to adapt the response of the cell to external stimuli.
It is true goal of systems biology to investigate the functional prop-
erties of a molecular system state which is defined and regulated by its
components as well as by the network of their associations. Within this
context, understanding of the system structure, such as gene regulatory
networks or signaling pathways, and of its dynamics, both in quanti-
tative and qualitative terms, are key milestones to understand the sys-
tem in its entireness. Each individual process (e.g. transcription, mRNA
degradation, translation, protein degradation, modulation of simple pro-
moter activity, post-transcriptional and post-translational modifications,
cell membrane ions channels,...) of a complex molecular system has been
extensively studied at individual level and mathematical models of dif-
ferent complexity were developed to reproduce their dynamic behavior.
The current challenging in these last years is to understand the combined
effects of individual regulatory processes on the functioning of complex
molecular system. In fact, to quote from T. Szkely Jr.
”The recent paradigm of systems biology sets out to examine biological phe-
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nomena at the systems level. This is in contrast to the widespread approach
of reductionism, whereby researchers attempt to understand entire systems by
studing them one small component at a time. The reductionist approach has
given us valuable insights and a detailed understanding of the molecular com-
ponents of biological processes. However, it is becoming clear that we need a
complementary approach that takes a holistic view of these processes by looking
at their systems-level dynamics: this is systems biology. Reductionism implicitly
assumes that the entire system is just the sum of its parts, which is not necessar-
ily true: complex patterns can arise from collections of simple components. The
challenge of systems biology is to understand extremely complex systems with-
out breaking them into easy-to-digest parts.” (Szekely Jr. and Burrage (2014))
Even if on the one hand the goal of systems biology is to develop for-
mal abstractions capable to capture the biological reality, on the other
hand the main aims are to truly understand the mechanisms that stay
beneath specific diseases and eventually the identification and/or de-
sign of an appropriate approach appropriately antagonize or even defeat
the disease. This can be accomplished by the identification of drugs that
can counterbalance the effects of the disease, or to appropriately design
a gene therapy in order to defeat the principal sources of the disease (e.g.
pathogens like viruses and bacteria or a DNA alteration), namely at DNA
level. In particular gene therapies are very promising and usually can be
implemented through the usage of reprogrammed viruses. In all this, the
proper methodologies of systems biology can be of great help.
1.1.1 HETEROGENEITY IN BIOLOGICAL SYSTEMS
Heterogeneity is a key property of biological systems at all scales: from
molecular up to the population level. During the past century and half
the contributions of ”nature vs nurture” to heterogeneity evoked endless
debate. Nowadays, thanks to new developmental technologies and ex-
perimental procedure that allow to investigate biological systems at all
the scales up to the capability to observe microscopic regulatory mecha-
3
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nisms following the single cell dynamics, a clearer idea behind the het-
erogeneity sources came out. We can classify the heterogeneity as aris-
ing from three sources: genetic (nature), environmental (nurture) and
stochastic (chance) (Szekely Jr. and Burrage (2014)).
The genetic heterogeneity has its roots in the Darwinism and actually
consists in the well accepted idea that cells and animals with different
genes should clearly be different.
However, even isogenic organisms or populations of cells can be very
different and the causes have to be sought in the other two heterogeneity
sources.
The environmental heterogeneity (usually referred as extrinsic espe-
cially in gene expression context as we’ll see better in the next section) is
defined, by exclusion, as the heterogeneity from neither genetic nor in-
trinsic sources. Actually this kind of heterogeneity depends on the con-
text and it can be: the external environment of a cell population, account-
ing for the pH or nutrient level in which a cell population is propagated;
the internal environment of the cells themselves accounting the numbers
and positions within each cell of shared gene expression machinery such
as ribosomes; cell states accounting the cellular cycle progression and the
cellular aging (Szekely Jr. and Burrage (2014)). Hence, we could say that
extrinsic noise usually account for the additional variability we see when
following multiple cells (i.e., cell to cell variability).
The stochastic heterogeneity, also referred as intrinsic heterogeneity,
arises from thermal fluctuations at the level of individual molecules. It
affects in general the whole gene expression machinery, from the tran-
scriptional and translational regulations to post-transcriptional and post-
translational regulations (Szekely Jr. and Burrage (2014), Elowitz et al.
(2002)). It ensures that the biochemical reactions occur randomly in time
in the intra and extra cellular environment. Therefore, at a single gene
level the intrinsic noise can be defined as the extent to which the activi-
ties of two identical copies of that gene, in the same intracellular environ-
ment, fail to correlate (Elowitz et al. (2002)). Hence they exhibit different
behaviors even in the absence of the other heterogeneity sources.
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1.1.2 STOCHASTICITY IN GENE REGULATORY NETWORKS
Of great interest in unveiling the control logic among the numerous cel-
lular mechanisms is the achieving of a profound comprehension of its
gene regulatory networks, as it represents the core of cellular regulation
machinery from which all the other control layers are orchestrated.
Both the topolgy and the dynamical structure of a complex gene reg-
ulatory network can be well described by a deterministic modeling ap-
proach able to predict its behavior in the context of a large system size
(high copy numbers of expressed mRNAs and proteins, and either the
case of large cell volumes or a large cell population size) and fast pro-
moter and splicing kinetics. However, especially in the past fifteen years
it has been extensively and deeply demonstrated the importance of the
inherent stochastic nature of the gene expression in its basic mechanisms,
as mentioned in the previous section, and by extension of a complex
system as a gene regulatory network can be. Stochasticity in gene ex-
pression (also known as stochastic noise) arises from fluctuations in tran-
scriptional, post-transcriptional, translational and post-translational pro-
cesses. These phenomena can lead identical cells exposed to the same
environmental conditions to show significant variation in molecular con-
tent. The comprehension of this varibility is of great interest since, on the
one hand, can lead to detrimental effects on cellular function with po-
tential implications for disease. On the other hand the stochasticity can
be advantageous and provides the flexibility needed by cells to adapt to
fluctuating environments or respond to sudden stresses, and a mecha-
nism by which population heterogeneity can be established during cel-
lular differentiation and development (Kaern et al. (2005)). As a result, a
deterministic approach in modeling a molecular system cannot capture
the potentially significant effects that cause stochasticity in gene expres-
sion, hence stochastic modeling and simulation methods are necessary in
order to appropriately describe the true dimension of the molecular in-
teractions. It is also of remarkable interest to develop experimental and
data-analysis techniques to allow the study of stochasticity in complex
5
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regulatory systems and to deeply understand the augmented dynamical
behavior driven by the stochastic noise.
In literature the stochasticity related to gene expression are usually
thought in terms of finite-number effects. This accounts for a fundamen-
tal relationship between system size and noise: namely that noise tends
to increase when the size of the system is decreased. This can happen
when the cell volume changes but more interestingly and usual it can
be interpreted as that, in general, when N denotes the chemical species
molecular abundance, a decrease in abundance results in a characteris-
tic 1/
√
N scaling of the noise (Kaern et al. (2005), Scott (2013)). Hence,
lower the chemical species copy number, higher the stochastic noise. This
is surely an important feature to have in mind about the noise contri-
bution with respect the system size. However, not less important, in
addition to a large system size, a second requirement for a strong ef-
fect of a molecular-level noise on gene expression is to have slow tran-
sitions between promoter states (e.g. in eukaryotic gene expression, for
which the presence of nucleosomes and the packing of DNA-nucleosome
complexes into chromatin makes promoter often inaccessible to the tran-
scriptional machinery and the corresponding flctuations of the promoter
states can be quite slow) (Kaern et al. (2005)).
1.1.3 MODELING OF GENE REGULATORY NETWORKS
The usual ”protocol” to follow in modeling a cellular system, in particu-
lar a gene regulatory network, is the following
• Develop a synthesis of the molecular biology with all the informa-
tion about the network topology and possibly all the other crucial
elements to develop a dynamical model (transcripts and proteins
half lives, reactions rate constants, promoters activity,...)
• The first modeling step is to translate the biological knowledge into
a set of biochemical equations about the promoter activities, splic-
ing sites, transcription synthesis and degradations,... and so on.
6
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Formally this is already a stochastic model since the chemical reac-
tions are acutally markov chains.
• Translate the biochemical set of equations in terms of Chemical Mas-
ter Equation
• Eventually approximate the system as a master equation (ME) dif-
fusion limit, in terms of Fokker-Planck Equations (FPE) or stochas-
tic differential equations (SDE). This is usually performed in that
cases the exact numerical simulation of the master equation (per-
formed by using the Gillespie’s exact stochastic algorithm (Gille-
sple (1977), Gillespie (2002), Gillespie (2007), Gillespie (2013)) are
particularly intensive, because the time scales of the various reac-
tions involved can be very different (Gillespie (2013), Kepler and
Elston (2001)).
• Develop a deterministic model by directly translating the biochemi-
cal equations by using the mass kinetics law or by a quasi-equilibrium
approximation of the model master equation (Kepler and Elston
(2001)).
1.1.4 CHEMICAL MASTER EQUATION
Given its importance, in this thesis, we dedicate this little subsection to
the Chemical Master Equation (CME).
Chemical Master Equation (CME) is currently the golden standard for
modeling the stochastic behavior or chemical and biochemical systems.
When molecules of a well-stirred mixture ofN molecular species {S1, . . . , SN}
interact through M chemical reactions {R1, . . . , Rn}, the state vector of
the system, X(t) ∈ RN , accounting for the copy number of each molec-
ular species Si at time t, changes stochastically because of the inherent
randomness of molecular collisions.
For each chemical species and reactions it is possible to define a state-
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change vector νj ∈ RNdefined as follows
νij , the change in the number ofSi molecules produced by oneRj reaction,
j = 1, . . . ,M ; i = 1, . . . , N
(1.1)
If the molecules are confined to a fixed volume and kept at constant
temperature it is possible to prove there exists a function, hj(x), called
propensity function, such that
hj(x) dt ,Pr[Rj reaction will occur in the system in the next
infinitesimal time interval [t, t+ dt)], j = 1, . . . ,M
(1.2)
The propensity function hj , together with the state-change vector, νj ,
completely characterizes reactions Rj , j = 1, . . . ,M .
Using only eq. 1.1 and 1.2 and the laws of probability theory, it is pos-
sible to prove that the probability P (x, t|x0, t0), that X(t) = x given the
initial condition X(t0) = x0 for t ≥ t0, obeys the chemical master equation
∂
∂t
P (x, t|x0, t0) =
M∑
j=1
[hj(x− νj)P (x− νj, t|x0, t0)− hj(x)P (x, t|x0, t0)]
(1.3)
The previous equations imply that the system state X(t) performs a
”random walk” on the integer lattice in the N dimensional species pop-
ulation space; in mathematical terms, X(t) is a jump Markov process
(Gillesple (1977), Gillespie (2002), Gillespie (2007), Gillespie (2013)).
From now on we’ll denote the chemical master equation with ”ME”
instead ”CME”.
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1.2 AIM OF THE THESIS
The first aim of the thesis is to explore deterministic and stochastic mod-
eling methods in order to understand and investigate general problems
related to the basic mechanisms of gene expression, such as the determin-
istic and stochastic design and response of cellular promoters, splicing
sites, polyadenylation sites, .... Secondly the aim consists in investigating
and understanding the modules responses after their interconnection to
form a complex regulatory system to be in line with the current holistic
paradigm of systems biology. We will accomplish this aim by studying
the gene regulatory network of the human papillomavirus (HPV).
The second aim is to develop a novel model of the HPV gene expres-
sion under different biological conditions and to have insights in its regu-
latory mechanisms, such as transcriptional and post-transcriptional reg-
ulation, and their interconnections in order to explain the complex regu-
lation the virus can exhibit during the infection.
1.3 HUMAN PAPILLOMAVIRUS: A NOVEL MODEL WITHIN
THE ACTUAL CONTEXT OF SYSTEMS BIOLOGY
HPVs cause a series of diseases of the cutaneous and mucosal epithelium,
ranging from minor lesions (e.g. benign warts on the hand and feet) to
precancerous cervical lesions and cervical cancer which is considered one
of the most common cancer in the women worldwide. Infection with HR-
HPV generally starts in the basal layer of the mucosal epithelium. In the
normal epithelium and in low grade lesions, HPV is generally found in
an episomal form and its entire genome is sequentially expressed and
involved in the regulation processes during the progression of viral life
cycle, as the infected basal epithelial cell differentiates and moves to up-
per keratinized epithelial layers. At variance, in high grade lesions and
in cancer, multiple copies of the HPV genome may integrate in the cel-
lular chromosomes in a manner that promotes and sustains cancer pro-
gression.The vast majority of HPV infections are cleared within 2 years,
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and long term persistence of the infection is rare. Continued stimulation
of host cell growth during these rare cases of persistence can result in
pre-malignant cervical lesions. These lesions might deteriorate further to
cervical cancer if left untreated.
HPV offers a case of study of great interest in molecular systems bi-
ology and clinical studies. It involves a number of relevant regulatory
mechanisms (e.g. transcription, translation, promoter modulation, poly
adenylation regulation, splicing,) connected together to form a complex
network, albeit its genome is relatively simple, thus suitable for an accu-
rate deterministic and even stochastic modeling. It contains two main
promoters, regulating the early and late phases of viral transcription.
Their regulation and timing of promoters activation was investigated be-
tween the end of 90s and the beginning of 2000. However, a compre-
hensive understanding of their switching, of the stochastic effects in their
host cell differentiation-dependent activity, and in more general terms of
the dynamic evolution of viral transcripts and proteins involved, finely
regulated by a complex post- transcriptional and post- translational con-
trol, is still lacking.
The development of a mathematical model of HPV genes and proteins
regulation, is of great interest in order to achieve a better comprehen-
sion of the basic mechanisms and their interconnection regulating the
first stages of viral infection evolution up to a cervical cancer condition,
making the HPV a very interesting and actual system to study, perfectly
in line with the current paradigm of systems biology, as argued before.
There is not so much literature about mathematical modeling of viruses
gene regulatory networks. The only virus having a long modeling history
is the HIV for which both deterministic and stochastic models where per-
formed over the years (Singh and Weinberger (2009), Singh et al. (2010),
Weinberger et al. (2008)). There exists also an interesting model on Epsetin-
Barr virus (Werner et al. (2007a), Werner et al. (2007b)) and on HTLV-1
(Corradin et al. (2010), Corradin et al. (2011)).
As far as we know there is no model of HPV gene regulation available
in literature, apart a first heuristic/deterministic model on the early pro-
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moter regulation we have developed (Giaretta et al. (2015)) and that we
will present in chapter 3.
1.4 OVERVIEW
In this thesis we develop a novel model of HPV gene regulatory network
with the purpose to condense the complex and wide biological knowl-
edge on different clinical conditions including HPV lytic replication in a
normal epithelium (both in the basal infection and in the whole viral cy-
cle progression) and integrated HPV into host cell chromosomes leading
to cancer development.
The first aim of the project is consistent with the development of a
mathematical model able to predict, both stochastically and determin-
istically, the dynamical behavior of early and late promoters and of all
the major viral transcripts and proteins during the entire life cycle. To do
that, the condensed biological knowledge will be translated into a set of
biochemical reactions stochastically modeling the molecular biology. The
system will be based on the Chemical Master Equation (CME). This for-
malism allows to describe the system of biochemical reactions in terms of
the evolution of the probability distribution of the system state variables,
related to the chemical species copy numbers. Since the CME will be
impossible to solve analytically for such a complex system, its whole dy-
namical behavior will be investigated with the aid of Gillespies stochastic
algorithm (golden standard for simulating stochastic chemical systems),
able to reproduce the exact numerical solution of the CME. Nevertheless
a simplified assumption consistent with considering the stochasticity as-
sociated to the only promoters and splicing sites markov chains will per-
mit to study their associated master equation in order to appropriately
design these important ”controllers” in gene expression and to oppor-
tunely tune their parameters to achieve the whole dynamical behavior
consistent with the biology. Finally, a Quasi-Equilibrium approximation
will be performed in order to provide a deterministic revisitation of the
stochastic system, under conditions of fast promoters and splicing sites
11
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fluctuations.
The second aim of the model is to achieve a better comprehension of
the basic mechanisms and their interconnections regulating the early and
late stages of viral infection evolution up to an HPV integrated condi-
tion. The stochastic predictions, by fixing/inferring parameters from lit-
erature, will permit to shed light into the stochasticity the HPV gene ex-
pression can exhibit, identifying the importance of a stochastic formula-
tion for the system and find interesting behaviors a deterministic mod-
eling dimension cannot achieve. Consequently, different in silico simu-
lations will be carried out in order to predict and investigate the biologi-
cal/clinical scenarios from the beginning of the infection up to integrated
HPV, typically present in cancer stages.
The last aim of the project is to use the model to identify the major
regulatory mechanisms under different biological conditions in order to
properly design an experiment that will be used in order to validate the
model, as will be argued in the final discussion.
In what follows, a brief description of the next chapters is reported.
In Chapter 2, a new synthesis on HR-HPV molecular biology condens-
ing the transcriptional, post-transcriptional, translational and post- trans-
lational regulation underlying the early and the late viral promoters is
presented, placing the emphasis in collecting/inferring the main avail-
able data from literature (mRNA and protein half-lifes, promoters time
usages, protein and transcripts appearance post infection, ) that are use-
ful to design a dynamical model and placing emphasis on what is still
lacking in literature that could be important in order to properly validate
and optimize the structure of a dynamical model about HPV gene ex-
pression regulation.
In Chapter 3, a first heuristic/deterministic model we have developed
(Giaretta et al. (2015)) in collaboration with the Department of Molecular
12
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Medicine (DMMD) of the University of Padova, based on Ordinary Dif-
ferential Equations (ODE), is presented with the purpose to describe the
early promoter regulation in a context of either large cell population size
and fast promoter fluctuations.
In Chapter 4, a second more formal and complete stochastic and deter-
ministic model both regarding the early and the late promoter, developed
in collaboration with the Elston Lab at the School of Medicine at Chapel
Hill, University of North Carolina (UNC), is presented. This is done by
first translating the molecular biology of two promoters gene expression
regulation into a stochastic model presented in a set of biochemical reac-
tions highligting the involved chemical species as chemical reactants and
products and the correspondent rate constants.
In Chapter 5, we present the Chemical Master Equation of the model
reported in Chapter 4.
In Chapter 6, we present the Quasi-Equilibrium Approximation of the
developed stochastic formulation as a useful deterministic version of the
developed model.
In Chapter 7, we report the dataset available from literature, the in sil-
ico simulations we plan to show and the correspondent fixed parameters
we have gathered/inferred from literature.
In Chapter 8, we present a set of in silico experiments in different bi-
ological and clinical conditions to test the model capability in predicting
the dynamical behaviors of all its of gene expression mechanisms (i.e.
transcription, splicing, ...) that is in good agreement with the priori bio-
logical knowledge presented in literature and highlighting the complex
patterns that can arise from the interconnection of different layers of con-
trol in gene expression. Some predictions is also reported to explore the
augmented dynamical behavior associated with the intrinsic noise that
13
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only a stochastic formalism can predict.
In Chapter 9, a discussion inherent the achieved modeling results and
their goodness with the present available biological knowledge is pre-
sented. Moreover immediate and long term future developments will be
argued.
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Human Papillomavirus (HPV)
2.1 INTRODUCTION: HPVS AND DISEASES
HPVs (human papillomaviruses) are small double stranded DNA viruses.
They infect epithelial cells and cause a variety of lesions ranging from
common warts to cervical neoplasia and cancer. To date, more than 150
human papillomavirus types have been completely sequenced (Doorbar
et al. (2012)).
The most well studied HPV types are the mucosal Alpha types that can
cause cervical cancer. Cervical cancer is the second most common cancer
among women worldwide. Globally there are around 530,000 new cases
and 275,000 deaths due to cervical cancer annually (Raybould (2011)). For
centuries, cervical carcinoma has been recognised to behave as a sexually
transmitted disease and in the mid 1970s it was proposed that there was
an aetiological link with HPV. Infection with HPV is now recognised as
an essential factor for the development of cervical cancer. Importantly,
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these viruses are also associated with cancers at other sites, including the
penis in men, the anal transformation zone, the tonsils, oropharynx and
base of tongue (Doorbar (2006)).
2.1.1 HIGH- AND LOW-RISK TYPES
The Alpha HPVs are divided into cutaneous and mucosal types. These
latter are further subdivided into high-risk and low-risk HPVs (LR-HPVs).
A very studied low-risk type is HPV-11 and among the cutaneous Alpha
types we can find HPV-2 which causes common warts and HPV-3 and
-10 which cause flat warts. The low-risk mucosal types do not typically
cause neoplasia.
Carcinomas associated with the high-risk HPV types (HR-HPVs) are,
however, a far more significant burden. Twelve HPVs (16, 18, 31, 33, 35,
39, 45, 51, 52, 56, 58, and 59) are defined by the World Health Organisation
(WHO) as being high-risk cancer causing types (Doorbar et al. (2012)).
The most studied and aggressive version of HR-HPVs are HPV-16, -18
and -31. In particular, HPV-16 and -18 are responsible for approximately
70% of cervical cancer cases globally. Current vaccination programs serve
to protect women against these latter two types infection. Nevertheless
the vaccine is not a cure. It is important to develop new antiviral ther-
apies to defeat the viral infection; for this reason a deep understanding
of its molecular biology regulatory mechanisms could be vital in order to
better understand its life cycle and gene expression regulation in order to
develop a functioning antiviral therapy.
The model we will develop in the next chapters will account for HR-
HPVs, with particular reference to HPV-16, -18 and -31.
2.1.2 OVERVIEW OF THE HPV GENOME STRUCTURE
All papillomaviruses have a common genetic structure and a nonen-
veloped icosahedral capsid. The viral particles consist of a circular double-
stranded DNA molecule of about 8,000 bp that is bound to cellular hi-
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stones and contained in a protein capsid composed of 72 pentameric
capsomers (Cobo (2012)). The papillomavirus genome contains approxi-
mately eight open reading frames (ORFs) that are all transcribed from a
single DNA strand. This latter contains two main polycistronic promot-
ers and two polyadenylation sites. HPV genome is divided into three re-
gions as shown in Fig.2.1.1 (Cobo (2012), Johansson and Schwartz (2013),
Doorbar (2006), Doorbar et al. (2012)). The only elements shared by all
members of papillomavirus genus are the presence of an upstream reg-
ulatory region (URR), the early proteins E1 and E2, and the late proteins
L1 and L2. The first region is a noncoding upstream regulatory region
of 4001,000 bp named as upper regulatory region or long control region
(LCR). This region contains the early core promoter that regulates DNA
replication by controlling the transcription of the ORFs (Cobo (2012)).
The second region is the early region which contains the late core pro-
moter ORFs that encode proteins necessary for viral DNA replication
and oncogenesis transformation, named as ORFs E1, E2, E4, E5, E6 and
E7. The three latter genes are the oncogenes, even if the last two (E6
and E7) are the most important and studied (Cobo (2012)). The third and
last region consists of a late region which encodes viral structural pro-
teins, including the major capsid proteins necessary for productive viral
replication (L1 and L2) (Cobo (2012)). In particular the early promoter
initiates and regulates a polycistronic primary transcript encoding for all
the early proteins, while the late promoter initiates and regulates a poly-
cistronic primary transcript that encodes for the late proteins (L1 and L2)
and all the early genes but E6 and E7 (i.e. E1, E2, E4, E5).
2.1.3 PRINCIPAL FUNCTIONS OF THE HPV GENES/PROTEINS
The early genes and hence proteins are regulatory in function, namely
they are deputated for the viral DNA replication, transcriptional regu-
lation, cell cycle control, cell signalling and apotosis control, structural
modifications, etc..., while the late genes are important for the assemble
of the viral DNA into virions. In what follows we describe the main func-
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Figure 2.1.1: We show the HR-HPV genome structure. Its genome is shown as a
black circle with the early (PE) and late (PL) promoters marked by arrows. The six
early ORFs [E1, E2, E4 and E5 (in green) and E6 and E7 (in red)] are expressed
from either PE or PL at different stages during epithelial cell differentiation. The
late ORFs [L1 and L2 (in yellow)] are also expressed from PL, following a change in
splicing patterns, and a shift in polyadenylation site usage [from early polyadenylation
site (PAE) to late polyadenylation site (PAL)]. All the viral genes are encoded on one
strand of the double-stranded circular DNA genome. The long control region (LCR)
is enlarged to allow visualization of the E2-binding sites and the TATA element of
the PE promoter. The location of the E1- and SP1-binding sites is also shown.
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tions of HPV genes and proteins.
2.1.3.1 E1 PROTEIN
E1 is a viral protein of 73 kDa that is required for viral replication. This
protein binds to a specific DNA sequence and assembles into hexameric
complexes through E2 protein, in order to enhance the replication effi-
ciency. The resultant complex has helicase activity necessary for oligomer-
ization. E1 also interacts with replication protein A (RPA), which results
in the rapid stabilization of single-stranded DNA generated by E1 heli-
case activity (Cobo (2012)).
2.1.3.2 E2 PROTEIN
E2 is a viral protein of 40 kDa to 45 kDa, depending on the HPV type.
Expression of E2 protein in human cells results in the repression of tran-
scription from the viral promoter. E2 also plays an important role in the
production of new, replicated viral DNA with mitotic chromosomes for
the distribution of this DNA in the divided cells. Moreover, E2 interacts
with L2 and leads to the amplification of viral DNA to facilitate the pro-
duction of new viral progeny (Cobo (2012)).
2.1.3.3 E4 PROTEIN
E4 gene is located in the E region, overlapping with E2, and is a heteroge-
neous protein. The functions of the E4 protein are oligomerization, phos-
phorylation and proteolytic cleavage. E4 also plays a role in supporting
viral genome amplification, the regulation of late gene expression and the
control of viral maturation (Cobo (2012)). It is produced by a transcript
usually called E1ˆE4.
2.1.3.4 E5 PROTEIN
This protein is considered to be a transforming protein and enhances the
potential of immortalization of E6 and E7 proteins. In addition, this pro-
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tein enhances the activity of epidermal growth factor receptor (EGFR).
With EGFR, E5 could interfere with several signal transduction path-
ways, including the mitogen-activated protein (MAP) kinase pathway
(Cobo (2012)).
2.1.3.5 E6 PROTEIN
E6 is a viral protein with molecular weight around 18 kDa (Ayeda Ayed
(2010)). The main function of E6 protein is its ability to bind and degrade
the tumour suppressor protein p53 through the protein ligase E6 associ-
ated protein. This activity results in the inhibition of the transcriptional
activity of p53 and the inhibition of apoptosis. E6 protein binds to several
cellular proteins such as the proteins involved in cell polarity and motil-
ity, tumour suppressors and inducers of apoptosis, as well as the proteins
for DNA replication and repair factors. Finally, E6 induces the expression
and activity of telomerase and further cell immortalization (Cobo (2012)).
2.1.3.6 E7 PROTEIN
E7 is a viral protein that can be processed in three different isoforms
with different molecular weights, probably because it undergoes differ-
ent posttranslational modifications (Valdovinos-Torres et al. (2008)). The
different isoforms are described as E7a1 (17.5 kDa), E7a (17 kDa) and E7b
(16 kDa) (Valdovinos-Torres et al. (2008)). E7 binds with the tumour sup-
pressor protein p105Rb that leads to the loss of p105Rb control over E2F
transcription factors. E7 can also bind to p107 and p130. These inter-
actions could produce the immortalization of cells and abrogate normal
responses to DNA damage (Cobo (2012)).
2.1.3.7 L1 AND L2 PROTEINS
L1 is the major structural protein of papillomavirus. L1 are highly im-
munogenic, present conformational virus-neutralizing epitopes and could
be used to detect HPV antibodies in the sera of patients with high speci-
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ficity. However, L2 is the minor capsid protein of papillomavirus. L2
contributes to the interaction of the virion with the cell surface (Cobo
(2012)).
2.2 VIRAL LIFE CYCLE AND VIRAL INFECTION
Infection is generally belevied (especially for HR-HPVs) to start in the
basal layer of the mucosal epithelium to which HPV gains access through
small wounds or abrasions in the mucosal epithelium. The virus initially
gets to the basal lamina, and subsequently interacting with heparin sul-
phate proteoglycans and possibly also laminin (Doorbar (2006), Doorbar
et al. (2012), Johansson and Schwartz (2013)). Structural changes in the
virion capsid, facili- tate transfer to a secondary receptor on the basal
keratinocyte, which is necessary for virus internalization and subsequent
transfer of the viral genome to the nucleus (Doorbar (2006), Doorbar et al.
(2012)). Once internalised, virions undergo endosomal transport, uncoat-
ing, and cellular sorting. The L2 protein-DNA complex ensures the cor-
rect nuclear entry of the viral genomes, while the L1 protein is retained in
the endosome and ultimately subjected to lysosomal degradation (Door-
bar (2006), Doorbar et al. (2012)).
2.2.1 GENOME MAINTENANCE AND CELL PROLIFERATION
Infection is followed by an initial phase of genome amplification, and
then by maintenance of the viral episome at low copy number (Doorbar
(2006), Doorbar et al. (2012)). The copy number in the basal layer lesions
is often proposed around 100/200 copies per cell (?).
The viral replication proteins E1 and E2 are thought to be essential
for this initial amplification phase; in fact it was suggested they are ex-
pressed at the same time and they are the sole proteins we can find just 4
hours post infection (McKinney et al. (2015), Ozbun (2002)). E2 also reg-
ulates viral transcription, and has multiple binding sites in the viral LCR
(long control region or upstream regulatory region [URR]), and (during
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viral DNA replication) can recruit the viral E1 helicase to a specific E1
binding motif in the viral origin of replication, making efficient the DNA
replication. The level of replication must be tightly controlled during the
maintenance phase of the viral life cycle. An interesting feature charac-
terizing the DNA replication efficiency is the ratio E1/E2, which in the
mantainance and proliferation phase is around 0.9-1.2 (McKinney et al.
(2015), Ozbun and Meyers (1998)). The ratio is small since initially the
genome replicates to low levels Johansson and Schwartz (2013).
It has been speculated that the use of a viral DNA helicase (i.e., E1),
which is distinct from the cellular replication helicases (MCM proteins),
allows viral DNA replication to be disconnected from cellular DNA repli-
cation during genome establishment and amplification ((Doorbar (2006),
Doorbar et al. (2012), Blakaj et al. (2009)). Moreover, another proposed
role for E2 is the regulation of accurate genome partitioning during basal
cell division. In HPVs, other E2 binding proteins appear to be involved
in the tethering of viral episomes to the cellular chromatin during cell
division ((Doorbar (2006), Doorbar et al. (2012)).
The precise role of the HPV E6 and E7 proteins in infected basal cells
is uncertain for the low-risk HPV types, but it is clear for high-risk HPV
types, where they are important in driving cell proliferation in the basal
and parabasal cell layers, especially at cervical sites where neoplasia can
occur (Doorbar (2006), Doorbar et al. (2012)).
The remaining early genes (i.e. E4, E5) are not important at this stage
and probably they are not transcribed or just in negligible quantities. The
late genes (i.e. L1 and L2) are not transcribed at this stage but only in the
final infection stages, thanks to the activation of the late promoter.
2.2.2 FROM GENOME MAINTENANCE TO GENOME AMPLIFICATION
As the infected cells in the basal layer divide, the daughter cells migrate
to the upper cell layer and start to differentiate (Johansson and Schwartz
(2013)). The cells that commit differentiation, reaching the top stratum
of the epithelium, are destined to die. This is counterproductive for the
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HPVs, that have infected the cell, because they can’t replicate themselves
anymore, once the cell is dead. To overcome this apparent drawback,
the HPV amplifies its genome replication before the infected cell death,
hence guaranteeing a numerous progeny. It must be precised that the
differentiation is just an apparent disadvantage for the virus, being the
most efficient, if not the only one, way to spread out the infection to the
neighborhood cells.
In embarking on the road of differentiation, the cell downregulates the
expression of cellular factors that are required for replication of the viral
genome. This downregulation is counteracted by E6 and E7 whose func-
tion is to stimulate cell cycle re-entry in the mid-epothelial layers in order
to allow genome amplification (Doorbar (2006), Doorbar et al. (2012)).
In low-risk HPV infection, the basal cell proliferation is regulated by
the presence of growth factors, as seen in uninfected cells. The primary
role of E6 and E7 viral proteins is to drive cell cycle entry above the basal
layer in order to facilitate HPV genome amplification. This is dependent
on the fact E7 can bind to pRb family member p130 and to displace this
latter and the associated E2Fs transcriptional repressors from target pro-
moters required for S-phase gene expression. The transcriptional activa-
tors E2F1, 2 and 3 can the occupy the vacant sites in the latter promoters,
hence stimulating expression of the host cell genes necessary for DNA
replication and cell cycle progression.
In high-risk HPV infection the mechanism is the same presented in
low-risk HPV infection with the main difference that E7 displaces p105
(Rb protein member) instead of p130. Another interesting dynamical fea-
ture of both low and high risk infection, consists in a compromising func-
tion of MDM in degrading p53, which subsequently leads to an increase
in p53 abundance that tends to induce the cell cycle arrest. This latter
is counteracted by E6 protein that mediates the degradation of p53 by
means of the ubiquitin-proteasome pathway.
We have ascertained that E6 and E7 can promote the infected cell re-
enter in the mid-epithelial layers. However their expression in the upper
epithelial layers allows to re-enter S-phase and to enhanc of viral genome
23
Human Papillomavirus (HPV)
copy number. To enhance viral genome copy number it is also required
a strong amplification of the replication proteins E1 and E2. These latter
are upregulated thanks to the late promoter which in turn is primarily
activated by the cellular differentiation program. During this phase, to
enhance the replication efficiency the E1/E2 ratio increased up to 2 fold
for HR-HPV 31 (Ozbun and Meyers (1998)). HPV genome amplification
persists as the differentiating cells move from S to G2 phase of the cell
cycle, with viral genome amplification occuring primarily in G2 phase
after cellular DNA replication has been completed (Banerjee et al. (2011),
Wang et al. (2009)). Besides E1 and E2, also E4 and E5 are thought to
have some marginal role indirectly contributing to genome amplification
success by modifying the cellular environment. E5 regulation is not well
understood, given its expression profile particularly elusive, mainly due
to the absence of reliable E5-specific antibodies. However, it is thought to
give an important contribution to genome amplification success through
its ability to stabilize EGFR and to enhance EGF signalling and MAP ki-
nase activity (Genther et al. (2003), Fehrmann et al. (2003), Straight et al.
(1993)) and to modulate both ERK 1/2 and p38 indipendently of EGFR
(Crusius et al. (2000)).
The MAP Kinases ERK 1/2 are also important regulators of E1 accumu-
lation inside the nucleus of the cell. This could be important, as reported
in recent works suggesting that an accumulation of E1 in the nucleus
should increase viral DNA replication at the expense of cellular replica-
tion through induction of a DNA damage response (Doorbar (2006)).
About E4, given its primary function in virus release it has a secondary
role in this phase, optimizing the amplification indirectly thanks to its
growth arrest function.
2.2.3 PACKAGING AND RELEASING PHASE
The final step of the viral life cycle involves the production of L2, to exit
the cell from its life cycle, and the expression of L1 to allow genome pack-
aging in order to assembly the icosohedral viral capsid in the nucleus
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able to protect the virus in the extracellular environment. Virus mat-
uration occurs in the most superficial, dying keratinocytes, which lose
mitochondrial oxidative phosphorylation and convert from a reducing
to an oxidizing environment just before virus release. Assembled parti-
cles contain 360 molecules of L1 arranged into 72 pentameric capsomeres,
with a smaller and variable number of L2 molecules, which can occupy
capsomeres at the 5-fold axis of symmetry (Buck et al. (2008)).
Besides L1 and L2 the third protein of pivotal importance is E4. In
this phase and the previous one it has been accumulated in order to con-
tribute to virion release and infectivity in the upper epithelial layers. In
fact, it assembles into amyloid fibers (McIntosh et al. (2008)) that disrutp
keratin structure and compromise the normal assembly of the cornified
enevelope (Brown et al. (2006)) of the upper keratinized strata, allowing
the newly formed viruses to spread out in the neighborhood cells.
In fig. 2.2.1 we report the classical evolution of the viral proteins during
the entire viral life cycle.
2.2.4 PRECANCEROUS AND CANCEROUS LESIONS PROGRESSION
The HPV infection starts in the keratinocyte forming the basal layer of
the epithelium and ends with that cells, embarking the road of differen-
tiation, that reach the upper epithelial strata. In carcinogenic progression
the next stage, after this ”classical” infection cycle, consists in the devel-
opment of low and high grade precancerous lesions (Cervical Intraep-
ithelial Neoplasia or CIN), and eventually Squamous Cell Carcinoma
(SCC) or adenocarcinoma (ADC) conditions. In particular CIN condition
is classified into three different grades: CIN-1, -2, -3.
CIN-1 is the first precancerous stage and is confined to the basal 1/3
of the epithelium (Kumar Vinay (2007)). It is the least risky stage and
is usually reversible by the immune response or if opportunely treated.
Moreover, CIN-1 is the only precancerous lesion that typically retains the
ability to mantain a ”normal” HPV life cycle as in the classical infection
(maybe with just a higher oncogenes production) and produce viral par-
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Figure 2.2.1: HPV starts the infection in the basal epithelium. During genome
manteinence the first genes to be expressed are E1 and E2 to maintain a reservoir of
viral DNA. When the cells start proliferating the oncogenes are produced in higher
amount to restart the cell cycle. Upon differentiation and during the genome ampli-
fication phase the late promoter is activated and E1 and E2 are produced in higher
amount in order to amplify the viral DNA. Even E4 is produced given its importance
in breaking down the cell membrane ath the end of the viral life cycle. During virus
assembly and release fase the viral capsid genes are expressed in order to build up
the viral capsid. At the end of the life cycle a new population of virus spread out,
ready to infect the neighbourhood cells.
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ticles in the upper epithelial strata (Johansson and Schwartz (2013),Ku-
mar Vinay (2007)).
CIN-2 is a moderate dysplasia confined to the basal 2/3 of the epithe-
lium and the most of the infected cells produce basically just the onco-
genes and only in the very last epithelial strata there is a chance for
the viral life cycle to be completed (Johansson and Schwartz (2013),Ku-
mar Vinay (2007))
CIN-3 is a severe dysplasia extended to the whole epithelium without
the normal viral life cycle and with, practically, the sole expression of the
oncogenes, that are upregulated than in the normal infection. This stage
is very difficult to be reversed and usually lead to invasive cancer. In gen-
eral, persistent high-grade disease such as CIN-2, -3 are associated with
an increasing risk of genome integration into the host cell chromosome
and progression to cancer (Johansson and Schwartz (2013),Kumar Vinay
(2007)).
The spatio-temporal progression of viral transcripts and proteins through
the epithelium is completely deregulated in CIN-2,-3 and cervical cancer
conditions. It is generally thought that levels of E6 and E7 expression
increase from CIN-1 to CIN-3, and that these changes in gene expression
directly underlie the neoplastic phenotype.
2.3 EARLY PROMOTER TRANSCRIPTIONAL REGULATION
The early promoter transcriptional regulation can be performed by either
an endogenous way or an exogenous way. In the former the viral proteins
are able to modulate the promoter activity, while in the second the early
promoter is regulated by transcription factors produced by the infected
cell. Both the ways are carried out in the LCR, which does not contain
any open reading frames. LCR can be divided into three regions: 5’ LCR
(bordering at the termination codon of the L1 gene), central LCR, and 3’
LCR (bordering at the transcription start site of the E6 gene), as shown
in fig. 2.3.1 (Bernard (2002), Bernard (2013)). The 5’ LCR encodes the
transcription termination signal of the late transcripts, the 3’ LCR con-
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Figure 2.3.1: General organization of the long control region (LCR) of all alphapa-
pillomaviruses.
tains the replication origin and the early promoter and the central LCR
contains binding sites for the host cell enhancers and silencers transcrip-
tion factors that exogenously regulate the early promoter (Bernard (2002),
Bernard (2013)).
2.3.1 ENDOGENOUS REGULATION
Like in many promoters which makes use of the RNA polymerase II, the
transcription start site is recognised by the pre-initiation complex com-
posed of TFIID, which binds the TATA box (TATAAA, 31 to 26 bp up-
stream of the transcription start site), and five other general transcription
factors (GTFs). 37-32 bp upstream of the TATA box there is a G rich hex-
amer, which is a binding site for SP1. This latter is a transcription fac-
tor necessary for the early promoter activation (Bernard (2002), Bernard
(2013), Thierry (2009)), as shown in fig. 2.3.2.
The most important regulator of the early promoter endogenous mod-
ulation is the E2 viral protein, produced by the same promoter, that can
bind in form of a dimer (DE2) upstream the promoter. More precisely,
there are four specific E2 binding sites (E2BS) inside the LCR upstream
the early promoter (Muller and Demeret (2012), Soeda et al. (2006), Bernard
(2002), Demeret et al. (1997), Bernard (2013), Thierry (2009)), as shown in
fig. 2.3.2. Two of these sites (E2BS #1 and #2) are about 50 bp upstream
of the transcription start site, positioned exactly between the Sp1 binding
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site and the TATA box; a third site (E2BS #3) is about another 100 bp fur-
ther upstream, and a fourth site (E2BS #4) about halfway between the end
of L1 and E2BS #3. The E2BS #1, #2 and #3 control the repression of the
early promoter, while E2BS #4 control its activation(Muller and Demeret
(2012), Soeda et al. (2006), Demeret et al. (1997), Bernard (2013), Tan et al.
(1994)). The four E2 binding sites have similar affinities (Demeret et al.
(1997)), hence the E2 dimer (DE2) can bind with more or less the same
probability all of its binding sites. However, the binding sites have dif-
ferent stabilities and precisely the half lives of the complexes DE2-DNA
are ordered as follow: tE2BS#4h > t
E2BS#2
h > t
E2BS#3
h > t
E2BS#1
h (Demeret
et al. (1997)). These half lives contain the information of the DE2 dimer
dissociation rate constant from its binding site in the DNA (Dukhovich
(2002)). The dissociation rate constant is proportional to the dissociation
probability of the DE2 dimer from its E2BS in the DNA. Consequently,
from the previous information we can observe that it’s more difficult to
detach from E2BS #4, controlling the promoter activation, than respect to
the other three binding sites, controlling the promoter repression.
The transcription starts when the pre-initiation complex (GTFs, TFIID,
RNA polymerase II) and the Sp1 transcription factor are bound upstream
the promoter. Transcripts that result from this event encode all the early
genes, hence E2 gene, too. E2 protein translated from its transcript can
bind, as a dimer DE2, to the promoter binding sites E2BS #ith. E2 can dis-
places Sp1, binding E2BS #1, #2 and #3, thus leading to a down-modulation
of the early promoter (Bernard (2002), Bernard (2013)). At a high concen-
tration of E2 protein, E2 does not only displace Sp1 but also TFIID, as it
binds to E2BS #1, leading to efficient repression of the promoter (Bernard
(2002), Bernard (2013)). It is interesting to notice that, the necessity of a
high E2 concentration to efficiently bind the E2BS #1 is consistent, with
the previously reported experimental evidence, that this latter binding
site has the lowest dissociation half life for the DE2 dimer (i.e. the DE2
dimer dissociation probability is very high, thus only when in high con-
centration we can be sure it will be bound most of the time). This is
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Figure 2.3.2: Endogenous minimal model of HPV transactivation. A basal transcrip-
tion starts when Sp1 human transcription factor binds the early promoter. When E2
is in low concentration it induces a positive feedback binding, in form of a dimer, to
BS4. When E2 is in high concentration it binds, in form of a dimer to all the binding
sites inducing a negative feedback on the early promoter.
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clearly a negative feedback loop that keeps the early promoter at a low
steady-state activity, as increased promoter activity raises also the level
of E2 transcripts and consequently of E2 proteins.
Besides the negative feedback regulation, it is widely accepted in lit-
erature that when E2 is in low concentration it can positively regulate
the early promoter. In fact, as previously reported, E2BS #4 has the low-
est dissociation probability and being the latter binding site associated
to the positive regulation of the early promoter, this is an experimental
proof that when E2 is in low concentration the positive feedback should
win over the negative one. Actually, even if we know that E2 can pos-
itively regulate the early promoter, the mechanism behind still remains
not well understood, yet. However, a quite recent work had partially
shed light on this important question. It was proven that high levels of
the co-activator CBP/p300 and the transcription factor CEBP/alpha can
synergize with E2 in order to strongly activate the early promoter up to
12 fold increase (Kru¨ppel et al. (2008)). This shows the possibility to have
a strong positive feedback on the early promoter regulation. CEBP/alpha
and CBP/p300 were shown to increase during the keratinocyte differen-
tiation (Kru¨ppel et al. (2008)) where the late promoter is activated and
negatively regulates the early promoter. Nevertheless, this latter regula-
tion performed by the late promoter does not mean the early promoter
must be completely shut down, but just strongly controlled in order to
contain the oncogenes expression. Probably this strong positive regula-
tion of the early promoter can happen in the first phase of the differenti-
ation. This could be consistent with the sustained oncogenes expression
in CIN-1,-2 with respect the normal viral life cycle. In fact, p300 expres-
sion is high in the suprabasal layers of HPV16 CIN-1,-2 pre-cancerous
conditions (Kru¨ppel et al. (2008)).
The consequence of these various mechanisms is a feedback that bal-
ances between strong repression, which would lead to termination of the
viral life cycle, and strong expression with a more fulminant course of the
HPV infection.
In Cahpter 7 we will report an interesting data set about the early pro-
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moter activity of HPV-16 and -18 in function of E2 protein concentration
(Hou et al. (2002)). This data set takes into account the sole repression
function of E2. Unfortunately we haven’t any available data about E2
positive regulation. However, this data set is an interesting and impor-
tant state of the art of the biological knowledge about the early promoter
functioning and it will be used in to accurately tune the model of the
promoter activity we have designed and show it is able to fit the experi-
mental data.
Another interesting and important regulatory feature of the early pro-
moter is the E2 regulation mediated by E1. In particular, E1 is able to
stabilize E2 by a direct protein- protein interaction (King et al. (2011)). In
general, in HPV-16 and -18, E2 has an half-life ranging from 45 min to 3
h (Bellanger et al. (2001), McBride (2013), Taylor et al. (2003)). However,
it was shown the E2 half-life can increase, in the presence of E1, from
2.6 h to 3.5 h in 293 T cells line, and from 3.6 h to 5.7 h in C33A cervical
carcinoma cell line.
HPV16 E2 is turned over via the proteasome following ubiquitinyla-
tion pathway (Taylor et al. (2003)) and therefore E1 presumably stabilises
E2 by preventing this turnover. Recent studies have proven that the Brd4
C-terminal domain can inhibit the interaction between E2 and the pro-
teosome pathway, thus increasing E2 stability. It is possible that E1 acts
in a similar manner preventing E2 degradation (King et al. (2011)).
Since E2 also interacts with some components of the SUMO proteins
(King et al. (2011)), it is alternatively possible that the Sumoylation of
the E1 and E2 proteins is, in turn, involved in E2 protein turnover reg-
ulation (King et al. (2011)). Probably, even the E1/E2 tetramer complex
formation stabilizes E2 due its importance in recruiting E1 at the origin
of replication and increasing the E1 binding specificity. Another impor-
tant function of E1 co-regulation is that it increases the E2 transcription
up to 2-4 fold (King et al. (2011)). This is probably accomplished at a
post-transcriptional level since the early promoter produces a pre-mRNA
encoding all the early genes. Unfortunately, the exact mechanism hasn’t
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been found yet, nevertheless we’ll show in chapter 4 how we’ll handle
the modeling of this important dynamical feature.
2.3.1.1 REGULATION OF VIRAL DNA REPLICATION
The double-stranded circular DNA replicates as a multi-copy extrachro-
mosomal plasmid in the nucleus of infected cells. The replication of pa-
pillomavirus DNA is initiated from the origin of replication consisting of
binding sites for E1 and E2 proteins (Bernard (2013), Kurg (2009)).
The papillomavirus origin of replication consists of three E2 binding
sites (E2BS), from which only one is absolutely required for replication,
and an AT rich region containing a cluster of E1 protein binding sites
(E1BS) (Kurg (2009), Robert L. Garcea (2007)). In particular, E1 is the main
initiator protein of HPV DNA replication. E1 is responsible for recogni-
tion of the replication origin, as well as for subsequent unwinding of the
double helix (Kurg (2009), Robert L. Garcea (2007)). The viral E1 protein
is an ATP-dependent helicase which binds as a dimer to a pair of its bind-
ing sites, but E1 by itself binds to the origin with low specificity. How-
ever, in the presence of E2 the specificity is increased. In fact, the E1 and
E2 proteins form a tetramer complex, called E1/E2 (a dimer composed
by one DE1 and one DE2 dimers), through multiple protein-protein inter-
actions and bind cooperatively with high specificity to adjacent binding
sites in the origin of replication.
In the next step, additional E1 molecules are added by displacing E2
from the DNA-bound complex in an ATP-dependent manner. Subse-
quently, two additional E1 molecules are recruited to the origin, which
results in the formation of two E1 trimers on the ori, followed by forma-
tion of two hexamers in the presence of ATP. E1 hexameric complex has
the DNA helicase activity which is able to unwind the DNA and start the
viral DNA replication (Kurg (2009), Robert L. Garcea (2007)). It is not well
understood what kind of regulation the early promoter can be subjected
when the E1/E2 complex is bound to the ori. It was proposed a model
for HPV-11 that suggests there is a minimal replication at the same time
33
Human Papillomavirus (HPV)
of the transcription in the basal cells, where only the early promoter is ac-
tivated, while in differentiating keratinocyte the transcription is stopped
during the replication (Hartley and Alexander (2002)). However, despite
this latter model, since the E1/E2 complex binds to the origin of repli-
cation, made of E1 binding sites and E2BS just related to the promoter
repression, it is reasonable to hypothesize a transcriptional repression
when E1/E2 is bound. The dissociation constant for E1/E2 from its DNA
binding site was found to be kd = 2.2[nM ] for HPV-11 (Chao et al. (1999)).
However, it can be inferred a similar, if not equal, dissociation constant
for high-risk HPV-16, -18, too. Unfortunately, the dissociation constant
of the E1/E2 complex into its DE1 and DE2 dimers seems to be unavail-
able in literature and the same for its half life. However, since E2 is more
stable in the presence of E1, as reported in the previous paragraph, it is
reasonable to assume E1/E2 half life higher than E2 monomer half life
and probably higher than DE2 dimer.
2.3.2 EXOGENOUS REGULATION BY THE INFECTED CELL
The central LCR is divided into two parts: i) the silencer part (bordering
the 3’LCR to the right) containing binding sites for exogenous transcrip-
tion factors (TFs) coming from the infected cell that have the capabil-
ity to strongly repress the early promoter activity; ii) the enhancer part
(bordering the 5’ LCR to the left and the silencer LCR part to the right)
containing binding sites for exogenous TFs from the host cell that can
strongly activate the early promoter.
In fig. 2.3.3 is shown the complete LCR TFs. There are around 15 TFs
among enhancers and silencers, however half of them are not well under-
stood yet. In what follows we are reporting just the principal enhancers
and silencers.
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Figure 2.3.3: Regulation of the early promoter, mediated by exogenous transcription
factors that can enhance or silence the transcription.
2.3.2.1 AP-1 ENHANCER
AP-1 is a heterodimer composed of subunits of the fos and jun gene fam-
ily and its typical AP-1 binding DNA element is the sequence TGANTCA
(Bernard (2002)).
AP-1 is considered the principal activator of the HPV enhancers and it
could be important in modulating the transcriptional activity even dur-
ing the epithelial differentiation, hence during the whole viral life cycle
(Bernard (2013)).
2.3.2.2 NFI ENHANCER
NFI constitutes a family of factors derived from four genes, NFI-A, B, C
and X. NFI factors occur in dimeric form, with the two subunits poten-
tially derived from the four different NFI genes and also from different
spliced products, even if in the epithelial cells NFI is mostly composed
by NFI-C subunits, while in non-epithelial cell it is mostly composed by
NFI-X subunits (Bernard (2013), Bernard (2002)). Its binding sites repre-
sent the most conspicuous binding elements of the central LCR and is a
cluster of half-palindromic TTGGCT/A sequences.
NFI is a transcriptional weak activator, that appears to play an impor-
tant role even in the modulation of HPV16 carcinogenesis; moreover, its
binding sites activate HPV enhancers in synergy with other factors (i.e.
there is a cooperation between the TFs) (Bernard (2013)).
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2.3.2.3 OCT1 ENHANCER
Oct1 is a member of POU factors and its recognition binding site is rep-
resented by the DNA sequence ATGCAAAT. Oct1 motifs exist in the HR-
HPV LCR and it is usually very close (2 bp) from a hal-palindromic NFI
binding site. Oct1 is not really an enehancer, but it seems to tether NFI to
the enhancer LCR zone rather than being a transcriptional activatore by
itself (Bernard (2013)).
2.3.2.4 TEF1 ENHANCER
TEF1 is an enhancer not well understood yet. It is known that it binds
multiple sites in HPV-16 LCR enhancer zone, especially the motifs ACAT-
ACCG and ACATATTT. TEF1 requires a cofactor (not identified yet), that
does not directly bind the DNA and helps TEF1 in contributing to the
epithelial specific function (Bernard (2013), Bernard (2002)).
2.3.2.5 YY1 SILENCER
YY1 is a transcription factor that can exhibit positive and negative con-
trols and usually binds the DNA sequence CCGCCATNTT. It can activate
or repress transcription directly, by interacting with histone-deacetylases
or histone-acetyltransferase, or indirectly by interacting with other tran-
scription factors such asC/EBPβ (Bernard (2013), Bernard (2002)). How-
ever, there are numerous binding sites inside the LCR where YY1 neg-
atively regulates the promoter. An opportune modulation of YY1 can
counteract the transcriptional stimulation by enhancers such as AP-1,
NFI, Oct1 and TEF-1 (Bernard (2013)).
2.3.2.6 CBP AND CBP/P300
CBP (CREB binding protein) and p300 (also called CBP/p300) are cel-
lular co-activators of transcription, usually involved in control of HPV
gene expression. They are co-activators for the exogenous cellular tran-
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scription factors, such as AP1, C/EBP but also for the endogenous E2
viral protein (Kru¨ppel et al. (2008)).
CBP/p300 is active in several biological processes, such as differenti-
ation control, apoptosis and cell cycle regulation (Kru¨ppel et al. (2008)).
It can also synergize with E2 as briefly explained in the following para-
graph.
2.3.2.7 C/EBPS REGULATORS
C/EBPα, β and δ are three transcription factors of the C/EBPs family,
that can usually bind the sequence ATTGCGCAAT and have different ef-
fects on HPVs. C/EBPδ and C/EBPα are repressors for both HPV16
and HPV11 (Bernard (2013)). Besides, C/EBPα bound at the position
480, downstream the early promoter, can sinergize with the E2 viral pro-
tein and CBP/p300 cofactor in order to strongly activate the early pro-
moter (Kru¨ppel et al. (2008)).
A C/EBP site in the LCR silencer zone of HPV18 is capable to sinergize
with YY1 and repress the promoter in the HeLa cells line (Bernard (2013)).
C/EBPbeta, together with its isoforms, is also proposed to be one of
the most important regulator in the activation of the Late promoter, as
better discussed in later paragraphs.
2.3.2.8 CDP SILENCER
CDP (that stands for CCAAT-displacement protein) is a transcription fac-
tor able to repress the transcription and at the same time negatively reg-
ulate the DNA replication (?). This latter function is possible thanks to
its binding sites (sequences TATAATAAT and TACAATAAT) that over-
lap the E1 binding site. Hence CDP can interfere with the normal E1
function in replicating the viral DNA (Bernard (2013)).
CDP is an interesting silencer even during the differentiation, since it
is usually decreased in differentiated epithelial cells (Bernard (2013)).
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2.4 POST-TRANSCRIPTIONAL REGULATION
In this section we report the biological state of the art knowledge about
the post-transcriptional regulation of HPV.
Both the early and the late promoters produce a polycistronic pre-mRNA.
The arely pre-mRNA encodes for all the early genes while the late pre-
mRNA encodes for the late genes and for all the early genes but the onco-
genes. Thus, HPV splicing regulation is really very important for un-
derstanding how the different mRNAs are generated from the respective
pre-mRNA and modulated during the entire viral life cycle.
We will refer to HPV-16 splicing regulation, if not differently specified,
since it is the most studied and understood in terms of post-transcriptional
and post-translational regulations. Nevertheless, HPV-16 splicing regu-
lation seems to be preatty similar to the other HPV-18 and -31.
2.4.1 THE MAJOR 3’ SPLICE SITE
SA3358 is the major 3’ splie site used in HPV-16. It is maybe, as far as
we know, the most important and commonly used splicing site, having
a central role in the production of the early mRNAs encoding E6, E7, E4
and E5 but preventing the production of E1 and E2 mRNAs (Johansson
and Schwartz (2013), Somberg and Schwartz (2010), Schwartz (2013)). It
is also used for the production of the late genes (Johansson and Schwartz
(2013), Schwartz (2013)), as we will see later. The region between SA3358
and SD3632 contains the binding sites for different SR proteins that act
as splicing enhancers and silencers, as shown in fig. 2.4.1, that are SR.
Splice site SA3358 is enhanced by binding of SRSF1 splicing factor (for-
merly known as ASF1/SF2) to the downstream enhancer site and seems
to be inhibited by the binding of SRSF9 (formerly known as SRp30C) and
SRSF3 (formerly known as SRp20) splicing factors to the downstream en-
hancer and silencer splicing sites, respectively.
38
2.4 Post-transcriptional regulation
Figure 2.4.1: Splicing regulation of the major 3’ splicing site; splicing regulation of
the oncogenes between splicing sites SD226 and SA409. Positive regulation of early
polyadenylation signal pAE.
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2.4.2 E1, E2 AND E4 SPLICING REGULATION
As far as we know, the most important splicing mechanism that regu-
lates E2, E4 and E1 is regarding the mutual exclusivity between the ma-
jor splicing site SA3358 and SA2709 site. Splicing site SA3358 generates
E4 but not E2, since SA3358 competes with SA2709 E2 splicing site (Jo-
hansson and Schwartz (2013)). Conversly, when the splicing site SA2709
is activated E2 mRNA is generated but not E4 mRNA. Both E1 and E2
mRNAs are derived from the same pre-mRNA (Chow et al. (2010)) and
when SA3358 is activated the E1 mRNA production is prevented, as well.
A better comprehension of E1, E2 and E4 splicing regulation is required
in order to achieve a better understanding on how their transcripts are
regulated during both the early and late stage of the infection.
We could observe that since the 3’ end of the E1 ORF overlaps the 5’
end of the E2 ORF (Chow et al. (2010)) there is a possibility they are al-
ternatively transcribed (i.e. they couldn’t be generated at the same time).
Nevertheless, we know that E1 and E2 are present at the same time (King
et al. (2011)), probably due to their important co-regulations previously
argued, and actually they appear to be synchronous to each other (Ozbun
and Meyers (1998)).
2.4.3 ONCOGENES SPLICING REGULATION
Probably the most important knowledge about the oncogenes splicing
modulation is that high levels of SRSF1, in the basal layers of the ep-
ithelium, drives E6 and E7 mRNAs expression eventually reducing E2
expression. This is because high levels of SRSF1 stimulate splicing at
SA3358 at the expense of splicing to the E2 mRNAs site S2709, because of
their mutual exclusivity (Johansson and Schwartz (2013)).
E6 and E7 are not produced at the same time due to another splicing
mechanism involving a cluster of splicing sites upstream SA3358 site. In
fact, splicing between SD226 and SA409, by retention of the first intron,
generates mRNAs that are translated to E6*I (an E6 protein variant) and
E7 proteins (by leaky scanning (Stacey et al., 1995), by a ribosomal shunt-
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ing mechanism (Remm et al., 1999) or by a translation-reinitiation mecha-
nism (Tang et al., 2006)) whereas mRNAs that remain unspliced between
SD226 and SA409 produce full-length E6 (Schwartz (2013)). Splicing be-
tween SD226 and SA409 are stimulated by heterogeneous nuclear ribonu-
cleoprotein hnRNP A1 and hnRNP A2 (as shown in fig. 2.4.1), whose
expression is downregulated in differentiated keratinocytes.
The post-transcriptional regulation of the oncogenes is regulated even
by the epidermal growth factor (EGF). High levels of EGF lead to the
activation of ERK1-ERK2 pathway, resulting in the inhibition of splicing
between SD226 and SA409, thus leadng to E6 mRNAs. Conversly, a re-
duction in EGF favours E6*I and E7 mRNAs production.
2.4.4 EARLY POLYADENILATION REGULATION
The main role of the early polyadenylation signal, pAE, is to efficiently
regulate the expression of the late genes L1 and L2. This is crucial in order
to prevent a too early production of the late proteins that could jeopar-
dise the ability of the virus to persist long enough to be spread out in the
neighborhood cells or to be transmitted to another individual. The ac-
tivity of the pAe is enhanced by the binding of human factor FIP1 to the
early 3’ UTR (eUTR) located upstream the pAE, but it is also enhanced by
downstream stimulatory elements such as hnRNP H and the polyadeny-
lation factor cleavage stimulation factor 64 kDa subunit (CSTF4) (Johans-
son and Schwartz (2013), Schwartz (2013)). The schematic regulation of
the early polyadenylation by these latter factors is reported in (2.4.1).
The last, and maybe most important, interesting mechanism in reg-
ulating the pAE is mediated by the viral protein E2. This can be pro-
duce by both the early and late promoters. This latter produces E2 in
higher concentrations with respect the early promoter can do (as better
explained in the paragraph about the late promoter regulation). When
E2 reaches enough high concentrations, can repress the pAE, allowing
readthrough into the late region of the HPV genome, paving the way for
the production of the late mRNAs L1 and L2 (Johansson and Schwartz
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Figure 2.4.2: E2 negatively regulate the early promoter and inhibits the early
polyadenylation signal pAE, paving the way for L1 and L2 transcription.
(2013)). Nevertheless, we have to specify that E2 does not bind directly
to some pAE upstream or downstream binding site. It targets the gen-
eral factor CPSF30 that is required for polyadenylation of the majority of
the mRNAs in the cell (Johansson et al. (2012)). Therefore E2 acts as a
co-factor in inhibiting the early polyadenylation pAE. The main mecha-
nisms mediated by E2 are reported in fig. 2.4.2.
We recall the packaging of viral genomes and virus release phases to re-
port a last interesting fact linked to the polyadenylation regulation. Actu-
ally, the completion of the HPV life cycle requires to exit the cell from the
cell cycle, the expression of L2 and of L1 to allow genome packaging of
the viral genetic makeup. This definitely requires a post-transcriptional
regulation leading to transcripts that are polyadenylated at the late polyade-
nilation site (pAL) rather than the early site (pAE). This results in a switch
from the late promoter production of E1ˆE4 and E5 mRNAs (besides E1
and E2) to a production of E1ˆE4, L1 and L2 mRNAs (besides E1 and E2)
(Doorbar (2005), Doorbar et al. (2012)).
2.4.5 LATE GENES SPLICING REGULATION
The most important mechanism in regulating the late genes transcription
is probably the regulation of the early polyadenylation site pAE. Never-
theless, we report the other poorly understand additional regulations.
The expression of the late genes seems to be linked to the downregula-
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tion of different SR proteins during keratinocyte terminal differentiation.
L1 mRNA is exclusively spliced to the splice sites SD3632 and SA5639 (Jo-
hansson and Schwartz (2013), Schwartz (2013)). Conversly with the idea
that late genes are expressed when SR proteins are downregulated, it was
found out that SRSF9 and SRSF1 can enhance splicing to the 3’ splice site
SA5639, thus promoting L1 mRNA production. In a similar manner hN-
RNP A2/B1 cand induce HPV late gene expression, while hNRNP A1
inhibts late gene expression (Johansson and Schwartz (2013), Schwartz
(2013)).
SD3632 is suppressed by some splicing factors both upstream and down-
stream the splice site but they haven’t been identified yet. What is for sure
is that SD3632 is totally inhibited in in cervical cancer cells due to their
lack of differentiation (Johansson and Schwartz (2013), Schwartz (2013)).
L2 mRNA splicing regulation is understood even less than L1. It is
spliced from splice donor SD880 to splice acceptor SA3358. Its transla-
tion is repressed when the molecular complex composed by the hetero-
geneous nuclear ribonucleoprotein K (hnRNP K), poly(C)-binding pro-
tein 1 (PCBP1) and PCBP2 is bound to L2 coding region (Johansson and
Schwartz (2013), Schwartz (2013)).
We will not report the regulation of the late polyadenylation site (pAL)
since its biological knowledge is poor and its regulatory importance is
not well understood yet.
2.4.6 SPLICING FACTOR SRSF1
Given the importance of SRSF1 in regulating the major 3’ HPV splicing
site we dedicate a little section to its molecular biology.
SRSF1 is an important protein, of the Serine/Arginine-rich (SR) pro-
teins family, for the regulation of constitutive and alternative splicing of
cellular pre-mRNAs. It has an half life of about 1.5 h in T cells (Moulton
et al. (2014)). Overexpression of SRSF1 has been reported in various tu-
mors types and this has consequences for the alternative splicing profile
expressed in tumor cells.
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We have seen it is involved in the regulation of the HPV major 3’
SA3358 splice site and it is vital to effciently produce the regulatory el-
ements (E1 and E2) and the oncogenes (E6 and E4). However it is impor-
tant to drive E4 expression during the cellular differentiation, at expense
of E2 and E1, and to enhance the late genes (L1 and L2) transcription.
It was found that SRSF1 can autoregulate its own expression and this
involves multiple layers of post-transcriptional and translational control.
SRSF1 has a negative auto feedback and seems that this auto-regulatory
dynamics is quite slow, around 3 days (Sun et al. (2010)). Its autoregula-
tion is mediated by its alternative splicing regulation, translational con-
trol and potential contribution of some miRNAs not identified yet. In
particular, the 3’ UTR is necessary and sufficient for autoregulation (Sun
et al. (2010)). Probably nuclear SFRSF1 affetcs the mRNA composition of
its own transcript, which in turn affects how efficiently it is translated in
the cytoplasm (Sun et al. (2010)).
It can enhance splicing at SA5639 splicing site (Somberg and Schwartz
(2010)), controlling the expression of L1 mRNA in the late phases of the
viral life cycle. In particular, SRSF1 has a molecular weight of around 30
kDa and to have some effects on L1 regulation its molar concentration
should vary between 0.2 and 2 [nM] (Somberg and Schwartz (2010)).
Interestingly, it can also increase up to 2-3 fold upon epithelial differen-
tiation (Mole et al. (2009)), hence during the late promoter usage. In this
way it can up-regulate the expression of E4 and L1 during the late stages
of the infection.
2.4.7 LATE PROMOTER REGULATION
The discovery of the late promoter existence is pretty recent. The pa-
per reviews about the molecular biology of Human papillomavirus be-
gan to support the possibility of the existence of a such promoter around
the beginning of 2000 (Bernard (2002)). The late promoter, located in-
side the E7 ORF, controls the expression of the early genes, with the
exception of the oncogenes, and the late genes in host cells that have
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started terminal differentiation (Kukimoto et al. (2006)). The tight linkage
of viral late-gene expression and epithelial differentiation suggets that
differentiation-specific cellular factors are involved in the regulation of
the late promoter. Unfortunately, little information is available in litera-
ture about the identity of these factors and hence about the regulation of
the late promoter itself. In this paragraph we gather the most important
knowledge about this important promoter in order to have some minimal
insights in its transcriptional regulation in order to be able to develop at
least a first minimal model as we’ll see in chapter 4.
Most of the transcriptional regulators of the late promoter are not even
discovered yet. Nevertheless, it is pretty sure that one of the most im-
portant regulators is the C/EBPβ transcription factor (as previously re-
ported). It was found that C/EBPβ and its isoforms have different bind-
ing sites in the LCR where can help in repressing the eraly promoter (Gu-
nasekharan et al. (2012)) and two binding sites upstream the late pro-
moter region (Kukimoto et al. (2006)). When C/EBPβ binds to the late
promoter binding sites the late promoter transcription starts and can be
enhanced (Kukimoto et al. (2006), Gunasekharan et al. (2012)).
It has been shown that a rearrangement of chromatin occurs around
the late promoter region on epithelial differentiation (Longworth and
Laimins (2004)). C/EBPβ recruits SWI/SNF chromatin complex to the
upstream region of the HPV late promoter. This mechanism induces re-
arrangement of the nucleosome structure around the promoter, resulting
in the appearance of a nucleosome-free region where transcription ini-
tiates (Kukimoto et al. (2006), Kowenz-Leutz and Leutz (1999)). This is
an interesting molecular evidence since the chromating remodeling can
take time, hence the activation of the transcription mediated by C/EBPβ
could insert a delay in the activation of the late promoter.
The gene that encodes forC/EBPβ is intronless, hence it is transcribed
into a single mRNA that in turn, through the usage of alternative start
codons, gives rise to three isoforms: two full length C/EBPβ proteins
LAP and LAP* referred to as liver-enriched transcriptional activator pro-
teins and the LIP proteins, a short repressive isoforms. LIP lacks the
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transactivating domain found in the N terminus of LAP and LAP*, and is
unable to recruit histone acetyltransferases to activate transcription. Usu-
ally, LIP dimerizes with LAP in order to form the LIP-LAP heterodimer
acting as a strong repressor of the late promoter activity (Gunasekharan
et al. (2012)).
The most recent biological idea of a model about the transcriptional
regulation of the late promoter in HR-HPV 31 is the following one. In un-
differentiated cells, LIP-LAP heterodimers predominate over LAP-LAP
dimers, thus repressing the late promoter activity. Upon differentiation
LAP-LAP homodimers predominate, resulting in a strong activation of
the late promoter (Gunasekharan et al. (2012)). In fact, it was found that
C/EBPβ (in its LAP forms) is expressed in high levels in the middle and
upper stratum spinosum of the epithelium, where the cells are differen-
tiating and the HPV late genes are actively transcribed (Kukimoto et al.
(2006)).
We think we could extend the latter biological idea of the late promoter
regulation to the other HR-HPVs in particular to HPV-18 and -16 whose
structure is similar to HPV-31.
The late promoter produces the early genes with the exception of the
oncogenes in higher amount compared to what the early promoter does.
Moreover, there are experimental evidences indicating the slow increase
in time of E1 and E2 mRNAs produced by the late promoter. They could
take more than half of the total differentiation time to reach their max-
imum level (Ozbun and Meyers (1998)), where the differentiation time
is among 6 and 16 days for in vitro systems. This is consistent with
the regulatory mechanism of the late genes (L1 and L2) mediated by E2,
namely when E2 reaches enough concentration the early polyadenilation
site pAE is repressed, paving the way for the late genes production as
explained in section (2.4.4). The late genes are procued in the terminal
phase of the viral life cycle therefore there is the necessity of a delay in
their production and this is probably guaranteed by a slow rate increase
of E2 protein accumulation. This could be done by a stabilization of E2
protein mediated for example by the ubiquitin proteasome pathway as
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speculated in literature (King et al. (2011)). Another possible mechanism
to slowly reach high E2 protein levels consists in a slow increase to higher
level of its transcript, as well. As far as we know from the literature, the
latter mechanism seems to be the dominant one.
To slowly increase the transcripts conversion from the primary tran-
script we could speculate the possibility of a delay in the post- transcrip-
tional regulation. This is surely possible because of the SA3358 major
3’ splicing site is controlled by SRSF1, in turn activated by E2. Higher
the E2 level is, higher SRSF1 should be, resulting in an increased prob-
ability of SA3358 to be activated. This imply a higher conversion of E4
mRNA at the expense of E1 and E2 mRNAs. However, it is very likely
that the primary transcript in vivo is processed, converted and degraded
(the non converted part) with a very fast dynamics, from around 0.4 min-
utes (Audibert et al. (2002)) up to 1.2 hours (Hicks et al. (2005)). This is
the kinetics for eukaryotic cells splicing where the transcription is me-
diated by RNA pol II. Probably the virus will follows the same kinetics
in splicing regulation being a DNA virus, therefore it makes use of the
DNA replication machinery of the host cell and of the RNA pol II for its
transcriptional regulation. It is most likely the slow dynamical increase
in mRNAs produced by the late promoter is due to a slow modulation in-
crease in its activity. This is consistent with the dynamical behavior of its
major activator, the transcription factor C/EBPβ. It was found out that
C/EBPβ has an half life between 2 and 6 h (Sears and Sealy (1994). Nev-
ertheless, in an interesting experiment where was induced differentia-
tion for 6 days, mediated by calcium, was shown an increase in C/EBPβ
up to 4 days upon the beginning of differentiation (Maytin and Habener
(1998)). This evidence, compared with the transcription factor half-life,
suggests a presence of some kind of regulatory mechanism in delaying
the growth of C/EBPβ. In fact, recently was experimentally proven that
C/EBPβ-LAP*/LAP expression has a marked increase during differen-
tiation of monocytes. This increase can be delayed up to 3 days and is
essentially due to MEK-RSK-dependent signalling cascade (Huber et al.
(2015)). Interestingly, this regulation doesn’t occur at a transcriptional
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level but at post-translational regulation. This latter can strongly stabi-
lize LAP*/LAP proteins which levels in the absence of differentiation-
inducing stimuli are almost completely degraded in 12 h, while upon
differentiation the complex half-life was shown to be ≥ 24h (Huber et al.
(2015)). In some cases it takes up to 3 days to reach the steady state con-
dition. All the previous evidences where in the context of experiments
with a total duration of a week, we can observe that C/EBPβ takes most
of the differentiation time to reach its steady state level.
In a recent study it was found the importance of p63 protein (of the
oncosuppressor protein p53 family) in the activation of the late promoter.
p63 is one of the major regulator of the keratynocyte differentiation act-
ing in a crosstalk with Notch1, codifying for membrane proteins, another
important gene for achieving a good differentiation. These two impor-
tant proteins in the control of differentiation act in order to negatively
repress each other (Nguyen et al. (2006), Dotto (2009)). During normal
keratynocyte differentiation, p63 is decrease to barely detectable levels
and Notch is in high concentration. Although p63 levels also decrease
upon differentiation in HPV-positive cells, the p63 levels are retained at
higher levels than in normal keratinocytes. It is necessary a minimum
level of p63 to activate the late promoter (Mighty and Laimins (2011). It
was speculated the presence of a binding site for p63 to the late promoter
but it was not found so far. Nevertheless, this show the complexity of
late promoter regulation and even if, as far as we know from the current
biology, the major regulator seems to be C/EBPβ, the regulation is prob-
ably orchestrated by a lot of other co-factors that in turn could accelerate
or most likely delay the promoter activation.
2.5 INTEGRATED HPV
Persistent infections with high-risk human papillomaviruses (HPVs) in-
duce dysplastic lesions of the lower genital tract. Some of these lesions
eventually progress to invasive cancers, particularly of the uterine cervix.In
many advanced preneoplastic cervical lesions and most derived carcino-
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mas, HPV genomes are found to be integrated into the host cell chro-
mosomes.Although HPV integration seems to play an important role in
the progression of cervical dysplasia, the underlying mechanisms are still
unclear. DNA integration occurs in the presence of Double Strand Breaks
(DSBs). DSBs occur in regions of DNA in which the DNA repair process
has failed. Regions that harbour DNA instability, known as Chromo-
some Fragile Sites (CFSs), are distributed throughout the genome. Stud-
ies have reported an increased frequency of HR-HPV integration in re-
gions of DNA that contains CFSs (Raybould (2011), Schmitz et al. (2012),
Shin et al. (2014)).
Different studies have demonstrated that upon viral integration, differ-
ent parts of the HPV genome are disrupted; fragments containing E2, E4
and E5 ORFs are missing whereas the entire E1, E6 and E7 ORFs are inte-
grated and retained. These phenomena bring to an over expression of the
oncogenes since E2 is not produced anymore, resulting in a decreasing of
the negative feedback strength (Raybould (2011), Schmitz et al. (2012)).
2.6 ANTIVIRAL THERAPIES PROPOSALS
In the past years different antiviral therapy proposals were investigated.
It was proposed to target E1 and E2 fro the development of antiviral
agents. This is because of the replication of the viral genome is accom-
plished by the viral E1 and E2 proteins in concert with the cellular DNA
replication machinery (Bernard (2002)).
L1 and L2 are other possible targets since they are responsible for the
viral capsid formation. If we could stop their synthesis the viral DNA
wouldn’t have a protecting envelope in the extracellular environment, re-
sulting in the impossibility for the virus to spread out the infection (Seth
(2008)).
When the virus is integrated E2 ORFs are disrupted, resulting in an
overexpression of theE6 andE7 oncogenes. In these cases, targeting these
latter or the cellular proteins mediating their oncogenicity is clearly the
only antiviral possible approach. E7 from high-risk HPV types stimu-
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lates cells to undergo DNA synthesis by binding to Rb family members
and promoting their degradation whereas E6 prevents growth arrest and
apoptosis by promoting degradation of the p53 tumour suppressor. It has
been shown that downregulation ofE6 andE7 expression, by transfection
of a functional E2 or by small interfering RNAs, results in restoration of
the p53 and Rb pathways and the subsequent induction of cellular senes-
cence (Seth (2008)).
Another proposed therapy aims preventing assembly of the initialE1E2-
ori complex, in order to treat HPV lesions, in which the viral genome
is maintained in episomal form, such as condylomas. Assembly of the
E1E2ori complex depends on the interaction of E1 and E2 with DNA and
on a critical proteinprotein interaction between the TAD of E2 and the
C-terminal helicase domain of E1. Actually, a small molecule inhibitor of
the E1E2 protein interaction has been identified (?).
Finally it was proposed to target Sp1 human transcription factor, too,
due to its importance in activating the early promoter (Seth (2008)).
Even if different antiviral therapies were proposed during the past
years, there is no antiviral drug currently available for the treatment of
HPV associated diseases.
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A first deterministic model for
HPV early promoter regulation
In this chapter we present a first deterministic model of the early pro-
moter regulation, we have developed (Giaretta et al. (2015)). In what
follows we will report the model as in the paper with the same nomen-
clature.
To develop this model we have followed an heuristic approach without
really translating the biology in a set of biochemical reactions as reported
in chapter 1. We have mathematically translate the biology in terms of a
compartmental-logic approach (Cobelli Claudio (2008)). In this model we
consider the only early promoter regulation mediated by E1 and E2. We
account for the early promoter repression by the late promoter, modeling
mE1 as a forcing function.
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3.1 MODEL TOPOLOGY
The main mechanisms of HPV early promoter model designed here are
summarized and depicted in Fig. 3.1.1:
• The early promoter controls the primary polycistronic transcript x.
In the early stages of the viral life cycle, transcription of x generates,
by alternative splicing, mRNAs encoding all the early genes.
• The spliced mRNA E2 (mE2) encodes for E2 protein.
• The spliced mRNA E1 (mE1) encodes for E1 protein.
• E2 protein is the main regulator of the early promoter. It generates a
slight positive feedback effect when present in low concentration, a
negative feedback effect when present in high concentration, even-
tually inhibiting the early promoter activity.
• E1 acts with a positive regulation enhancing themE2 transcript and
with a negative regulation on E2 degradation, hence increasing its
stability.
3.2 MODEL EQUATIONS
Model equations, based on mass action, are:
dx
dt
= Sx(E2)− ks x (3.1)
dmE1
dt
= k1s(t) ks x− δ1mmE1 (3.2)
dmE2
dt
= k2s(E1) ks x− δ2mmE2 (3.3)
dE1
dt
= β1mE1 − δ1pE1 (3.4)
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Figure 3.1.1: Background knowledge on the HPV-16 gene circuit. Solid arrows
represent fluxes, dashed arrows controls. In blue the primary transcript, in green the
transcripts (and their respective proteins) of early non-oncogenes and in red the early
oncogenes.
dE2
dt
= β2mE2 − δ2p(E1)E2 (3.5)
dmEi
dt
= kis(E1)x− δimmEi, i = 4, 5, 6, 7 (3.6)
where the state variables are the concentrations [nM] of: the primary
transcript x, mRNAs mEi, i = 1,2,4,5,6,7, proteins E1 and E2.
Sx refers for the transcription of x enhanced by low values of E2 con-
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centration and repressed by elevated E2 concentration (Fig. 8.2.1A) (as
explained in chapter 2) according to 3.7.
Sx(E2) =

Sb +
a1 E
q1
2
λ
q1
1 +E
q1
2
E2 < E
th
2
a2 λ
q2
2
λ
q2
2 +(E2−Eth2 )q2
E2 > E
th
2
(3.7)
k1s represents the splicing flux for the mE1 transcript (Fig. ??B) and is
modeled as a time variant forcing function (3.8), tightly bounded to the
host cell differentiation program as reported in. In particular, the variable
t in is the time evolution associated to the keratinocytes differentiation
program.
k1s(t) =

kmin1s +
a3 tq3
λ
q3
3 +t
q3
t < th
a4 λ
q4
4
λ
q4
4 +(t−th)q4
t > th
(3.8)
k2s accounts for the splicing flux for the mE2 transcript (3.9) and it is
positively regulated by E1.
k2s(E1) =
(f1 − 1)1, kmin2s
1 + exp
(
λ5−E1
σ1
) + kmin2s (3.9)
δ2p is the degradation of E2 (3.10) which is negatively regulated by E1.
δ2p(E1) = (f2 − 1) δmin2
1− 1
1 + exp
(
λ6−E1
σ2
)
 (3.10)
β1 and β2 are the rate constants for E1 and E2 protein translation as-
sumed to be linearly related to the cognate mRNAs, see (3.4, 3.5). δim and
δip are degradations of transcripts and proteins (see (3.2-3.6)), assumed to
be first order processes with the only exception of δ2p, see (3.10).
We can observe that in this first attempt we have condensed, for sim-
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plicity, the late promoter higher production of E1 mRNA as a forcing
function (dependent on time) accounting for the E1 mRNA synthesis,
namely k1s(t).
In what follows the rate constants of the system. In the results chapter
we will show an in silico experiment in order to investigate the behavior
of this first HPV model.
Figure 3.2.1: A. Synthesis of the primary transcript regulated by E2 (7). B. Rate
constant for mE1 splicing regulated by cellular differentiation (8). C. E2 degradation
mediates by E1 concentration (9). D. Rate constant for mE2 splicing positively
regulated by E1 concentration (10).
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What we have reported here was just a first heuristic attempt in mod-
eling the basics viral regulatory network. In the next chapters we will
formally develop a novel and much more complete model in terms of
biochemical reactions and a stochastic and deterministic formulation.
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4.1 INTRODUCTION TO THE MODEL STRUCTURE
The model structure of the HPV gene regulatory network is made of two
main subsystems in cascade: early and late promoter. The early promoter
part is composed of a regulatory core managed byE1, E2 and the splicing
factors, and a secondary subsystem about the oncogenes control. These
latter don’t have any direct regulatory function on the regulatory core.
The late promoter is not controlled by the early promoter but is activated
by the differentiation program of the cell. Nevertheless the late promoter
is able to have a negative regulatory function on the early promoter.
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Figure 4.1.1: Schematic representation of the HPV regulatory network main struc-
ture.The virus has a regulatory core mediated by E1 and E2 inducing the transac-
tivation. The oncogenes are controlled by the regulatory core. The late promoter
negatively regulates the erly promoter but it is not regulated by this latter.
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In this chapter, as in chapter 5 and 6, we denote, where not differently
specified, with ”E” and ”L” apexes the chemical species derived by the
early and late promoter, respesctively. These species are in common be-
tween the two promoters and are E1, E2, DE1, DE2, E1E2. Let’s call this
notation, the ”EL” notation. This notation won’t be applied neither to
their degradations nor to the association/dissociations rate constants for
the multimeric complexes. This is because E1 and E2 have the same ki-
netics properties regardless the promoter.
4.2 MODELING THE ERALY PROMOTER
In this section we do not use the ”EL” notation to keep the treatment as
general as possible, since the early promoter can be controlled by the late
promoter, too.
In modeling the early promoter regulation we do not consider the LCR
regulation from the infected cell transcription factors (TFs) that can mod-
ulate the early promoter (EP) activity. We consider these latter in higher
concentration with respect to the viral transcripts and proteins, in order
to neglect their dynamical contributions. We assume two binding sites, in
place of four, for the E2 dimer (DE2) binding to EP. We also consider the
binding of the tetramer E1/E2 to the DE2 binding sites regulating in turn
the EP activity in the same mannerDE2 does. With two binding sites and
two molecules , which can bind them, we consider five possible promoter
states denoted by PEi ,i = 0, 1, 2, 3, 4. In particular, when the dimer DE2
and the tetramer E1E2 are in low concentration it is more likely there is
only one binding site occupied most of the time, conversely when they
are in high concentration both the binding sites will be occupied most of
the time.
In particular we will have a basal transcription when no molecule is
bound, a positive feedback when only a DE2 dimer molecule is bound
(i.e. low DE2 concentration) while a negative feedback when a E1E2
tetramer is bound to the replication origin, as argued in chapter 2, or
when two molecules are bound (two DE2 dimers or one DE2 dimer and
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one E1E2 tetramer). For simplicity, we do not distinguish which binding
site is occupied when just one molecule is bound (otherwise, we should
consider other two additional states) and which one is occupied by the
dimer or the tetramer when two mixed binding occurs. Additionally, in
our model DE2 or E1/E2 binding occurs non-cooperatively in this sys-
tem, meaning that the binding of an individual DE2 dimer or E1/E2
tetramer occurs entirely independently of the others.
The biochemical reactions for theEP states can be written as the markov
chain in Fig. 4.5.1. The state PEP0 accounts for basal transcription, state
PEP1 accounts for positive feedback (only one DE2 bound to the pro-
moter), and states PEP2 , PEP3 and EP4 account for negative feedback. In
particular, PEP2 takes account for two DE2 molecules bound to the pro-
moter, PEP3 the condition with E1E2 bound to the origin of replication
and able to negatively affect the promoter, and finally PEP4 accounts for
the mixed effects (i.e., two molecules bound, one DE2 dimer and one
E1E2 tetramer).
In the markov chain in Fig. 4.5.1 k1 and k5 are the forward rates to
transit from the basal transcription state, PEP0 , to the states PEP1 and PEP3
respectively, while k2 and k6 are the reverse rates for coming back to the
basal transcription state; k3 and k9 are the forward rates to transit from
the positive feedback state PEP1 to the negative feedback states PEP2 and
PEP4 , respectively, while k4 and k10 are the reverse rates for coming back
to PEP1 state. Finally, k7 is the forward rate to transit from the state PEP3 to
the PEP4 state and k8 is the correspondent reverse constant. In particular,
the forward rates are multiplied by the concentration of the DE2 dimer
or the E1/E2 tetramer to take into account for the positive and negative
feedback behaviors on the promoter.
The EP markov chain shows a closed cycle between the EP states (PEP0 →
PEP1 → PEP4 → PEP3 → PEP0 ) to maintain a physical equilibrium consis-
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Figure 4.2.1: Early promoter (EP ) Markov chain modeling the EP chemical states
modulated by the binding of DE2 and E1E2. In particular state P0 accounts for
basal transcription, state P1 accounts for the positive feedback and states P2, P3
and P4 account for the negative feedback.
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tency we have imposed the detailed balance condition
k9E1/E2 p
EP
1 = k10 p
EP
4 (4.1)
k7DE2 p
EP
3 = k8 p
EP
4 (4.2)
k5E1E2 p
EP
0 = k6 p
EP
3 (4.3)
k1DE2 p
EP
0 = k2 p
EP
1 (4.4)
where pEPi are the probabilities to be in the i − th state of the early pro-
moter markov chain in Fig.4.5.1.
Solving the previous system we can obtain the following constraint among
the EP markov chain parameters
k1 k6 k8 k9 = k2 k5 k7 k10 (4.5)
4.3 MARKOV CHAIN MODELS OF SPLICING SITE AND PRO-
MOTER SPLICING FACTOR
In this section we will not use the ”EL” notation since the splicing mod-
eling we present here is in common to both the promoters.
In chapter 2 we have seen the importance of HPV splicing regulation to
properly modulate the viral proteins during the entire life cycle, strictly
linked to the differentiation program of the infected cell. In this section
we model the splicing regulation related to the early promoter regulatory
”core”. We develop a minimal model with a unique splicing site (SS1)
condensing the SA3358 and SA2709 splicing sites given their mutual ex-
clusivity. We do not consider the regulation, at SA3358, of the remaining
splicing factors (e.g. SRSF9m SRSF3), because they are not important as
SRSF1; besides their temporal evolution is not well understood. Hence,
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in modeling this splicing mechanism we consider two states for SS1 de-
noted by SSi1, i = 0, 1. When SS1 is occupied (state SS11 ) we assume that
SRSF1 splicing factor is bound to SA3358 with SA2709 inactive, while
the opposite when SS1 is unoccupied (state SS01 ), as shown in Fig. ??. The
biochemical reactions for the SS1 states can be written as the following
two state markov chain
SS01 + SRSF1
k
SS1
on−−−−−⇀↽ −
k
SS1
off (E1)
SS11 (4.6)
where kSS1on and k
SS1
off (E1) are the rate constants for SRSF1 binding and
dissociation, respectively. kSS1off (E1) depends on the E1 concentration. Be-
cause it is clear that E1 enhances the E2 transcription but it is not clear
what mechanism by which this control is performed, we have assumed a
Hill functional response such that
kSS1off (E1) = k˜
SS1
off +
kˆSS1off E
nSS1
1
λ
nSS1
SS1
+ E
nSS1
1
(4.7)
where λSS1 is the Michaelis constant and denotes the E1 concentration
at which kSS1off (E1) is half its maximum value kˆ
SS1
off . The Hill coefficient,
nSS1 , determines the sharpness of the transition about λSS1 . Thus, higher
the concentration of E1, higher the probability to get SS11 , hence having
a higher E2 transcription. k˜SS1off represents a minimal basal detachment
rate constant for SS1 splicing site. From literature we know that when
the splicing occurs at SA3358 splicing site, actually even E1 is not tran-
scribed. Therefore we consider E1 controlled by SS1 splicing site in the
same manner E2 was. In this case we have to observe that E1 can posi-
tively regulates itself and even this thing was suggested in literature (see
chapter 2).
The HPV splicing regulation is very complex and not completely un-
derstood yet. The choice to make a minimal model of the splicing reg-
ulation considering only the splicing sites SA3358 and SA2709 is due to
their importance in modulating E2, representing the main regulator of
the early promoter. We consider the sole SRSF1 splicing factor as, for
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the current biological knowledge, it represents one of the most signifi-
cant splicing regulators thanks to its capability in driving the oncogenes
expression (we’ll model them in the next section) eventually diminishing
E2 transcription. Moreover, SRSF1 is in turn positively regulated by E2,
as shown in Fig. 3. All these features make SRSF1 an interesting molec-
ular actor in the context of the HPV post-transcriptional regulation, ca-
pable to directly connect this latter to the transcriptional regulation. To
model the SRSF1 activation we consider a two state promoter (P SRSF1),
denoted by the states P SRSF1i , i = 0, 1, with a positive regulation induced
by the E2 binding. The biochemical reactions for the P SRSF1 states can be
written as the following two state markov chain
P SRSF10
kSRSF1on (E2)−−−−−−−⇀↽ −
kSRSF1off
P SRSF11 (4.8)
where kSRSF1on (E2) and kSRSF1off are the rate constants controlling the two
states of the SRSF1 promoter. kSRSF1on (E2) is modeled as a Hill functional
response such that
kSRSF1on (E2) =
kˆSRSF1on E
nSRSF1
2
λnSRSF1SRSF1 + E
nSRSF1
2
(4.9)
where λSRSF1 is the Michaelis constant and denotes the E2 concentration
at which kSRSF1on (E2) is half its maximum value kˆSRFS1on . The Hill coef-
ficient, nSRSF1, determines the sharpness of the transition about λSRSF1.
Thus, higher the concentration ofE2, higher the probability to get P SRSF11 ,
hence having a higher SRSF1 transcription. We have modeled kSRSF1on (E2)
as a function of E2 because this latter doesn’t directly bind SRSF1 pro-
moter. It binds as a co-regulator to another transcription factors which in
turn binds the promoter (chapter 2, SRSF1 section).
The biochemical reactions relating the SRSF1 transcription are the fol-
lowing
∅ SmSSRSF1(P
SRSF1
i )−−−−−−−−−−−−⇀↽ −
δmSRSF1
mSRSF1 (4.10)
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where mSRSF1 denotes the SRSF1 mRNA, δmSRSF1 is the mSRSF1
degradation rate, and SmSRSF1(P SRSF1i ) is the mSRSF1 synthesis depen-
dent on the two promoter states
SmSRSF1(P
SRSF1
i ) =
{
sSRSF10 if P
SRSF1
i = P
SRSF1
0
sSRSF11 if P
SRSF1
i = P
SRSF1
1
(4.11)
when E2 is bound to the promoter (P SRSF11 state) mSRSF1 is produced
with sSRSF11 rate, otherwise (P SRSF10 state) mSRSF1 is produced with
sSRSF10 , with the constraint sSRSF11 > sSRSF10 to account for the positive
regulation induced by E2. The transcript is then translated into protein
∅ k
SRSF1
p mSRSF1−−−−−−−−−−⇀↽ −
δSRSF1
SRSF1 (4.12)
where production rate of the SRSF1 protein is assumed to be propor-
tional to mSRSF1 through the rate constant kSRSF1p , and δSRSF1 is the
SRSF1 degradation rate. It is known from literature that the SRSF1 auto
negative feedback is mostly implemented through both translational ef-
ficiency and post-transcriptional regulation. Since our purpose is to keep
a minimal model of the HPV post-transcriptional regulation, considering
that SRSF1 splicing regulation is complex and not well characterized in
the HPV context, we choose to consider the sole translational efficiency as
the principal mechanism accountable for the auto negative regulation on
SRSF1. To model this latter, we assume the formation of a heterodimer
between SRSF1 transcript and its own protein (as reported in chapter 2)
with the constraint of a higher degradation than SRSF1 transcript
∅ kfms−−−⇀↽ −
krms
mSRSF1/SRSF1
δSRSF1mp−−−−→ ∅ (4.13)
where kfms and krms are the association and dissociation rate constants
for the heterodimer mSRSF1/SRSF1, respectively; while δSRSF1mp repre-
sents its degradation rate, with the constraint δSRSF1mp > δmSRSF1 to model
the auto negative feedback on SRSF1 in terms of translational efficiency.
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In fig. 4.3.1 we show the schematic representation of the splicing regu-
lation we have modeled so far.
4.4 ADDITIONAL REACTIONS
Once the control part of the transcriptional and post-transcriptional reg-
ulation of the early promoter ”core” (i.e. promoters regulation and the
major splicing site regulations) has been modeled, what remains to model
are the biochemical reactions pertaining to the synthesis, degradation of
the viral transcripts, proteins and the dimers and tetramers formation,
dissociation and degradation. The early promoter regulates the produc-
tion of the early primary transcript pME
∅ SpME (P
E
i )−−−−−−→ pME (4.14)
where SpME (PEi ) is the early pME synthesis dependent on the EP states
SpME(P
E
i ) =

spM
E
0 if P
E
i = P
EP
0
spM
E
1 if P
E
i = P
EP
1
spM
E
2 if P
E
i ∈ {PEP2 , PEP4 }
spM
E
3 if P
E
i = P
EP
3
(4.15)
with the constraint spM
E
1 > s
pME
0 > s
pME
3 ≥ spM
E
2 to account for the
positive feedback (spM
E
1 ), the negative feedback (s
pME
2 and s
pME
3 account
for weak and strong negative feedback, respectively), and the basal tran-
scription (spM
E
0 ), to be consistent with the previous treatment about the
early promoter markov chain.
The primary transcript is then converted into its transcripts
pME
k
EE1
m (SS
i
1)−−−−−→ mEE1 (4.16)
pME
k
EE2
m (SS
i
1)−−−−−→ mEE2 (4.17)
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Figure 4.3.1: Minimal model of HPV post-transcriptional regulation. a. transcrip-
tional and translational regulation of the splicing factor SRSF1. E2 can co-activate
(by binding to a transcription factor TF) the SRSF1 promoter. The formation of the
tetramer mSRSF1/SRSF1 with a higher degradation with respect to mSRSF1 is
assumed to model the negative auto feedback on SRSF1 in terms of translational
efficiency mechanism. b. Modeling of the splicing site SS1 regulation relating to
the E2 and E1 post-transcriptional regulation through the SRSF1 binding. The off
rate is dependent on the E1 concentration to account for the E2 enhancement in the
presence of E1.
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mEE1
δ
EE1
m−−→ ∅ (4.18)
mEE2
δ
EE2
m−−→ ∅ (4.19)
pME
kEs−→ ∅ (4.20)
where mEE1 and mEE2 are the transcripts of EE1 and EE2 early genes tran-
scribed by the EP, respectively. kE
E
1
m (SS1) and k
EE2
m (SSi1) are the rate con-
stants relating to the primary transcript (pME) conversion into mEE1 and
mEE2 , respectively. In particular, k
EE1
m (SSi1) and k
EE2
m (SSi1) are dependent
on the splicing site (SSi1) state through the relationship
kE
E
1
m (SS
i
1) =
{
kˆ
EE1
m if SSi1 = SS
0
1
0 if SSi1 = SS
1
1
(4.21)
kE
E
2
m (SS
i
1) =
{
kˆ
EE2
m if SSi1 = SS
0
1
0 if SSi1 = SS
1
1
(4.22)
where kˆE
E
1
m and kˆ
EE2
m are the mE2 and mE1 conversion rates, respectively,
from the primary transcript when the splicing site is unoccupied (there-
fore splicing occurs at SA2709 splicing site). When SS1 is occupied then
k
EE1
m (SS1) = 0 and k
EE2
m (SS1) = 0. this is because both E1 and E2 are
not transcribed when splicing occurs at SA3358 splicing site. The rate kEs
takes into account for the conversion of the primary transcript into the
early transcripts we are not interested to model: EE4 , EE5 , EE6 , EE7 . How-
ever, we will model the oncogenes in the next section. The transcripts are
then translated into proteins
∅ k
E1
p mE
E
1−−−−−→ EE1 (4.23)
EE1
δ
E1
p−−→ ∅ (4.24)
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∅ k
EE2
p mE
E
2−−−−−−→ EE2 (4.25)
EE2
δ
E2
p−−→ ∅ (4.26)
where EE1 and EE2 are the proteins translated from the transcripts mEE1
and mEE2 , respectively. The translation rates for these latter are propor-
tional to their transcripts through the constants kE
E
1
p and k
EE2
p , respectively.
δE1p and δE2p are the degradation rates forEE1 andEE2 , respectively. EE1 and
EE2 can form dimers DEE1 and DEE2 , respectively, as well as these latter
can form a tetramer E1EE2
EE1 + E
E
1
k
DE1
f−−−⇀↽ −
k
DE1
r
DEE1
δDE1−−−→ ∅ (4.27)
EE2 + E
E
2
k
DE2
f−−−⇀↽ −
k
DE2
r
DEE2
δDE2−−−→ ∅ (4.28)
DEE1 +DE
E
2
k
E1E2
f−−−⇀↽ −
k
E1E2
r
E1E
E
2
δE1E2−−−→ ∅ (4.29)
where kDE1f , k
DE1
r are the forward and reverse rate constants regarding
the formation of the dimer DEE2 , respectively and k
DE2
f , k
DE2
r are the
forward and reverse rate constants regarding the formation of the dimer
DEE1 , respectively. k
E1E2
f and k
E1E2
r are the forward and reverse rate con-
stants regarding the formation of the tetramer E1EE2 , respectively; δE1E2 ,
δDE2 and δDE1 are the degradation rates for the tetramer and the dimers,
respectively. To take into account of the stabilization effect mediated by
EE1 on EE2 , we have assumed the constraint δE1E2 < δE2 .
4.4.1 MODELING THE ONCOGENES
So far, we have modeled the only regulatory ”core”. It accounts for only
the two genes E1 and E2, since, as far as we know from literature, they
seem to be the only elements, originating from the virus, capable to reg-
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ulate the early promoter activity. About the splicing regulation we have
made the choice to design a minimal model of just the major 3’ splicing
site SA3358 (in turn controlled by E2) and of the splicing site SA2709.
These latter were modeled as a unique splicing site thanks to their mu-
tual exclusivity.
In this section we present a model extension, to the early promoter
”core”, in order to account for the oncogenes regulation. We observe that
the oncogenes, as far as we know from the current biology, do not have
any regulatory roles on the early promoter. This means we don’t have to
change the early promoter markov chain but simply update the model
for the post-transcriptional regulation.
We won’t model neither E4 nor E5 genes. About E5, it is still a very elu-
sive gene and, even if its function is nowadays clearer (especially about
its role in the apoptosis pathway) than in the past, its transcriptional reg-
ulation is not understood at all. About E4 the reason is that its main role
is during the late phase of the infection when produced by the late pro-
moter and its contribution to the early phase is negligible.
To model the splicing of the oncogenes we consider two splicing sites.
The first is actually SS1. In fact, when SS1 is unoccupied we have the al-
ready modeled the production of E1 and E2, and now when it is occupied
we will consider the production of E6 and E7.
Nevertheless, E6 and E7 transcripts are also spliced between the splic-
ing donor site SD226 and the splicing acceptor site SA409 (chapter 2). E6
and E7 mRNAs are not spliced at the same time: E7 is transcribed by
retention of the first intron between SD226 and SA409, while E6 is the
mRNA which remains unspliced between SD226 and SA409.
To model the alternative production of the oncogenes we need a sec-
ond splicing site, SS2, designed as a two state model. The new post-
transcriptional regulation model is shown in Fig. 4.4.1.
Thanks to the alternative production of the oncogenes, we assume that
if SS2 site is occupied, then we have the retention of the first intron, be-
tween SD226 and SA409, with the consequent production of E7 mRNA.
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Figure 4.4.1: Same model for the splicing regulation presented before, with the
addition of SS2 splicing site to model their alternative production.
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Conversly, when the splicing site is not occupied, E6 mRNA is produced.
In this model we don’t consider the modulation effect of the heteroge-
neous nuclear ribonucleoprotein hnRNP A1 and A2 that can stimulate
the splicing between SD226 and SA409 (chapter 2) since their modula-
tion during time is not understood yet. Probably they account for a finer
modulation of SS2. Anyway, we can get a good qualitative behavior even
without considering their possible co-regulations.
The biochemical reactions for the new splicing site SS2 can be written
as the following two state markov chain
SS02
k
SS2
on−−−⇀↽ −
k
SS2
off
SS12 (4.30)
where SS02 and SS12 are two states (free and occupied, respectively) of the
splicing site SS2, and where kSS2on and koffSS2 are the rate constants for
switching from the unoccupied state to the occupied one and vice versa,
respectively.
The conversion rates of the primary transcript into E6 and E7 mRNAs
are now function of both SS1 and SS2 splicing sites and are written as
follows
kE6m (SS
i
1, SS
i
2) =
{
0 if SS01 = SS
0
1
kˆE6m if SS
i
1 = SS
1
1 ∧ SSi2 = SS02
(4.31)
kE7m (SS
i
1, SS
i
2) =
{
0 if SSi1 = SS
0
1
kˆE7m if SS
i
1 = SS
1
1 ∧ SSi2 = SS12
(4.32)
in the previous definitions a necessary condition for the oncogenes is the
activation of the splicing site SA3358, hence the site SS1 has to be occu-
pied by the SRSF1 splicing factor in order to drive the oncogene produc-
tion, as reported in (chapter 2).
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4.5 MODELING LATE PROMOTER
The late promoter (LP) is quite intriguingly since it is controlled by the
differentiation program of the cell, hence by forcing functions exogenous
to the viral system.
In modeling the late promoter we consider the two C/EBPβ dimer
binding sites in order to regulate its activity (chapter 2). We do not con-
sider the binding of the differentC/EBPβ isoforms (LIP, LAP, LAP* ,(sec-
tion late promoter chapter 2)) to the promoter, since we won’t model their
translation (as specified below). We do not account for other regulators
or co-regulators of the late promoter such as p63. This is because all the
other possible regulatory factors are not known or their action mecha-
nism is not currently understood. We do not consider any auto-feedback
effect on the promoter since there is no evidence in the literature.
The late promoter produces its transcripts very slowly (Ozbun and
Meyers (1998)) following the differentiation program of the infected cell.
We also know that C/EBPβ recruits the SWI/SNF chromatin complex
to the upstream region of the late promoter. This mechanism induces re-
arrangement of the nucleosome structure around the promoter, resulting
in the appearance of a nucleosome-free region where transcription initi-
ates. This recruitment, mediated by C/EBPβ, could insert also a quite
strong delay (Kaern et al. (2005)) in the late promoter activation as well
as other possible regulators or co-regulators could induce. To account for
these possible delays, in the upstream promoter regulatory region, we
will consider an intrinsic delay in the promoter markov chain as we’ll see
later.
With two binding sites and only the C/EBPβ dimer that can bind
to them, we consider a three state promoter. The states are denoted by
PLi , i = 0, 1, 2, as shown in the following markov chain
PLP0 +DC/EBPβ
kLP1−−⇀↽−
kLP2
pLP1 +DC/EBPβ
kLP3−−⇀↽−
kLP4
PLP2 (4.33)
where DC/EBPβ is the C/EBPβ dimer that binds to the late promoter.
73
Stochastic Model Development
DC/EBPβ condenses the possible LAP-LAP homodimers or LAP-LAP*
heterodimer that can bind the promoter. kLP1 and kLP2 are the forward
rates to transit from the state PLP0 to PLP1 and from PLP1 to PLP2 , respec-
tively. While, kLP3 and kLP4 are the backward rates to transit from PLP1
to PLP0 and from PLP2 to PLP1 , respectively. We assume a basal or absent
transcription (PLP0 state) when no DC/EBPβ molecule is bound, an in-
termediate transcription when just one site is occupied (PLP1 state) and a
high transcription level when both theDC/EBPβ binding sites are occu-
pied (PLP2 state). A scheme of the later promoter model is shown in fig.
4.5.1.
The parameters of the late promoter markov chain will be tuned in
order to orchestrate the probabilities of each state to satisfy an intrinsic
duringDC/EBPβ slow transient growth, as we’ll see in the results chap-
ter. In this way, the parameters will not account for only the DC/EBPβ
binding but they will condense other possible delays that could occur in
the promoter activation as previously discussed (e.g. C/EBPβ mediated
rearrangement of the nucleosome structure).
4.6 SPLICING SITES, SPLICING FACTORS AND POLYADENY-
LATION SITES
The late promoter can produce all the early genes with the exception of
the oncogenes. Morover during the differentiation phase, E4 is produced
at higher levels due to its importance in breaking down the cell mem-
brane. Since E4 is driven by SA3358 in a mutually exclusive manner than
respect to E2 and E1, then the splicing markov chain regulating the late
promoter early genes is the same of the early promoter with the only SS1
splicing site (late promoter does not produce the oncogenes). However,
E1 co-regulation, on the splicing site, is now dependent on the total E1
produced by both the promoters. Hence we can rewrite the equation 4.6
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Figure 4.5.1: Late promoter model. C/EBPβ forms a dimer that is delayedto
account for its strong stabilization mediated by different pathways. Its dimer can
activate the late promoter by binding to it.
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as follows
SS01 + SRSF1
k
SS1
on−−−−−−−−⇀↽ −
k
SS1
off (E1
TOT )
SS11 (4.34)
where all the other parameters and variables are the same as we have
previously reported. kSS1off (E1
TOT ), modeled as a hill function, depends
onE1TOT = E1E+E1L, whereE1E andE1L are theE1 proteins produced
by the early and late promoter, respectively. We consider the contribution
of the early promoter because, even if it is down regulated by the late one,
it probably does not completely turn off at all. It is just more repressed.
SRSF1 promoter markov chain, reported in the equation ?, is rewritten
as follows
P SRSF10
kSRSF1on (E
TOT
2 )−−−−−−−−−⇀↽ −
kSRSF1off
P SRSF11 (4.35)
we see that the markov chain is the same as reported for the early pro-
moter with the exception that we consider the total E2, E2TOT , E2E +
E2L.
All the other reactions about the mSRSF1, SRSF1, mSRSF1/SRSF1
synthesis and degradation are the same we have reported in the previous
sections.
About the late genes we know that when E2 is in enough high con-
centration the early polyadenylation site is inhibited, paving the way for
L1 and L2 production. In a similar manner hNRNP A2/B1 cand induce
HPV late gene expression, while hNRNP A1 inhibts late gene expression.
Moreover, splicing at SA5639 is enhanced by SRSF1 and SRSF9, result-
ing in the production of L1 mRNA. While L2 translation is repressed
when the molecular complex composed by the heterogeneous nuclear
ribonucleoprotein K (hnRNP K), poly(C)-binding protein 1 (PCBP1) and
PCBP2 is bound to L2 coding region.
In modeling L1 and L2 regulation we won’t consider all the previous
reported mechanisms. This is because they are mediated by factors ex-
ogenous to the viral system and because their time evolution and co-
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regulation is not still clear. We will adopt the same approach we have
done in modeling the early promoter. Therefore we assume all these fac-
tors in high concentration with respect to the viral endogenous regula-
tion, in order to neglect their dynamics.
Hence, we will model the early polyadenylation (pAE) switch medi-
ated by E2 in order to start producing the late transcripts. We know from
literature that E2 does not bind directly to pAE. It binds to CPSF30 that, in
turn, regulates pAE. We won’t model CPSF30 dynamics and its binding
to pAE, but just the E2 mediated control given its crucial function. Be-
sides, we won’t model FIP1, hnRNP H and CSTF4 co-regulation at pAE
for the same reason we argued before.
Moreover we won’t explicitly consider the SRSF1 positive regulation
in splicing at SA5639. This because the E2 regulation at pAE should be
enough, since E2 is inside a feedback loop with SRSF1, as well.
We have done several simplifying assumption but this is in line to keep
the model structure as minimal as possible, modeling only the major en-
dogenous regulatory mechanisms.
The polyadenylation two state markov chain is modeled as follows
pAE0
kpAEon (E2
TOT )−−−−−−−−⇀↽ −
kpAEoff
pAE1 (4.36)
where pAE0 corresponds to early polyadenylation signal activation, thus
without the L1 and L2 mRNAs production, while pAE1 regards the in-
hibition of pAE, thus permitting the late genes transcription. kpAEoff and
kpAEon (E2
TOT ) are the pAE activation and inhibition rate constants, re-
spectively. To model kpAEon (E2TOT ) we have assumed a Hill functional
response such that
kpAEon (E2
TOT ) =
kˆpAEon (E2
TOT )npAE
λ
npAE
pAE + (E2
TOT )npAE
(4.37)
where λpAE is the Michaelis constant and denotes the E2TOT concentra-
tion at which kpAEon (E2TOT ) is half its maximum value kˆpAEon . The Hill coef-
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ficient, npAE , determines the sharpness of the transition about λpAE . Thus,
higher the concentration of E2TOT is, higher the probability to get pAE1
is, paving the way for the late mRNAs production.
In fig. 4.6.1 we report the whole model accounting the post-transcriptional
regulation (splicing and polyadenylation).
4.6.1 ADDITIONAL REACTIONS
As we have done for the early promoter, after we have modeled the con-
trol part of the transcriptional and post-transcriptional regulation, what
remains to model are the biochemical reactions pertaining to the synthe-
sis, degrdation of the transcripts, proteins and the dimers formation, dis-
sociation and degradation.
These reactions will be nearly same of the early promoter with some
differences. Let’s report the remaining biochemical reactions.
The late promoter regulates the production of the late primary tran-
script pML
∅ SpML (P
L
i )−−−−−−→ pML (4.38)
where SpML (PLi ) is the pML synthesis dependent on the LP states
SpML(P
L
i ) =

spM
L
0 if P
L
i = P
L
0
spM
L
1 if P
L
i = P
L
1
spM
L
2 if P
L
i = P
L
2
(4.39)
with the constraint spM
L
0 < s
pML
1 < s
pML
2 to account for the gradual activa-
tion of the promoter by the slow increase of its main regulator C/EBPβ.
The late primary transcript is then converted into its transcripts
pML
kE1
L
m (SS
i
1)−−−−−−→ mE1L (4.40)
pML
kE2
L
m (SS
i
1)−−−−−−→ mE2 (4.41)
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Figure 4.6.1: Same model of the splicing control we have reported so far, with the
addition of the early polyadenylation site, pAE. When E2 is in high concentration the
polyadenylation site is inhibited, paving the way for L1 and L2 mRNAs.
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pML
kE1ˆE4
L
m (SS
i
1)−−−−−−−−→ mE1ˆE4 (4.42)
pML
kL1m (pAEi, SS
i
3)−−−−−−−−−→ mL1 (4.43)
pML
kL2m (pAEi, SS
i
3)−−−−−−−−−→ mL2 (4.44)
mE1L
δE1
L
m−−−→ ∅ (4.45)
mE2L
δE2
L
m−−−→ ∅ (4.46)
mE4L
δE1ˆE4
L
m−−−−−→ ∅ (4.47)
mL1L
δL1m−−→ ∅ (4.48)
mL2L
δL2m−−→ ∅ (4.49)
pML
kLs−→ ∅ (4.50)
where mE1L, mE2L, mE4L, mL1 and mL2 are the transcripts of E1L,
E2L andE1ˆE4L early genes produced by the late promoter, respectively,
while mL1 and mL2 are the transcripts of L1 and L2 late genes produced
by the late promoter, respectively. kE1m (SSi1), kE2m (SSi1), kmE1ˆE4m (SSi1),
kL1m (pAEi, SS
i
3) and kL2m (pAEi, SSi3) are the rate constants relating to
the late primary transcript (pML) conversion intomE1L,mE2L,mE1ˆE4L,
mL1 and mL2, respectively. The last four reactions account for the tran-
scripts degradation and δE1Lm , δE2
L
m , δE1ˆE4
L
m , δL1m and δL2m are the degrada-
tion constant rates for mE1L, mE2L, mE4L, mL1 and mL2, respectively.
The conversion rates of the early genes, transcribed from the late pre-
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mRNA, are dependent on the splicing site (SSi1) state through the rela-
tionships
kE1
L
m (SS
i
1) =
{
kˆE1
L
m if SS
i
1 = SS
0
1
0 if SSi1 = SS
1
1
(4.51)
kE2
L
m (SS
i
1) =
{
kˆE2
L
m if SS
i
1 = SS
0
1
0 if SSi1 = SS
1
1
(4.52)
kE4
L
m (SS
i
1) =
{
0 if SSi1 = SS
0
1
kˆE4
L
m if SS
i
1 = SS
1
1
(4.53)
where kE1Lm (SSi1), kE2
L
m (SS
i
1) and kE2
L
m (SS
i
1) are themE1L,mE2L andmE1ˆ4L
conversion rates, from the late primary transcript, respectively. From the
previous formulae we can observe that EL1 and EL2 mRNAs are produced
when the splicing site is free (splicing at SA2709 splicing site), while
E1ˆE4 mRNA is produced when the splicing site is occupied (splicing
at SA3358 splicing site).
Let’s observe that the oncogenes are not considered since they are not
transcribed from the late promoter.
The conversion rates of the late genes are dependent on the early polyadeny-
lation site, pAE, as reported below
kL1m (pAEi) =
{
0 if pAEi = pAE0
kˆL1m if pAEi = pAE1
(4.54)
kL2m (pAEi) =
{
0 if pAEi = pAE0
kˆL2m if pAEi = pAE1
(4.55)
where L1 and L2 are transcribed with conversion rates kˆL1m and kˆL2m when
the early polyadeylation signal is inhibited (pAE1).
The rate kLs , in formula 4.50, takes into account for the conversion of
the late primary transcript into the early transcripts we are not interested
to model: EL5 . From the literature, when the production of the late genes
starts there is also a switch from the transcription of E1ˆE4L and EL5 (be-
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sides EL1 and EL2 ) to the transcription of E1ˆE4L, L1 and L2. Therefore to
account for this latter mechanism with the following definition.
kLs (pAEi) =
{
kˆLs if pAEi = pAE0
0 if pAEi = pAE1
(4.56)
where kˆs is the value for the conversion of the primary transcript into E5
when the polyadenylation site is not inhibited, otherwise kLs (pAE) = 0
and EL5 is not produced anymore.
The transcripts are then translated into proteins
∅ k
EL1
p mE
L
1−−−−−→ EL1 (4.57)
EL1
δ
EL1
p−−→ ∅ (4.58)
∅ k
EL2
p mE
L
2−−−−−→ EL2 (4.59)
EL2
δ
EL2
p−−→ ∅ (4.60)
∅ k
E1ˆE
L
4
p mE1ˆE
L
4−−−−−−−−−−→ E1ˆEL4 (4.61)
E1ˆE
L
4
δ
E1ˆE
L
4
p−−−−→ ∅ (4.62)
∅ k
L1
p mL1−−−−−→ L1 (4.63)
L1
δ
L1
p−−→ ∅ (4.64)
∅ k
L2
p mL2−−−−−→ L2 (4.65)
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L2
δ
L2
p−−→ ∅ (4.66)
where EL1 , EL2 , E1ˆEL4 , L1 and L2 are the proteins translated from the
transcripts mEL1 , mEL2 , mE1ˆEL4 , mL1 and mL2, respectively. The trans-
lation rates for these latter proteins are proportional to their transcripts
through the rate constants kE
L
1
p , k
EL2
p , kE1ˆE4p , kL1p and kL2p , respectively. δ
EL1
p ,
δ
EL2
p , δ
E1EL4
p , δL2p and δL1p are the degradation rates for EL1 , EL2 , E1EL4 , L1
and L2, respectively. The biochemical reactions regarding the formation
of the DE1 and DE2 dimers and of the E1E2 tetramer are the same of that
explained in the early promoter section, just with the proteins produced
by the late promoter, and are the following.
EL1 + E
L
1
k
DE1
f−−−⇀↽ −
k
DE1
r
DEL1
δ
DEL1−−−→ ∅ (4.67)
EL2 + E
L
2
k
DE2
f−−−⇀↽ −
k
DE2
r
DEL2
δ
DEL2−−−→ ∅ (4.68)
DEL1 +DE
L
2
k
E1E2
f−−−⇀↽ −
k
E1E2
r
E1E
L
2
δ
E1E
L
2−−−→ ∅ (4.69)
where kDE1f , k
DE1
r are the forward and reverse rate constants regarding
the formation of the dimer DEL2 , respectively and k
DE2
f , k
DE2
r are the
forward and reverse rate constants regarding the formation of the dimer
DEL1 , respectively. k
E1E2
f and k
E1E2
r are the forward and reverse rate con-
stants regarding the formation of the tetramer E1EL2 , respectively; δE1EL2 ,
δDEL2 and δDEL1 are the degradation rates for the tetramer and the dimers,
respectively. To take into account of the stabilization effect mediated by
EL1 on EL2 , we have assumed the constraint δE1E2 < δE2 .
Finally, we model the exogenous forcing function, to the viral system,
depicted by the C/EBPβ transcription factor. It is very likely C/EBPβ
has a low stochasticity due to its very low degradation, and further sta-
bilization by other exogenous pathways. Moreover its differentiation-
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dependent regulation is not well characterized yet. We need it by slowly
modulate the late promoter activity during the cell differentiation so, in
the first place, we choose to model C/EBPβ as a simple birth and death
process, without modeling its promoter dynamics. We also choose to do
not distinguish its transcripts and proteins considering them as a unique
entity.
The synthesis and degradation of C/EBPβ are
∅ sC/EBPβ−−−−−→ C/EBPβ (4.70)
C/EBPβ
δ
C/EBPβ
p−−−−−→ ∅ (4.71)
where sC/EBPβ and δ
C/EBPβ
p are the synthesis and degradation rates of
C/EBPβ, respectively.
We know thatC/EBPβ undergoes post-translational modifications that
generate different isoforms (LIP, LAP, LAP*) that can associate together
and regulate the late promoter. We condense all these by modeling the
dimerization of C/EBPβ and assuming it can only activate the late pro-
moter, that is actually we are interested in when we want to describe the
late viral life cycle.
The dimerization reactions are
C/EBPβ + C/EBPβ
k
C/EBPβ
f−−−−−⇀↽ −
k
C/EBPβ
r
DC/EBPβ
δ
DEL2−−−→ ∅ (4.72)
where DC/EBPβ is the C/EBPβ dimer and when kC/EBPβf and k
C/EBPβ
r
are the forward and revers rate constants in forming the dimer.
We know from literature that C/EBPβ has a very low degradation.
However it is strongly stabilized by different mechanisms in order to
slowly increase during the cellular differentiation as well as other impor-
tant factors involved in the differentiation, like p63. We do not model
all the complex mechanisms that stabilize C/EBPβ because we want
to maintain a model structure as simple as possible. A trade-off among
these needs could be satisfied by condensing the numerous and complex
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mechanisms interacting with C/EBPβ with the insertion of an explicit
delay between the C/EBPβ dimer and its binding to the promoter. To
do this we can model a chain of delay reactions each of them with the syn-
thesis rate equal to the degradation rate in order to have a ”pure” delay
(i.e. the steady state will be the same of the non delayed DC/EBPβ). To
account for a strong delay the rate constants can be made small enough.
The delay chain is the following
DC/EBPβ
kdelay−−−→ DC/EBPβd1 kdelay−−−→ DC/EBPβd2 kdelay−−−→ DC/EBPβd3
kdelay−−−→ DC/EBPβd4
(4.73)
where kdelay is the delay rate constant for the delay chain, andDC/EBPβdelayedi
is DC/EBPβ after ”i” delays.
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5
Master Equation
All the chemical species of the system are random variables, because the
chemical reactions that change the state of the system occur randomly in
time. If we assume that the dwell time in any particular chemical state
of the system is exponentially distributed, then the system satisfies the
Markov property (Kepler and Elston (2001), Scott (2013)). Physically, this
means that the time evolution of the system is determined solely by its
current state and is independent of its past. The Markov property allows
us to write down a Master Equation (ME) for the time evolution of the
systems probabilities (VanKampen (2007), Gardiner (2009)).
The Master Equation of the whole system is quite complex and it is not
possible to solve it analitically. The simulations we’ll show in the results
chapter 8, will be performed by using the Gillespie’s algorithm: This lat-
ter reproduces the exact numerical solution of the Master Equation re-
lated to the whole system. However, to get some analytical insights, a
treatable simulation of the promoters probability distribution and a quite
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good and manageable deterministic version of the stochastic model, we
account for a simplified version of the master equation considering the
stochasticity only associated to the promoters, splicing sites and ploy-
adenylation sites, that are the major stochastic sources. This will be use-
ful to design the promoters and properly tune their parameters in order
to fit the available data set we will report in chapter 7. Moreover, by us-
ing the steady state probabilities of this simplified master equation we
will easily get a quasi-equilibrium approximation to the system in order
to get a possible deterministic formulation, as we will see in chapter 6.
5.1 MASTER EQUATION OF THE EARLY PROMOTER ”REGU-
LATORY CORE”
At any given time t, the state of the system, described by the biochemical
reactions, reported in the previous chapter, is specified by the random
vector
X =

PEi
P SRSF1i
SSi1
pM
mE1
mE2
E1
E2
DE1
DE2
E1E2

=
[
XC
XS
]
(5.1)
where XC is the sub-vector that corresponds to the states of the control
markov chains regarding the promoters and the splicing sites, while XS
is the sub-vector which is inherent the ”standard” chemical species.
The whole master equation would describe the time evolution of the
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probabilities of the entire state space
pX
C
XS (t) = p
PEi , P
SRSF1
i , SSi
pM,mE1,mE2, E1, E2, E1E2, DE2
(t) =
Pr
[
pM(t) = pM, mE1(t) = mE1, mE2(t) = mE2, E1(t) = E1
E2(t) = E2, E1E2(t) = E1E2, DE2(t) = DE2, P
E
i (t) = P
E
i
P SRSF1i (t) = P
SRSF1
i , SSi(t) = SSi
]
(5.2)
We will simulate the whole system with the aid of the Gillespie’s syochas-
tic algorithm, nevertheless, as we said in the chapter introduction, in this
section we will consider a simplified master equation of the early pro-
moter, the SRSF1 promoter and SS1 splicing site.
The ME of the early promoter markov chain in fig. 4.5.1 is described by
the following differential equations system
dpEP0
dt
= −(k1DE2 + k5E1E2) pEP0 + k2 pEP1 + k6 pEP3
dpEP1
dt
= −(k2 + k3DE2 + k9E1E2) pEP1 + k1DE2 pEP0 + k4 pEP2 + k10 pEP4
dpEP2
dt
= −k4 pEP2 + k3DE2 pEP1
dpEP3
dt
= −(k6 + k7DE2) pEP3 + k5E1E2 pEP0 + k8 pEP4
dpEP4
dt
= −(k8 + k10) pEP4 + k7DE2 pEP3 + k9E1E2 pEP1
(5.3)
where pEn denotes the probability of being in chemical state PEn at time t.
The initial conditions are pE0 = 1 and pEi = 0 for i 6= 0, so we start from
the basal transcription, coherently with literature. Where, since the states
are mutually exclusive, we can write, by applying the total probability
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theorem the constraint Pr
[⋃4
i=0 P
E
i (t)
]
=
∑4
i=0 p
E
i (t) = 1, ∀ t ≥ 0, since
the EP states are mutually exclusive (PEi (t) ∩ PEj (t) = ∅, i 6= j, ∀ t ≥ 0)
hence the probabilities of the intersection of two or more states are zero.
The ME of the SRSF1 promoter is
dpSRSF10
dt
= −kSRSF1on (E2) · pSRSF10 + kSRSF1off pSRSF11
dpSRSF11
dt
= kSRSF1on (E2) · pSRSF10 − kSRSF1off pSRSF11
(5.4)
where pSRSF1n denotes the probability of being in chemical state P SRSF1n at
time t. The initial conditions are pSRSF10 = 1 and pSRFS11 = 0, since at the
beginning E2 protein, positively regulating this promoter, is not present.
The two states of SRSF1 promoter are mutually exclusive, hence
Pr
[
P SRSF10 (t) ∪ P SRFS11 (t)
]
= pSRSF10 (t) + p
SRSF1
1 (t) = 1, ∀ t ≥ 0.
Finally, the ME of the SS splicing site is the following
dpSS10
dt
= −kSS1on SRSF1 pSS10 + kSS1off pSS11
dpSS11
dt
= kSS1on SRSF1 p
SS1
0 − kSS1off pSS11
(5.5)
where pSS1n denotes the probability of being in chemical state P SS1n at time
t. The initial conditions are pSS10 = 1 and p
SS1
1 = 0. This is coherent with
literature because at the beginning we have the only production of E1
and E2.
As in the previous two cases, the two states of SS1 splicing site are mutu-
ally exclusive, hence Pr
[
P SS10 (t) ∪ P SS11 (t)
]
= pSS10 (t) + p
SS1
1 (t) = 1, ∀ t ≥
0.
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5.1.1 MASTER EQUATION WITH ONCOGENES
Considering the oncogenes the state of the system for any time is the
following random vector
X =

PEi
P SRSF1i
SSi1
SSi2
pM
mE1
mE2
E1
E2
DE1
DE2
E1E2
mE6
mE7
E6
E7

=
[
XC
XS
]
(5.6)
where we have added to the XC sub-vector the SS1 splicing site random
variable.
We are interested in the only control part of the state. This latter is
exactly the same of the early promoter regulatory core with the only ad-
dition of the splicing site SS2. Then the ME will be the same of before,
hence the equations 5.3, 5.4 and 5.5, with the addition of the master equa-
tion for SS2 splicing site
dpSS20
dt
= −kSS2on · SRSF1 · pSS20 + kSS2off pSS21
dpSS21
dt
= kSS2on · SRSF1 pSS20 − kSS2off · pSS21
(5.7)
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where pSS2n denotes the probability of being in chemical state P SS2n at time
t. The initial conditions are quite irrelevant in this case because SS2 just
controls among E6 and E7 which of them has to be generated.
5.2 LATE PROMOTER MASTER EQUATION
At any given time t, the state of the system described by the biochemical
reactions modeling the late promoters (reported in chapter 4), is specified
by the random vector
X =

PLi
P SRSF1i
SSi2
SSi3
pAEi
PCEBPi
pML
mE1L
mE2L
mE1ˆE4L
mL1
mL2
E1L
E2L
E1ˆE4L
L1
L2
DE1L
DE2L
E1E2L
C/EBPβ
DC/EBPβ
DC/EBPβdelay

=
[
XC
XS
]
(5.8)
92
5.2 Late Promoter Master Equation
where XC is the sub-vector that corresponds to the states of the control
markov chains regarding the promoters and the splicing sites, while XS
is the sub-vector which is inherent the standard chemical species.
The ME of the late promoter markov chain, 4.33, is described by the fol-
lowing differential equations system
dpL0
dt
= −kLP1 ·DC/EBPβdelay · pLP0 + kLP2 pLP1
dpL1
dt
= −(kLP2 + kLP3 ) ·DC/EBPβdelay · pLP1 + kLP1 ·DC/EBPβdelay · pLP0
+ kLP4 p
LP
2
dpL2
dt
= −kLP4 pLP2 + kLP3 ·DC/EBPβdelay pLP1
(5.9)
where pLPn denotes the probability of being in chemical state PLPn at time
t. The initial conditions are pLP0 = 1 and pLPi = 0 for i 6= 0. This is because
at the beginning the late promoter is turned off.
Since the states are mutually exclusive, we can write, by applying the
total probability theorem the constraint Pr
[⋃2
i=0 P
LP
i (t)
]
=
∑2
i=0 p
LP
i (t), ∀ t ≥
0, since the LP states are mutually exclusive (PLPi (t) ∩ PLPj (t) = ∅, i 6=
j, ∀ t ≥ 0) hence the probabilities of the intersection of two or more states
are zero.
The ME of the polyadenylation site biochemical equation, 4.36, is
dppAE0
dt
= −kpAEon (E2TOT ) pAE0 + kpAEoff pAE1
dppAE1
dt
= −kSS2off pAE1 + kpAEon (E2TOT ) pAE0
(5.10)
where ppAEn denotes the probability of being in chemical state P pAEn at time
t. The initial conditions are ppAE0 = 1 and p
pAE
1 = 0. At the beginning the
late genes are not produced.
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As in the previous two cases, the two states of pAE polyadenylation
site are mutually exclusive, hence Pr
[
P pAE0 (t) ∪ P pAE1 (t)
]
= ppAE0 (t) +
ppAE1 (t) = 1, ∀ t ≥ 0.
The remaining ME results in the master equation for the SS1 splicing site,
5.5, we have already written down before. This is because the splicing
regulation of E1, E2 and E4 is the same for both the promoters.
5.3 WHOLE SYSTEM MASTER EQUATION
The ME for the entire system, consisting of both the early and the late
promoters, is exactly the union of all the master equations we have re-
ported so far. The only thing to consider is the repression of the early
promoter by the late one. To account of this regulation we have just to
consider the early promoter markov chain ME to be dependent on the
total DETOT2 = DEE2 +DEL2 dimer and E1ETOT2 = E1EE2 +E1EL2 concen-
trations produced by both the promoters. In the SRSF1 promoter ME we
have to consider the dependence on ETOT2 = EE2 + EL2 and finally for the
SS1 splicing site we have to consider ETOT1 = EE1 + EL1 concentration.
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From the stochastic model we can get a deterministic version in terms
of its quasi-equilibrium approximation. This latter is performed by ap-
plying the mass action kinetic law to the system of biochemical reactions
describing the model. Before doing that, it is important to deterministi-
cally revisit the contribution of the stochastic sources of the system. The
idea behind the quasi-equilibrium (QE) is to assume there exists two dis-
tinct time scales inside the system dynamics: one fast and the other slow.
The hypothesis is to consider the time scale of the control part of the sys-
tem (promoters, splicing sites, polyadenylation sites) fast with respect
to the other processes (transcription, degradations, dimerization,...) and
subsequently averaging over the fast variables. In particular, to satisfy
the assumption of fast fluctuations we’ll consider the steady state level
of master equation describing the control part of the system (Kepler and
Elston (2001), Gardiner (2009)).
The QE follows very well the average of the stochastic system when
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the control part of the system is under a fast fluctuations regimen. Other-
wise (in the presence of slower promoters, splicing sites and polyadeny-
lation sites fluctuations) the QE tends to fail in following the stochastic
predictions as we’ll see in the results chapter. This is good when we are
interested to investigate the additive stochastic behavior a deterministic
formulation cannot predict. In any case, QE is an easy approach to get a
good deterministic version of a model starting from its stochastic formu-
lation.
We will follow the same scheme of the previous chapters. At first we’ll
derive the QE for the early promoter regulatory core, secondly we’ll con-
sider the oncogenes and finally the late promoter.
6.1 EARLY PROMOTER QUASI-EQUILIBRIUM (QE)
For each promoter and splicing states we can build an indicator function
χEPi (t) =
{
1 if PEj (t) = P
E
i (t)
0 if PEj (t) 6= PEi (t)
(6.1)
χSRSF1i (t) =
{
1 if P SRSF1j (t) = P
SRSF1
i (t)
0 if P SRSF1j (t) 6= P SRSF1i (t)
(6.2)
χSS1i (t) =
{
1 if P SS1j (t) = P
SS1
i (t)
0 if P SS1j (t) 6= P SS1i (t)
(6.3)
where χEi (t), χSRSF1i (t) and χ
SS1
i (t) are the indicator functions for the
early promoter, SRSF1 promoter and SS1 splicing site. In this way we
can rewrite the formulae 4.11, 4.15,4.22,4.21 as follows
SpM(P
E
i (t)) =
4∑
i=0
spM
E
i χ
EP
i (t) (6.4)
SmSRSF1(P
SRSF1
i (t)) = s
SRSF1
0 χ
SRSF1
0 (t) + s
SRSF1
1 χ
SRSF1
1 (t) (6.5)
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kE2m (SS
i
1(t)) = kˆ
E2
m χ
SS1
0 (t) + 0χ
SS1
1 (t) = kˆ
E2
m χ
SS1
0 (t) (6.6)
kE1m (SS
i
1(t)) = kˆ
E1
m χ
SS1
0 (t) + 0χ
SS1
1 (t) = kˆ
E1
m χ
SS1
0 (t) (6.7)
The previous formulae being linear combination of indicator functions
are, in turn, stochastic variables. To get a deterministic approximation of
these latter we can calculate their expectation. From probability (Billings-
ley (2012)) we can write
E
[
χEPi (t)
]
= pEPi (t) (6.8)
E
[
χSRSF1i (t)
]
= pSRSF1i (t) (6.9)
E
[
χSSi (t)
]
= pSS1i (t) (6.10)
where E[·] is the expectation operator and pEi , pSRSF1i , pSSi are the proba-
bilities to be in the state i-th for the early promoter, the SRSF1 promoter
and for SS1 splicing site, respectively. To get the fast fluctuation assump-
tion verified we need to consider the steady state probabilities of the ME.
In what follows we’ll directly assume to be in the steady state master
equation regimen, in order to get the steady state probabilities when we
apply the expectation operator.
To get a deterministic approximation of 6.4, 6.5 and 6.26 we apply the
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expectation operator
S¯pM(P
EP
i ) = E
[
SpME(P
EP
i )
]
= E
[
4∑
i=0
spM
E
i χ
EP
i (t)
]
=
4∑
i=0
spM
E
i E
[
χEPi (t)
]
=
4∑
i=0
spM
E
i pˆ
E
i
=
4∑
i=0
E[SpME(PEPi |PEPj = PEPi ] pˆEPi
(6.11)
S¯mSRSF1(P
SRSF1
i ) = E
[
SmSRSF1(P
SRSF1
i )
]
= E
[
smSRSF10 χ
SRSF1
0 + s
mSRSF1
1 χ
SRSF1
1
]
= smSRSF10 E
[
χSRSF10
]
+ smSRSF11 E
[
χSRSF11
]
= smSRSF10 pˆ
SRSF1
0 + s
mSRSF1
1 pˆ
SRSF1
1
= E[SmRSF1(P SRSF1i |P SRSF1i = P SRSF10 ] pˆSRSF10 +
E[SmRSF1(P SRSF1i |P SRSF1i = P SRSF11 ] pˆSRSF11
(6.12)
k¯E2m (SS
i
1) = E
[
kE2m (SS
i
1)
]
= E
[
kˆE2m χ
SS1
0 + 0χ
SS1
1
]
= kˆE2m E
[
χSS10
]
= kE2m pˆ
SS1
0 = E[kE2m (SSi1)|SSi1 = SSo1 ] pˆSS10
(6.13)
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where pˆEi , pˆSRSF1i and pˆ
SS1
i are the steady state probabilities of the approx-
imated master equation presented in the previous paragraph. The steady
state probabilities are function of DE2 and E1E2 but they are not explic-
itly dependent on time anymore. Hence, we can interpret S¯pM(PEPi ),
S¯mSRSF1(P
SRSF1
i ), k¯
EE2
m (SSi1), k¯
EE1
m (SSi1) as weighted sums of the proba-
bility to stay in each of the markov chain state they refer to, where the
weights are the rate constants associated to each state. Actually these lat-
ter are the conditional expectations of the stochastic variable we defined
before as linear combination of indicator functions, conditioned to the
correspondent state of the markov chain.
Now, applying the mass action kinetics law and and using the formu-
lae 6.11, 6.12, 6.13 we can write down the quasi-equilibrium approxima-
tion
dpME
dt
= S¯pM(P
EP
i )− (kEs + k¯E
E
2
m (SSi1) + k¯
EE1
m (SSi1)) pM
E
dmEE2
dt
= k¯
EE2
m (SSi1) pM
E − δE2m mEE2
dmEE1
dt
= k
EE1
m (SSi1) pM
E − δE1m mEE1
dEE2
dt
= k
EE2
p mEE2 − δE
E
2
p EE2 − 2 kDE2f (EE2 )2 + 2 kDE2r DEE2
dEE1
dt
= k
EE1
p mEE1 − δE1p EE1 − 2 kDE2f (EE1 )2 + 2 kDE1r DEE1
dDEE2
dt
= kDE2f (E
E
2 )
2 − (kDE2r + δDE2) DEE2 − kE1E2f DEE1 ·DEE2 + kE1E2r E1EE2
dDEE1
dt
= kDE1f (E
E
2 )
2 − (kDE1r + δDE1) DEE1 − kE1E2f DEE1 ·DEE2 + kE1E2r E1EE2
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dE1E
E
2
dt
= kE1E2f DE
E
1 ·DEE2 −
(
kE1E2r + δE1E2
)
E1E
E
2
dmSRSF1
dt
= S¯mSRSF1(P
mSRSF1
i ) + krmsmSRSF1/SRSF1 +
− kfmsmSRSF1SRFS1− δSRSF1 SRSF1
dSRSF1
dt
= kSRSF1p mSRSF1 + krmsmSRSF1SRSF1 +
− kfmsmSRSF1SRSF1− δSRSF1 SRSF1
dmSRSF1/SRSF1
dt
= kfmsmSRSF1SRFS1 + krmsmSRSF1/SRSF1 +
− δmSRSF1/SRSF1mSRSF1/SRSF1
(6.14)
6.1.1 ONCOGENES QE EXTENSION
To perform the oncogenes quasi equilibrium approximation we have to
calculate the expectation of the oncogenes conversion rates by means of
the steady state probabilities of the simplified master equation, as we
have done so far.
RegardingE6, we can observe from the definition 4.31 that theE6 mRNA
conversion rate is non-zero only when the stochastic event {SSi1 = SS11}∧
{SSi2 = SS02} happens. Therefore we can define just an indicator function
for this latter event, as
χSS11∧SS02 (t) =
{
1 if {SSi1(t) = SS11} ∧ {SSi2(t) = SS02}
0 otherwise
(6.15)
Similarly, E7 mRNA conversion rate is non-zero only when the stochastic
event {SSi1 = SS11} ∧ {SSi2 = SS12} ir realized. Therefore we can define
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the indicator function
χSS11∧SS12 (t) =
{
1 if {SSi1(t) = SS11} ∧ {SSi2(t) = SS12}
0 otherwise
(6.16)
From the probability we can write the expectation of the indicator func-
tions as follows
E[χSS11(t)∩SS02 (t)] = Pr
[{SSi1(t) = SS11} ∩ {SSi2(t) = SS02}]
= Pr
[{SSi1(t) = SS11}] · Pr[{SSi2(t) = SS02}]
= pSS11 (t) · pSS20 (t) ,∀ t ≥ 0
(6.17)
E[χSS11(t)∩SS12 (t)] = Pr
[{SS11(t) = SS11} ∩ {SSi2(t) = SS12}]
= Pr
[{SSi1(t) = SS11}] · Pr[{SSi2(t) = SS12}]
= pSS11 (t) · pSS21 (t) ,∀ t ≥ 0
(6.18)
where Pr[·] is the symbol we use for calculating the probability of an
event, while lowercase p is the probability nomenclature we have de-
cided to write down the master equation probabilities. In the previous
formulae, we have written the probability of the intersection events (i.e.
the realizations of the stochastic processes SSi1(t) and SSi2(t) for a fixed
time t) as the product of of each event probabilities, thanks to the statisti-
cal independence of the two splicing sites binding dynamics.
As we have done so far, we can write the expectation of the conversion
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rates for the oncogenes mRNAs
k¯E6m (SS
i
1(t), SS
i
2(t)) = E
[
kE6m (SS
i
1(t), SS
i
2(t))
]
= E
[
kˆE6m χSS11(t)∩SS02(t)
]
= kˆE6m E
[
χSS11(t)∩SS02(t)
]
= kˆE6m pˆ
SS1
1 · pˆSS20
= E[kE6m (SSi(t))|{SSi1(t) = SS11} ∩ {SSi2(t) = SS02}] pˆSS11 · pˆSS20
(6.19)
k¯E7m (SS
i
1(t), SS
i
2(t)) = E
[
kE7m (SS
i
1(t), SS
i
2(t))
]
= E
[
kˆE7m χSS11(t)∩SS12(t)
]
= kˆE7m E
[
χSS11(t)∩SS12(t)
]
= kˆE7m pˆ
SS1
1 · pˆSS21
= E[kE7m (SSi(t))|{SSi1(t) = SS11} ∩ {SSi2(t) = SS12}] pˆSS11 · pˆSS21
(6.20)
where we have considered the steady state probabilities, of the simplified
master equation, in order to satisfy the fast fluctuation to get the quasi-
equilibrium approximation. We observe we haven’t indicated the steady
state probabilities as function of time.
The QE extended system accounting the oncogenes is pretty the same
we have already derived. WE just need to update the pre-mRNA equa-
tion to account for the oncogenes conversion and to add the E6 and E7
transcripts and proteins equation by using the mass action kinetic law
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and the formulae 6.19 and 6.20, we have just derived.
The QE update of the pre-mRNA is
dpME
dt
=S¯pME(P
EP
i )− (kEs + k¯E2m (SSi1)
+ kE1m (SS
i
1) + k¯
E6
m (SS
i
1, SS
i
2) + k¯
E7
m (SS
i
1, SS
i
2)) pM
E
dmE6
dt
= k¯E6m (SS
i
1, SS
i
2) pM
E − δE6m mEE6
dmE7
dt
= k¯E7m (SS
i
1, SS
i
2) pM
E − δE7m mE7
dE6
dt
= kE6p mE6 − δE6p E6
dE7
dt
= kE7p mE7 − δE7p E7
(6.21)
6.2 LATE PROMOTER QUASI EQUILIBRIUM APPROXIMATION
Following the same procedure of the previous sections, considering the
stochasticity associated to the only promoters, splicing sites and polyadeny-
lation sites, we can derive a deterministic formulation for the late pro-
moter pre-mRNA synthesis, and of the conversion rates of the transcripts.
Let’s define the indicator functions of the late promoter, splicing sites
and polyadenylation site markov chains defined in chapter 4.
The indicator function for the late promoter states is
χLPi (t) =
{
1 if PLj (t) = P
L
i
0 if PLj (t) 6= PLi
(6.22)
where uppercase PLi is the i-th state of the late promoter markov chain.
We can observe that the indicator function for the i-th state of the late
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promoter assumes the value 1 if and only if the promoter is exactly in
that state.
Late promoter needs of SS1 splicing site but we have already written
the indicator function for SS1 splicing site in 6.3.
Regarding L1 and L2 transcription, from the definition of their conver-
sion rates (4.54, 4.55) it is non-zero if only if the stochastic event {pAEi =
pAE1} happens. In other words when pAE is inhibited. Therefore we
define an indicator function for this latter stochastic event
χpAEi=pAE1(t) =
{
1 if pAEi = pAE1
0 if otherwise
(6.23)
As in the previous section we rewrite the formulae 4.39, 4.51,4.52, 4.53,
as the following stochastic variables
SpML(P
L
i (t)) =
2∑
i=0
spM
L
i χ
LP
i (t) (6.24)
kE1
L
m (SS
i
1(t)) = kˆ
E1L
m χ
SS1
0 (t) = kˆ
E1L
m χ
SS1
0 (t) (6.25)
kE2
L
m (SS
i
1(t)) = kˆ
E2L
m χ
SS1
0 (t) (6.26)
kE4
L
m (SS
i
1(t)) = kˆ
E4L
m χ
SS1
1 (t) (6.27)
kL1m (pAEi(t)) = kˆ
L1
m χpAEi=pAE1(t) (6.28)
kL2m (pAEi(t)) = kˆ
L2
m χpAEi=pAE1(t) (6.29)
The previous formulas, being linear combination of indicator functions
are, in turn, stochastic variables. To get a deterministic approximation of
these latter we can calculate their expectations.
Before doing that let’s calculate the expectations of their indicator func-
tions. Actually, we have already done that with the exception of the late
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genes L1 and L2
E[χpAEi=pAE1(t)] = Pr
[
χpAEi=pAE1(t)
]
= Pr
[
χpAEi=pAE1
]
= ppAE1 (t) ,∀ t ≥ 0
(6.30)
E[χpAEi=pAE1(t)] = Pr
[
χpAEi=pAE1(t)
]
= Pr
[
χpAEi=pAE1
]
= ppAE1 (t) ,∀ t ≥ 0
(6.31)
where ppAE1 is the probability to have the early polyadenylation site in-
hibited (by E2).
By inserting in the formulas 6.24, 6.25, 6.26, 6.27, 6.28 and 6.29 the pre-
vious expectations 6.30 and 6.31 we can get a deterministic formulation
for the late promoter pre-mRNA synthesis and for the transcript conver-
sion rates
SpML(P
LP
i (t)) =
2∑
i=0
spM
L
i χ
LP
i (t) (6.32)
k¯E
L
1
m (SS
i
1(t)) = E
[
kE
L
1
m (SS
i
1)
]
= E
[
kˆE1
L
m χ
SS1
0
]
= kˆE1
L
m E
[
χSS10
]
= kˆE1
L
m pˆ
SS1
0
(6.33)
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k¯E
L
2
m (SS
i
1(t)) = E
[
kE
L
2
m (SS
i
1)
]
= E
[
kˆE2
L
m χ
SS1
0
]
= kˆE2
L
m E
[
χSS10
]
= kˆE2
L
m pˆ
SS1
0
(6.34)
k¯E
L
4
m (SS
i
1(t)) = E
[
kE
L
4
m (SS
i
1)
]
= E
[
kˆE4
L
m χ
SS1
1
]
= kˆE4
L
m E
[
χSS11
]
= kˆE4
L
m pˆ
SS1
1
(6.35)
k¯L1m (pAEi(t)) = E
[
kL2m (pAEi(t))
]
= E
[
kˆL1m χpAEi=pAE1(t)
]
= kˆL1m p
pAE
1
= E[kL1m (pAEi(t))|pAEi(t) = pAE1] · pˆpAE1
(6.36)
k¯L2m (pAEi(t)) = E
[
kL2m (pAEi(t))
]
= E
[
kˆL1m χpAEi=pAE1(t)
]
= kˆL1m p
pAE
1 (t)
= E[kL1m (pAEi(t))|pAEi(t) = pAE1] · pˆpAE1
(6.37)
where, as usual pˆi are the steady state probabilities of the master equa-
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tion.
Using the mass action kinetics law and the synthesis and conversion rates
formulation we have just derived we can write the quasi equilibrium of
the late promoter
dpML
dt
= S¯pML(P
LP
i )−(ks + k¯E2
L
m (SS
i
1) + k¯
E1L
m (SS
i
1) + k¯
E4
m (SS
i
1)
+ k¯L1m (pAEi) + k¯
L2
m (pAEi)) pM
L
dmE2L
dt
= k¯E2
L
m (SS
i
1) pM
L − δE2m mE2L
dmE1L
dt
= kE1
L
m (SS
i
1) pM
L − δE1m mE1L
dmE4L
dt
= kE4
L
m (SS
i
1) pM
L − δE4m mE4L
dmL1
dt
= kL1m (pAEi) pM
L − δL1m mL1
dmL2
dt
= kL2m (pAEi) pM
L − δL2m mL2
dE1L
dt
= kE1
L
p mE1
L − δE1Lp E1L − 2 kDE2Lf (E1L)2 + 2 kDE1Lr DE1L
dE2L
dt
= kE2
L
p mE2
L − δE2p E2L − 2 kDE2Lf (E2L)2 + 2 kDE2Lr DE2L
dE4L
dt
= kE4
L
p mE4
L − δE4p E4L
dL1
dt
= kL1p mL1− δL1p L1
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dL2
dt
= kL2p mL2− δL2p L2
dDE2L
dt
=kDE2
L
f (E2
L)2 −
(
kDE2
L
r δDE2L
)
DE2L − kE1E2Lf DE1LDE2L
+ kE1E2
L
r E1E2
L
dDE1L
dt
=kDE1
L
f (E2
L)2 −
(
kDE1
L
r + δDE1L
)
DE1L − kE1E2Lf DE1LDE2L
+ kE1E2
L
r E1E2
L
dE1E2L
dt
= kE1E2
L
f DE1
LDE2L −
(
kE1E2
L
r + δE1E2L
)
E1E2L
(6.38)
6.3 WHOLE SYSTEM QUASI EQUILIBRIUM APPROXIMATION
The QE of the whole system is described by the same equations we have
written down so far in this chapter. The few thing we have to account
handle the two promoters together are
• The early promoter regulation depends on the totalE2 dimerDETOT2
= DEE2 +DE
L
2 and tetramer E1ETOT2 = E1EE2 +E1EL2 produced by
both the promoters.
• The SRSF1 promoter activation and the eraly polyadenylation sig-
nal, pAE, depend on the total ETOT2 = EE2 + EL2 produced by both
the promoters.
• The dissociation rate constant of SRSF1, from SS1 splicing site, de-
pends on the total ETOT1 = EE1 + EL1 produced by both the promot-
ers.
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7
Dataset, parameters and design of
in silico experiments
In this chapter we report the parameters we have gathered/inferred from
literature and that we have assumed to perform the model predictions.
We describe an available dataset gathered from literature about the
early promoter activity and the qualitative measurements about the tem-
poral evolution of E1 and E2 transcripts during the infected cell differen-
tiation.
Finally we’ll design some in silico experiments to investigate the dy-
namical behavior of the developed model and test its capability to quali-
tative reproduce the expected biology. The predictions will be performed
in the next chapter.
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7.1 DATASET
7.1.1 EARLY PROMOTER ACTIVITY
A dataset about the early promoter activity for HPV16 and 18 is available
in literature (Hou et al. (2002)). In this dataset there are considered early
promoters with all the four binding sites for E2 dimer and the promoter
activities was tested under different E2 concentration levels. Only the
negative feedback effect was evaluated.
In tables 7.1.3 and 7.1.2 we report the experimental data about the pro-
moter activity. In fig. 8.1.1 and 8.1.2 we report the plot of the data.
Table 7.1.1: HPV16 early promoter activity
E2 [nM] promoter activity
0 1
1.67 0.6
8.33 0.08
41.67 0.02
166.67 0.02
Table 7.1.2: HPV18 early promoter activity
E2 [nM] promoter activity
0 1
1.67 0.98
8.33 0.55
41.67 0.08
166.67 0.04
In the next chapter we’ll show the fit of both the promoter activities
performed by using the early promoter markov chain model we have
developed.
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Figure 7.1.1: HPV16 early promoter activity.
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Figure 7.1.2: HPV18 early promoter activity.
7.1.2 E1 AND E1 MRNAS DURING DIFFERENTIATION
The only available time series about HPV transcripts is a qualitative mea-
surements aboutE1 andE2 mRNAs (measured as relative change in band
intensity from a Northen blot analysis) upon induced differentiation and
a total experiment duration of 16 days (Ozbun and Meyers (1998)). Most
likely these transcripts are produced by the late promoter.
In table... we report the qualitative data and inf fig..... we plot them.
We specify that the last temporal data has to be neglected as it accounts
for an experimental set up inaccuracy.
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Table 7.1.3: E1 and E2 mRNAs during differentiation
time [days] mE1 [Relative change] mE2 [Relative change]
0 1.4 2
4 0.67 0.34
8 2.13 0.81
12 5.72 1.91
16 2.19 1.72
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Figure 7.1.3: E1 and E2 mRNAs produced by the late promoter during differentia-
tion.In red are indicated the last temporal data to neglect.
7.2 PARAMETERS
In this section we report the parameters of the model in different tables
(to distinguish between rate constants, degradations, splicing control,...)
Most of them are gathered or inferred from literature. Some of them are
inferred during the first qualitative assessment of the model. In fact a first
validation is always performed during model formulation in order to re-
produce the qualitative behavior we expect from the biological knowl-
edge present in literature (Cobelli Claudio (2008)). Some inferred param-
eters were fixed in order to satisfy a fast fluctuation regimen. This is the
case for the markov chain rate constants of SRSF1 promoter and SS1
splicing site. We have made this choice in order to have, at first, a good
agreement with the quasi equilibrium approximation. However, these
parameters will be varied in different in silico experiments (reported in
the next section) to account for stronger stochastic noise contribution.
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Table 7.2.1: Rate constants Early promoter markov chain HPV16
parameter value unit of measure reference
kEP1 1.89 e-2 nM−1min−1 Mok et al. (1996), Demeret et al. (1997), Hartley and Alexander (2002), Hou et al. (2002)
kEP2 1.92 e-2 min−1 Demeret et al. (1997)
kEP3 2.00 e-2 nM−1min−1 Mok et al. (1996), Demeret et al. (1997), Hartley and Alexander (2002), Hou et al. (2002)
kEP4 1.15 e-1 min−1 Demeret et al. (1997)
kEP5 2.58 e-2 nM−1min−1 Demeret et al. (1997), Chao et al. (1999)
kEP6 5.0 e-2 min−1 Demeret et al. (1997), Chao et al. (1999)
kEP7 2.00 e-2 nM−1min−1 Mok et al. (1996), Demeret et al. (1997), Hartley and Alexander (2002), Hou et al. (2002)
kEP8 1.15 e-1 min−1 Mok et al. (1996), Demeret et al. (1997), Hartley and Alexander (2002), Hou et al. (2002)
kEP9 4.54 e-3 nM−1min−1 Demeret et al. (1997), Chao et al. (1999),
kEP10 5.0 e-2 min−1 Demeret et al. (1997), Chao et al. (1999)
Table 7.2.2: Rate constants Early promoter markov chain HPV18
parameter value unit of measure reference
kEP1 1.89 e-2 nM−1min−1 Mok et al. (1996), Demeret et al. (1997), Hartley and Alexander (2002), Hou et al. (2002)
kEP2 1.92 e-2 min−1 Demeret et al. (1997)
kEP3 2.98 e-2 nM−1min−1 Mok et al. (1996), Demeret et al. (1997), Hartley and Alexander (2002), Hou et al. (2002)
kEP4 1.15 e-1 min−1 Demeret et al. (1997)
kEP5 2.58 e-2 nM−1min−1 Demeret et al. (1997), Chao et al. (1999)
kEP6 5.7 e-2 min−1 Demeret et al. (1997), Chao et al. (1999)
kEP7 2.98 e-2 nM−1min−1 Mok et al. (1996), Demeret et al. (1997), Hartley and Alexander (2002), Hou et al. (2002)
kEP8 1.15 e-1 min−1 Mok et al. (1996), Demeret et al. (1997), Hartley and Alexander (2002), Hou et al. (2002)
kEP9 6.79 e-3 nM−1min−1 Demeret et al. (1997), Chao et al. (1999)
kEP10 5.7 e-2 min−1 Demeret et al. (1997), Chao et al. (1999)
Table 7.2.3: Degradations
parameter value unit of measure reference
δE1 3.3 e-3 min−1 Ozbun and Meyers (1998)
δmE1 1.65 e-2 min−1 Ozbun (2002)
δE2 3.3 e-3 min−1 King et al. (2011),McBride (2013), Bellanger et al. (2001), Taylor et al. (2003)
δmE2 1.65 e-2 min−1 Ozbun (2002)
δE1ˆE4 1.9 e-3 min−1 Assumed
δmE1ˆE4 1.65 e-2 min−1 Assumed
δE6 1.54 e-2 min−1 Ajiro Masahiko (2015)
δmE6 3.08 e-2 min−1 Ozbun (2002)
δE7 1.24 e-2 min−1 Ajiro Masahiko (2015)
δmE7 2.48 e-2 min−1 Ozbun (2002)
δL1 1.9 e-3 min−1 Collier et al. (2002)
δmL1 1.93 e-2 min−1 Assumed
δL2 3.9 e-3 min−1 Finnen et al. (2003)
δmL2 3.85 e-2 min−1 Assumed
δDE1 6.6 e-4 min−1 Hou et al. (2002)
δDE2 6.6 e-4 min−1 Hou et al. (2002),Mok et al. (1996), Demeret et al. (1997)
δE1E2 3.3 e-4 min−1 King et al. (2011), Hartley and Alexander (2002)
δmSRSF1 7.7 e-3 min−1 Moulton et al. (2014)
δSRSF1 7.7 e-4 min−1 Assumed
δmSRSF1/SRSF1 1.54 e-2 min−1 Sun et al. (2010)
δC/EBPβ 4.81 e-4 min−1 Maytin and Habener (1998), Huber et al. (2015)
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Table 7.2.4: Rate constants multimeric complexes
parameter value unit of measure reference
kE1E2f 4.2 e-4 nM
−1min−1 Chao et al. (1999), Demeret et al. (1997),Hou et al. (2002)
kE1E2r 5.00 e-2 min−1 Chao et al. (1999), Demeret et al. (1997),Hou et al. (2002)
kDE1f 3.97 e-4 nM
−1min−1 Graham (2012)
kDE1r 1.00 e-2 min−1 Graham (2012)
kDE2f 3.97 e-4 nM
−1min−1 Demeret et al. (1997),Hou et al. (2002)
kDE2r 1.0 e-2 min−1 Demeret et al. (1997),Hou et al. (2002)
kmsf 9.94 e-3 nM
−1min−1 Somberg and Schwartz (2010), Sun et al. (2010)
kmsr 1.00 e-3 min−1 Somberg and Schwartz (2010), Sun et al. (2010)
k
C/EBPβ
f 3.00 e-4 nM
−1min−1 Assumed
k
C/EBPβ
r 2.00 e-2 min−1 Assumed
Table 7.2.5: Synthesis and conversion rates
parameter value unit of measure reference
spM
E
0 7.55 e-1 nM min−1 Hou et al. (2002)
spM
E
1 2.00 e-0 nM min−1 Hou et al. (2002)
spM
E
2 2.52 e-2 nM min−1 Hou et al. (2002)
spM
E
3 4.03 e-1 nM min−1 Hou et al. (2002)
kˆE1m 4.50 e-1 min−1 Ozbun and Meyers (1998)
kˆE2m 5.00 e-1 min−1 Ozbun and Meyers (1998)
kˆE6m 2.00 e-1 min−1 Assumed
kˆE7m 2.00 e-1 min−1 Assumed
kˆE1p 3.00 e-2 min−1 Assumed
kˆE2p 3.50 e-2 min−1 Hou et al. (2002)
kˆE6p 8.00 e-3 min−1 Assumed
kˆE7p 8.00 e-3 min−1 Assumed
kˆEs 6.93 e-2 min−1 Audibert et al. (2002)
kˆSRFS1p 3.00 e-3 min−1 Somberg and Schwartz (2010), Sun et al. (2010)
sSRSF10 1.01 e-2 nM−1min−1 Assumed
sSRSF11 5.03 e-2 nM−1min−1 Assumed
Table 7.2.6: Splicing sites parameters and rate constants
parameter value unit of measure reference
kSS1on 2.00 e-0 nM−1min−1 Somberg and Schwartz (2010), Sun et al. (2010),Johansson and Schwartz (2013)
kˆSS1off 1.70 e-2 min
−1 Somberg and Schwartz (2010), Sun et al. (2010),Johansson and Schwartz (2013)
k˜SS1off 1.00 e-5 min
−1 Assumed
λSS1 3.50 e-0 nM Somberg and Schwartz (2010), Sun et al. (2010),Johansson and Schwartz (2013)
nSS1 2.00 e-0 − Assumed
kˆSRSF1on 9.93 e-0 nM−1min−1 Sun et al. (2010)
kSRSF1off 7.0 e-1 min
−1 Sun et al. (2010)
λSRSF1 5.00 e-0 nM−1min−1 Johansson and Schwartz (2013)
nSRSF1 6.00 e-0 − Assumed
kSS2on 0.1 e-0 min−1 Assumed
kSS2off 0.3 e-0 min
−1 Assumed
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Table 7.2.7: Rate constants Late promoter markov chain
parameter value unit of measure reference
kLP1 1.98 e-1 nM−1min−1 Assumed
kLP2 2.00 e-1 min−1 Assumed
kLP3 1.98 e-2 nM−1min−1 Assumed
kLP4 1.00 e-1 min−1 Assumed
Table 7.2.8: Additive splicing sites parameters and rate constants
parameter value unit of measure reference
kˆpAEon 3.00 e-1 nM−1min−1 Johansson and Schwartz (2013)
kpAEoff 5.00 e-3 min
−1 Johansson and Schwartz (2013)
npAE 6.00 e-0 − Assumed
λpAE 1.25 e+1 nM Johansson and Schwartz (2013)
Table 7.2.9: Synthesis and conversion rates Late promoter
parameter value unit of measure reference
spM
L
0 2.5 e-1 nM min−1 Assumed
spM
L
1 1.25 e-0 nM min−1 Assumed
spM
L
2 2.51 e-0 nM min−1 Assumed
kˆE1
L
m 5.00 e-1 min−1 Ozbun and Meyers (1998)
kˆE2
L
m 2.00 e-1 min−1 Ozbun and Meyers (1998)
kˆE1E4
L
m 3.00 e-1 min−1 Johansson and Schwartz (2013)
kˆL1m 3.00 e-1 min−1 Finnen et al. (2003)
kˆL2m 3.50 e-1 min−1 Finnen et al. (2003)
kˆLs 6.93 e-2 min−1 Audibert et al. (2002)
kˆE1
L
p 5.00 e-3 min−1 Assumed
kˆE2
L
p 1.00 e-2 min−1 Assumed
kˆE1E4
L
p 5.00 e-3 min−1 Assumed
kˆL1p 3.00 e-2 min−1 Finnen et al. (2003)
kˆL2p 5.00 e-2 min−1 Finnen et al. (2003)
sC/EBPβ 2.3 e-2 nM min−1 Assumed
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7.3 in silico EXPERIMENTS DESIGN
We design five in silico experiments in order to investigate the behavior
of the model. We’ll consider four experiments about the early promoter
since it presents a more complex structure with an autoregulated pro-
moter and the splicing regulation too. The last experiment will test the
late promoter functioning.
All the experiment have been designed by assuming a keratynocyte
cell diameter between 15 to 35 µm and a nuclear diameter of 8.6 µm
(Gareau (2011)).
In all the experiments, with the exception of Experiment 1, will show
the chemical species in copy number, suitable with a stochastic approach.
7.3.1 EARLY PROMOTER
The early promoter in silico experiments can be useful to describe differ-
ent scenarios: a basal infection situation; a precancerous lesion where the
early promoter can stay active for most of the differentiation time before
being strongly repressed; HPV integration into the human DNA where it
over expresses the oncogenes to sustain the cancer condition.
Even if the late promoter should strongly repress the early promoter,
there is no evidence the early promoter is completely turned off.
We know from literature that the copy number of different viral pro-
teins should be around some thousands per cell. However, these num-
bers should consider the entire amount of proteins and transcripts from
three contributions: basal infected cells, cell that committed the differen-
tiation and integrated HPV. We know that the late promoter can gener-
ate higher amount of E1 and E2 and of their multimeric complexes; we
also know that the integrated HPV can overexpress the oncogenes. Ac-
tually, for a qualitative investigation it is not very important to respect
the real amount of molecules, unless to consider very high copy number
where the stochastic contributions become negligible. We have chosen to
consider a steady state copy number around some hundreds for the tran-
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scripts and few thousands for the proteins. This choice, on the one hand
could be consistent with the real copy number magnitude the early pro-
moter should produce, and on the other hand is a good choice to inves-
tigate the stochastic effects coming from a slow promoters and splicing
sites fluctuations, and a finite number effect, as well.
The predictions will be simulated for an in silico experiment duration
of a week. We are interested in investigating the qualitative dynamical
behavior of the early promoter and if the purpose is to investigate the
stochastic dynamics, the effective duration of the experiment is not so
crucial. Anyway, a biological consistency with a simulation period of a
week could be consistent with the situation with the virus in the basal
cells that not differentiate; another case could be relative to cells in a pre-
cancerous stage where the effect of the late promoter can be strongly de-
layed.
Since in this section we are interested in the investigation of the early
promoter dynamics we do not account for the repression effect medi-
ated by the late promoter. Actually the late promoter repression on the
first one is not so interesting dynamically speaking, since there isn’t a
co-regulation between the two promoters.
7.3.1.1 EXPERIMENT 1
In this experiment we consider the early promoter heuristically mod-
eled in (Giaretta et al. (2015)). The main purpose is to verify the E1 co-
regulation mediated on E2 and the possible repression of the early pro-
moter that in this first attempt we have assumed condensed as a forcing
function modulating E1 mRNA. In this chapter we have made the choice
to report only the parameters for the new model version. The parameters
fixed for this simulation are reported in (Giaretta et al. (2015)). Moreover
in this in silico experiment we will show the results expressed in concen-
tration, with a synthesis rate assumed to an indicative value (consistent
with the upper bound copy number limit we have inferred from litera-
ture, considering the average volume of a keratynocyte).
117
Dataset, parameters and design of in silico experiments
7.3.1.2 EXPERIMENT 2
In this experiment we consider the early promoter markov chain with the
parameters in table 7.2.1, in order to perform an experiment with the pro-
moter structure and parameters we have used to fit the experimental data
about its activity, as we’ll show in chapter 7. In particular, we consider a
eak positive feedback and a medium strong negative feedback. The onco-
genes are not produced in a very hogh concentration deterministically, in
order to show a first interesting stochastic behavior. The promoters and
splicing sites fluctuations are imposed to be quite fast in order to have a
good agreement with the quasi-equilibrium approximation, hence with
the deterministic behavior of the system.
The in silico experiments will account for a total duration of a week.
7.3.1.3 EXPERIMENT 3
In this experiment we investigate the stochastic behavior of the early pro-
moter in the context of slow fluctuations of both SRSF1 promoter and SS1
splicing site. Hence investigating a slow dynamics of the splicing control
part of the system. The SRSF1 and SS1 markov chains parameters will
be fixed two order of magnitude lower than respect to the previous ex-
periment to be sure the slower fluctuations make the difference. All the
other parameters are the same we have reported in the tables from 7.2.1
to 7.2.6.
7.3.1.4 EXPERIMENT 4
In this experiment we investigate the stochastic behavior of the early pro-
moter in the context of medium slow fluctuations (i.e., on/off rates one
order of magnitude lower than the values reported on tables) of both
SRSF1 promoter and SS1 splicing site.
The early promoter feedback are the same of the previous experiments.
In partcular we put to zero the parameter k˜SS1off in equation 4.7. In this
way, the SS1 splicing site detachment rate constant, described in equation
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4.7, is a ”pure” Hill function depending on E1 concentration, account-
ing for the enhancement regulation of E2 transcription. We’ll see that in
enough slow fluctuations a very interesting complex pattern will arise.
7.3.1.5 EXPERIMENT 5
In this experiment we consider the same promoter feedback strength but
we make the early promoter markov chain rate constants slower of one
magnitude order with respect the parameters inferred from literature.
Then, we consider a quite fast SRSF1 promoter fluctuations (i.e., on/off
rates one order of magnitude lower than the values on the tables) and a
quite slow SS2 splicing fluctuations (i.e., on/off rates two order of mag-
nitude lower than the values on tables). Moreover, we have considered
a lower total conversion rate of the oncogenes (i.e., about one third the
values on tables) with respect to that of the regulatory genes E1 and E2.
This experiment has the purpose to study a case with slower fluctua-
tions dynamics of the early promoter regulatory module together with a
slower dynamics of the splicing regulation.
7.4 LATE PROMOTER
The early promoter in silico experiments can be useful to describe dif-
ferent scenarios upon differentiation: normal infection with the differen-
tiation commitment; precancerous stages CIN-1,-2,-3 with a progressive
strong delay in the activation of the late promoter.
We won’t show an experiment for each of the previous cases since, as
far as we know the only difference in the dynamics are different delays
in the promoter activity and among the transcripts but qualitatively the
behaviors should be the same.
7.4.0.6 EXPERIMENT 6
In this experiment we want to show the capability of the late promoter
model to reproduce the qualitative behavior we expect from the litera-
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ture. We consider an in silico experiment of 16 days of duration and a
quite strong delay to slowly activate the late promoter.
The fixed parameters are reported in the previous tables.
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In this chapter we will show the in silico experiments designed in the
previous chapter. The predictions are perfomed in MATLAB by fixing
the parameters indicated in chapter 7 for all the experiments, unless dif-
ferently specified in the figures caption or in the text.
The stochastic simulations were predicted by using the Gillespie’s stochas-
tic algorithm (Gillespie (2002), Gillespie (2007), Gillespie (2013)).
8.1 EARLY PROMOTER FIT
In this section we show the predicted early promoter activity, modeled
in terms of the early promoter markov chain reported in chapter 4, can
fit very well the experimental data for both HPV16 and HPV18, actually
by keeping the early promoter parameters very close to what we could
directly inferred from literature.
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Figure 8.1.1: HPV16 early promoter activity fit.
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Figure 8.1.2: HPV18 early promoter activity fit.
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8.2 EXPERIMENT 1
In this section we report the qualitative behavior of the early promoter
repression predicted by the first heuristic model we have developed (Gi-
aretta et al. (2015)).
Figure 8.2.1: Model state variables with and without E1 regulation during cellular
differentiation. A. Early promoter pre-mRNA x. B. mE2 transcript. C. E2 protein.
D. mE1 transcript.
The dynamic behaviour of state variables with and without E1 co-
regulation is shown in Fig. 8.2.1. In both cases the initial phase is very fast
and all transcripts reach a steady state nearly 6 hours after infection. This
is consistent with experimental evidences that have shown the presence
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of the early transcripts as early as 4-10 hours post infection.
We can see that bothE1 effect to enhanceE2 transcript and to knock down
E2 degradation are necessary for turning off the primary transcript dur-
ing the early stage.
In this first modeling attempt we remember that we have condensed the
late promoter effect in a forcing function explaining the high increase of
E1 mRNA.
8.3 EXPERIMENT 2
Here we show the experiment about the novel stochastic model of the
early promoter by fixing the parameters in order to maintain a fast fluc-
tuations regimen. In what follows we firstly show the deterministic pre-
dictions in terms of the QE.
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Figure 8.3.1: Quasi equilibrium predictions of Early pre-mRNA and E1 and E2
transcripts.
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Figure 8.3.2: Quasi equilibrium predictions of Early pre-mRNA and E6 and E7
transcripts.
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Figure 8.3.3: Deterministic comparison between E2 transcripts and the oncogenes
transcripts.
From this deterministic in silico experiment we can see an initial peak
in the production of the pre-mRNA and of E1 and E2 transcripts. This is
due to the transient response and the very small degradation of the pre-
mRNA consistent with literature, that makes the transient very fast. The
peak is also higher thanks to the presence of the positive feedback which
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Figure 8.3.4: Quasi equilibrium predictions of E1 and E2 proteins and comparison
with their transcripts.
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Figure 8.3.5: Quasi equilibrium predictions of E6 and E7 oncoproteins and compar-
ison with their transcripts.
acts in low DE2 and E1E2 concentrations, hence in particular at the be-
ginning of the viral infection. The transcripts are very fast, as well. This
is because they are a direct conversion of the very fast pre-mRNA and
their degradations are of the order of few hours. This quick response is
consistent with literature evidences (see chapter 2) that confirm a higher
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Figure 8.3.6: Quasi equilibrium predictions of DE1 and DE2 dimers and E1E2
tetramer.
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Figure 8.3.7: Quasi equilibrium predictions of SRSF1 transcript, protein and the
heterodimer resulting from their association.
production of E1 and E2 just after the infection to guarantee a minimal
replication level and consequent decreasing in their expression due to
the negative feedback control. The oncogenes E6 and E7 are delayed
with respect to E1 and E2 and they eventually win these latter produc-
tion. This is consistent with literature evidences (see chapter 2). In our
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Figure 8.3.8: Quasi equilibrium predictions of E2 transcript and protein and E1
proteins to investigate the positive regulation of E1 on E2.
simulations, in the comparison between E2 and the oncogenes transcript
we can clearly see the delay in the production of the oncogenes that can
be made even stronger by acting on the SS1 splicing site (formally con-
desing splicing SA3358 and SA2709 sites), on E1 enhancement or acting
through SRSF1 dynamics. Actually from Fig. 8.3.3 it does not seem, look-
ing at the steady states, the oncogenes win over E1 and E2. Nevertheless,
as we will see later in the stochastic simulations it is not really true. It
does not necessarily mean that if the deterministic steady state levels of
the oncogens is lower than the steady state of E1 and E2, then the onco-
genes do not win over these latter in the proceeding of the viral life cycle,
as we’ll see in what follows, when we’ll show the stochastic predictions.
The E1 and E2 proteins do not present the strong peak as their mRNAs.
This is because there is a delay in producing proteins during the transla-
tion and especially because of their much lower degradation rates (five
times lower in this case).
Then, we can observe SRSF1 is predicted in order to be around few
hundreds copy number as inferred from literature. It can be modulated
by the heterodimer mSRSF1/SRSF1 that induces a negative feedback
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on SRSF1 mRNA in terms of translational efficiency. In particular, SRSF1
takes around one day and half to completely reach its steady state, in
our predictions. This is consistent with literature (it can have a slow
dynamics up to 3 days due to its negative feedback regulation (as re-
ported in chapter 2, SRSF1 section) and can be modulated by acting on
mSRSF1/SRSF1 heterodimer dynamics.
Finally we can observe from fig. 8.3.8 that E1 can positively enhance
E2 mRNA and proteins, and this is in agreement with the qualitative be-
havior the first heuristic model has predicted. The difference is that the
positive regulation is implemented here at the splicing site control and
the E1-mediated enhancement happens immediately and not after some
days as in the first experiment. This is because, in this latter we consid-
ered the E1 positive regulation only modulated by the activation of the
late promoter. Most likely it happens immediately. We also observe that,
E1 positively regulate itself as we have assumed in the new version con-
sistently with literature (see chapter 2).
We won’t show the repression of the early pre-mRNA mediated by
the late promoter since the qualitative behavior would be the same as in
experiment 1 and wouldn’t add any new insights in the early promoter
dynamics.
Before proceeding with the stochastic simulations we investigate the
early promoter markov chain functioning with the aid of its steady state
probability distribution, reported in Fig. 8.3.9.
In fig. 8.3.9, the steady state probabilities are dependent on DE2 and
E1E2 concentrations, being the regulators of the promoter. We have cho-
sen to show the only dependence on DE2, due to its main importance,
and since in literature is usual to do that. Looking at the probabilities in
function of DE2 copy number we can see that the probability accounting
for the basal transcription (state pE0 ) is initially the highest (we started
with initial condition in the basal state, with probability 1) and then it
converges fast to zero when DE2 gets higher. Subsequently the positive
feedback (state pE1 ) wins over the other and finally we can see that, for
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Figure 8.3.9: Steady state Early promotr markov chains probabilities in function of
DE2 dimer copy number.
higher concentrations, the negative feedbacks dominate the scene (states
pE2 , pE3 and pE4 ). This also corresponds to a time dependence evolution in
the feedback control change, since the dimers and tetramers take time to
grow up to their steady state condition.
In what follows we present and discuss the stochastic simulations rel-
ative to the deterministic predictions we have discussed so far. For each
stochastic variables we have also plotted its probability distribution to
get insights in the state levels the variable can assume in its stochastic
switching dynamics, due to the multiple levels control coming from the
promoters and the splicing sites markov chains (that can change the syn-
thesis and conversion rates of pre-mRNA and transcripts conversions,
respectively).
These stochastic predictions were performed in a quite fast promot-
ers (early and SRSF1 promoters) and splicing sites (SS1 and SS2 splicing
sites) fluctuations regimen. In fact, we can see (from all the figures we
have plotted) the quasi-equilibrium approximation follows quite well the
average of the stochastic processes. In the limit of speed fluctuations tend
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to the infinity we would exactly get the quasi-equilibrium. Anyway, even
in a fast fluctuations regimen we can understand the unpredictable be-
havior, due to the intrinsic noise, and clearly the deterministic approach
cannot afford such a complex pattern predictions. Just to start, look at
the pre-mRNA dynamics in Fig. 8.3.10. We clearly see the very fast fluc-
tuations of the pre-mRNA due to its very fast conversion rate, into its
component transcripts. The quasi-equilibrium cannot follow such fast
variations and just predicts a weighted average among the different syn-
thesis values of the pre-mRNA, with respect to the permanence probabil-
ities in each of early promoter states. We can also see that, by looking at
the multi-modal pre-mRNA distribution (it seems bimodal or maybe tri-
modal from the simulations; but we can’t see very well the other peaks
due to fast fluctuations).
As we anticipated before, observing the stochastic amplitude and qual-
itative frequency in Fig. 8.3.11 in comparison with Fig. 8.3.10 that the
oncogenes win over E1 and E2 production (thanks to SRSF1 control on
SS2 splicing site). It is true that this stronger bursts are also due to the
higher oncogenes degradations, but anyway the probability to get their
expression is stronger than to get E1 and E2 expressions as we can see
from the SS2 splicing site steady state probabilities depicted in Fig 8.3.18.
In fact, in this figure we can see that the higher SRSF1 copy number
(growing during its transient), the higher the probability (of state SS11)
to transcribe the oncogenes. This is anyway qualitatively captured with
the only stochastic simulations, even if it would be clearer in a slower
fluctuations regimen.
About the other state variables we can see the stochastic fluctuations
are not so strong, and they follow quite well the quasi-equilibrium, as we
can also depict from their monomodal probability distribution (exclud-
ing the peak, in the distribution, due to the transient response of the state
variables), centered in the quasi-equilibrium steady state. The only vari-
able showing a hint of bimodality is, in this particular in silico experiment
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Figure 8.3.10: In the first coloumn: comparison between deterministic and stochas-
tic predictions of Early pre-mRNA and E1 and E2 transcripts. In the second coloumn:
probability distributions of the state variables
realization, the E7 protein as shown in Fig. 8.3.15.
In the next sections we will show some in silico predictions with slower
fluctuations of the promoters and the splicing sites. In this case the quasi-
equilibrium fails in following the stochastic trajectories as exemplified in
Fig. 8.3.19,8.3.20. In fact, in the first we can see the quasi-equilibrium
predict a constant steady state for both E2 protein and transcript, while
the stochastic predictions show a kind of excitable ”bursty” behavior for
the occurrence of E2 mRNA and huge variations of E2 proteins over pre-
dicted by the quasi-equilibrium. In the second figure we can see large
variations of the dimers and tetramer again overpredicted by a constant
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Figure 8.3.11: In the first coloumn: comparison between deterministic and stochas-
tic predictions of Early pre-mRNA and E6 and E7 transcripts. In the second coloumn:
probability distributions of the state variables
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Figure 8.3.12: In the first coloumn: comparison between deterministic and stochas-
tic predictions of E1 protein and comparison with its transcript.In the second coloumn:
probability distributions of the state variable.
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Figure 8.3.13: In the first coloumn: comparison between deterministic and stochas-
tic predictions of E2 protein and comparison with its transcript.In the second coloumn:
probability distributions of the state variable
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Figure 8.3.14: In the first coloumn: comparison between deterministic and stochas-
tic predictions of E6 oncoprotein and comparison with its transcript.In the second
coloumn: probability distributions of the state variable.
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Figure 8.3.15: In the first coloumn: comparison between deterministic and stochas-
tic predictions of E7 oncoprotein and comparison with its transcript.In the second
coloumn: probability distributions of the state variable.
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Figure 8.3.16: In the first coloumn: comparison between deterministic and stochas-
tic predictions of DE1 and DE2 dimers and E1E2 tetramer.In the second coloumn:
probability distributions of the state variables.
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Figure 8.3.17: In the first coloumn: comparison between deterministic and stochas-
tic predictions of SRSF1 transcritp, protein and the heterodimer resulting from their
association. In the second coloumn: probability distributions of the state variables.
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Figure 8.3.18: Probabilities of the SS1 splicing site (formally condensing SA3358
and SA2709 splicing sites) in function of SRSF1 copy number. The probability for
SS1 to be occupied wins when SRSF1 is in higher concentration, thus driving the
oncogenes , eventually diminishing E2 and E1 transcription.
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Figure 8.3.19: Comparison between quasi-equilibrium and stochastic predictions of
E2 protein and transcripts in a slow splicing fluctuations regimen.
quasi-equilibrium steady-state.
We could have a lot of interesting stochastic behaviors due to slow fluc-
tuations. In the next section we will show some interesting behaviors that
could be associated to interesting biological explanation. In what follows
we will show the only stochastic predictions since we already know the
quasi-equilibrium will fail.
8.4 EXPERIMENT 3
In this experiment we can interestingly observe that E1 and E2 tran-
scripts are produced in a sort of excitable manner, showing sudden strong
bursts. The same happens for the oncogenes in a mutually exclusive man-
ner (i.e., when E1 and E2 are produced the oncogens are not). Moreover,
the dimers and tretamer dynamics shows strong stochastic variation be-
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Figure 8.3.20: Comparison between quasi-equilibrium and stochastic predictions of
DE1, DE2 dimers and E1E2 tetramer in a slow splicing fluctuations regimen.
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Figure 8.4.1: Comparison between quasi-equilibrium and stochastic predictions of
E2 protein and transcripts in a slow splicing fluctuations regimen.
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Figure 8.4.2: Comparison between quasi-equilibrium and stochastic predictions of
DE1, DE2 dimers and E1E2 tetramer in a slow splicing fluctuations regimen.
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Figure 8.4.3: Comparison between quasi-equilibrium and stochastic predictions of
DE1, DE2 dimers and E1E2 tetramer in a slow splicing fluctuations regimen.
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cause of the sudden ”bursty” dynamics of E1 and E2. What is interesting
to observe is that, with the fixed parameters, looking at the steady state
probabilities (on which the quasi-equilibrium is based) of the SS1 splic-
ing site we would notice that the oncogenes should be generated with a
very low probability with respect toE1 andE2. However, the steady state
probabilities of the control markov chains are not reliable in a slow fluc-
tuations regimen. In fact, as we can see from the stochastic predictions in
figures 8.4.1 and 8.4.2 the oncogenes seem to have more or less the same
probabilities of E1 and E2 to be produced, even a bit more. That is why
the quasi-equilibrium cannot predict this situation.
We can also see that the oncogenes are produced in very strong bursts,
even stronger than the regulatory transcripts (E1 and E2). This is due
in part to their higher degradation rates than the regulatory transcripts.
The other reason has to be found in the regulatory transcripts (E1, E2)
bursts. In fact they induce, as argued before, strong variation of the
dimers and tetramer regulating the early promoter. In particular, these
latter are strongly decreased when there is no E1 and E2 production, re-
sulting in a weaker negative feedback on the early promoter and a con-
sequent strong burst of the oncogenes.
In a biological context this pulsatile ”bursty” expression of the regu-
latory transcripts and oncogenes, if it was experimentally verified in fu-
ture, could be a very interesting mechanism the virus could usein order
to efficiently control the eukaryotic cell DNA replication machinery by
E1 and E2, in order to properly replicate the viral DNA; or, alternatively,
to efficiently control the restart, mediated by the oncogenes, of the cell
cycle after the infection. In fact, it was recently proven that a frequency
pulsatile control could efficiently modulate gene expression (Cai et al.
(2008), Dalal et al. (2014)).
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8.5 EXPERIMENT 4
In this experiment, by placing to zero the parameter k˜SS1off , we create the
possibility to have an ”absorbing” state (also called a ”limbo” state) in
the SS1 two state markov chain. If E1 stochastically reaches the zero
copy number, there is no way to produce neither E1 nor E2 anymore
and the only oncogenes will be produced. Moreover, since the regula-
tory proteins cannot be produced anymore, their dimers and tetramer
will disappear by degrading in time. This will produce the effect to cre-
ate a reverse action on the early promoter transactivation feedback. The
negative feedback will became a positive feedback till to reach a basal
transcription that will last forever. This will, in turn, over express the
oncogenes (the basal transcription is higher than the negative feedback
transcription).
Anyway, all this is reached thanks to a proper balance between an
enough strong negative feedback and intrinsic noise strength to make
this complex dynamical regulation possible. Hence, this is one of the
complex pattern we look for when we consider the entire behavior of a
system composed by interconnected sub-modules. This is in line with the
actual holistic paradigm of systems biology.
This is a sort of bistable property for the system. The interesting fact is
that it is not due to the bistability of the early promoter but to the down-
stream splicing dynamics. This qualitative behavior the system can ex-
hibit can be very interesting biologically speaking. It could explain, in an
autoregulatory manner, the HPV integration event in the human DNA.
As reported in chapter 2, some HPVs, after infection, can integrate into
the human DNA with the consequent over expression of the oncogenes
and no more production of E1 and E2. Actually this is performed thanks
to the lost of splicing mechanisms and not to a change in the early pro-
moter structure. Finally, we observe that to dynamically exhibit this be-
havior we needed to eliminate k˜SS1off , resulting in a change of the splicing
model we had performed. This is acceptable since on the one hand the
virus upon integration loses part of its genome, resulting in a different
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regulatory network for the splicing control; on the other hand, because
our model is condensing more than one splicing mechanisms all together.
From Fig. 8.5.1 the pre-mRNA is initially, after its transient response,
subjected to the dominant negative feedback, but subsequently the early
promoter converges indefinitely to the basal transcription. This is be-
cause, as argued before, the E1 protein can stochastically reach a zero
copy number. When this happens no more E1 and E2 are produced as
their dimers, as we can see in the other figures 8.5.3, 8.5.4, 8.5.7. The only
genes that will be expressed (actually over expressed) are the oncogenes
as we can see in the Fig.8.5.2.
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Figure 8.5.1: In the first coloumn: stochastic predictions of Early pre-mRNA, E1
and E2 transcripts. In the second coloumn: probability distributions of the state
variables
142
8.5 Experiment 4
0 5 10
0
200
400
pM
E
0 0.005 0.01 0.015 0.02
0
200
400
ρ(pME)
0 5 10
0
2000
4000
m
E 6E
0 0.5 1
x 10−3
0
2000
4000
ρ(mE6)
0 5 10
0
2000
4000
time [days]
m
E 7E
0 0.5 1
x 10−3
0
2000
4000
ρ(mE7)
Figure 8.5.2: In the first coloumn: stochastic predictions of Early pre-mRNA, E6
and E7 transcripts. In the second coloumn: probability distributions of the state
variables
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Figure 8.5.3: In the first coloumn: comparison between predictions of E1 protein and
its transcript. In the second coloumn: probability distributions of the state variables.
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Figure 8.5.4: In the first coloumn: comparison between predictions of E2 protein and
its transcript. In the second coloumn: probability distributions of the state variables.
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Figure 8.5.5: In the first coloumn: comparison between predictions of E6 protein and
its transcript. In the second coloumn: probability distributions of the state variables.
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Figure 8.5.6: In the first coloumn: comparison between predictions of E7 protein and
its transcript. In the second coloumn: probability distributions of the state variables.
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8.6 EXPERIMENT 5
This experiment was performed in order to have an insight in the slower
dynamics of both the early promoter, the SRSF1 promoter and the splic-
ing sites.
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Figure 8.6.1: In the first coloumn: stochastic predictions of Early pre-mRNA, E1
and E2 transcripts. In the second coloumn: probability distributions of the state
variables
We can see from Fig. 8.6.1 that the early promoter can exhibit lower fre-
quent and strong bursts. With slower fluctuations it is also more demar-
cated its multimodal probability distribution. E1 and E2 transcripts ex-
hibit strong bursts and we can see their protein and expecially the dimers
and tetramer can exhibit stronger and more lasting busrts, as shown in
Fig. 8.6.3, 8.6.4 and especially in Fig. 8.6.7.
About the oncogenes in this situation they are produced in low quan-
tity and frequency as we can see from their isolated strong like-excitable
bursts behavior. It is interesting to note that when the oncogenes occur
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Figure 8.6.2: In the first coloumn: stochastic predictions of Early pre-mRNA, E6
and E7 transcripts. In the second coloumn: probability distributions of the state
variables
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Figure 8.6.3: In the first coloumn: comparison between predictions of E1 protein and
its transcript. In the second coloumn: probability distributions of the state variables.
we can observe a stronger ”bursty” spike in the pre-mRNA. In this case
is more evident than in the other experiments, because we made the total
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Figure 8.6.4: In the first coloumn: comparison between predictions of E2 protein and
its transcript. In the second coloumn: probability distributions of the state variables.
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Figure 8.6.5: In the first coloumn: comparison between predictions of E6 protein and
its transcript. In the second coloumn: probability distributions of the state variables.
conversion rate of the oncogenes lower than the total conversion of the
regulatory proteins (E1 and E2). In this manner, when the oncogenes are
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Figure 8.6.6: In the first coloumn: comparison between predictions of E7 protein and
its transcript. In the second coloumn: probability distributions of the state variables.
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Figure 8.6.7: In the first coloumn: stochastic predictions of DE1 and DE2 dimers
and E1E2 tetramer.In the second coloumn: probability distributions of the state
variables.
produced the pre-mRNA has a lower ”degradation” (i.e., sum of conver-
sion rates) than in the case when the regulatory genes are transcribed, re-
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Figure 8.6.8: In the first coloumn: stochastic predictions of SRSF1 transcritp,
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probability distributions of the state variables.
sulting in a stronger burst response, given the very fast conversion rates.
We can see in this case that the joint regulation of the early promoter and
the splicing control layer add a sort of another state to the early promoter
that the early promoter alone couldn’t exhibit, from its designed markov
chain alone.
To find a possible interesting biological context of this dynamical behv-
ior, we could think about the basal infected cells, where the main purpose
of the virus is to maintain a viral DNA reservoir through a major regula-
tion of the only E1 and E2. Their pulsatile like excitable response could
be interesting to effciently control in a pulsatile manner the cellular repli-
cation machinery.
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8.7 EXPERIMENT 6
In this experiment we will investigate the late promoter functioning.
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Figure 8.7.1: Deterministic quasi-equilibrium prediction of the HPV transcripts and
proteins copy numbers produced by the late promoter.
As we can see from QE predictions in fig. 8.7.1 the replication proteinsEL1
and EL2 are the first to be produced and this is consistent with the neces-
sity to get an immediate and higher replication of the viral DNA during
the differentiation. Moreover we can observe that for E1 and E2 mRNAs
we can get the same qualitative pattern (they initially decrease and then
strongly increase) in the dataset reported in the previous chapter. EL4 is
produced just after EL1 and EL2 since it is dependent on higher values of
SRSF1 splicing factor. Since this latter is activated by E2 the system needs
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more time to grow up EL2 to enough level in order to produce EL4 ; more-
over we have to remember that EL2 and EL4 are mutually exclusive and at
the beginning the production of the replication proteins has the priority.
L1 and L2 transcripts and proteins are produced with a stronger delay
with respect to the early genes. This happens when E2 reaches enough
high concentrations to inhibit the early polyadenylation site, as we can
see from fig. 8.7.2, paving the way to the late genes transcription. This
is consistent with the biological knowledge. In fact the late genes, are
produced in the upper epithelium strata. In fig. 8.7.3 we can see the pAE
site is inhibited (state pAE1) when E2 gets higher concentration.
All these reciprocal delays among the viral transcripts and proteins are
possible thanks to a complex regulation at post-transcriptional level in
terms of splicing and polyadenylation regulations.
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Figure 8.7.2: Time evolution of pAE site.
However, the slow modulation increase of all the transcripts is ob-
tained at the late promoter level. The late promoter was designed to
reproduce the modulation by C/EBPβ and to consider other possible in-
trinsic delays such as the nucleosome recruitment mediated byC/EBPβ,
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Figure 8.7.3: Probabilities distribution of polyadenylation site pAE in function of
E2 copy number.
as argued in chapter 2. To account for these delays we have assumed
three different increasing levels of the late pre-mRNA production for
each state of the late promoter markov chain. Moreover, the synthesis
parameters and the markov chain parameters were tuned in order to
make a quite good intrinsic stochastic delay, before reaching its full regi-
men functioning. We can see this dynamical features in the late promoter
probability distribution, in function of C/EBPβ copy number, as shown
in fig. 8.7.5. From the distributions we observe the basal transcription
(state pLP0 ) starts at the beginning in low C/EBPβ concentration. The
intermediate transcripton level occurs when C/EBPβ reaches medium
concentrations and finally, the regimen condition accounting for a strong
transcription has the highest probability to occur when C/EBPβ is in
high concentration. The temporal transition between the states of the
promoter markov chain will occur very slowly in time, as shown in fig.
8.7.5. This is because C/EBPβ grows very slowly because of its very
high half life and because of its strong stabilization, at post-translational
levels we are accounting with the insertion of a delay, as explained in
Chapter 4.
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Figure 8.7.4: Late promoter markov chain probability distribution in function of
C/EBPβ copy number concentration. pLP0 is the probability of basal transcription,
pLP1 when C/EBPβ has medium concentration and the transcription is not so strong
yet. pLP2 is the probability accounting late promoter regimen functioning.
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Figure 8.7.5: Time evolution of the late promoter markov chain states in function
of the C/EBPβ slow modulation. At the beginning only p0 state is active, then P1
state is activated and finally P3 state. Each state temporal evolution is a dichotomous
random process describing when the state is active and when it is not.
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In what follows we show the stochastic simulations of the most inter-
esting state variables.
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Figure 8.7.6: In the first coloumn: stochastic predictions of Late pre-mRNA, EL1
and EL2 transcripts. In the second coloumn: probability distributions of the state
variables
In fig. 8.7.6 the late pre-mRNA is slowly modulated to it higher tran-
scription regimen by a combined effect due to an intrinsic delay in the late
promoter markov chain and a strong delay in C/EBPβ dynamics. The
stronger spike bursts we can observe in the late phase are due, as was
for the early promoter, to a dynamical change in time of the total con-
version rate of the pre-mRNA. This results in the presence of bursts-like
spikes. In some way the splicing modulation insert an additive state, as
we can see from the multimodal distribution of the pre-mRNA, to the late
promoter transcription that cannot be produced by the promoter alone.
This is another example of complex pattern that can arise from the inter-
connection of more control layers, in line with the current paradigm of
systems biology.
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Figure 8.7.7: In the first coloumn: stochastic predictions of E1EL4 , L1 and L2
transcripts. In the second coloumn: probability distributions of the state variables
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Figure 8.7.8: In the first coloumn: comparison between predictions of E1 and E2
proteins. In the second coloumn: probability distributions of the state variables.
Transcripts and proteins follows the induced delay arising from the
pre-mRNA. In particular the late mRNAs are strongly delayed in the
stochastic predictions too, thanks to the E2-mediated control of the early
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Figure 8.7.9: In the first coloumn: comparison between predictions of E1EL4 , L1 and
L2 proteins. In the second coloumn: probability distributions of the state variables.
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Figure 8.7.10: In the first coloumn: stochastic predictions of DE1 and DE2 dimers
and E1E2 tetramer.In the second coloumn: probability distributions of the state
variables.
polyadenylation signal, pAE.
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We can observe that both the stochastic and the deterministic formula-
tion can predict the late promoter behavior in good agreement with the
current biological knowledge.
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9.1 NOVELTIES
9.1.1 MODELS OF SPECIFIC MECHANISMS
The novelty of this project is both on methodological and biological /clin-
ical site. The former is in line with the current challenge in recent years to
have a holistic view of the basics regulatory mechanisms interconnected
to form a complex machinery where complex patterns can arise only form
the interconnection of basics modules. The purpose is thus the develop-
ment and the study of a complex regulatory system made up of most of
the main individual processes both at a deterministic and stochastic de-
scription level. In fact, the developed model accounts for different control
layers, having a general validity, such as transcriptional regulation by
means of the promoters regulation activity, post-transcriptional regula-
tion by modeling alternative splicing and polyadenylation, translational
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regulation by modeling the protein synthesis from the transcripts and
post-translational regulation by modeling proteins stabilization mecha-
nisms and translational efficiency. These modules were interconnected
together in order to develop a complex control system capable to predict
complex dynamical patterns that can arise only from the interconnection
of the above-mentioned modules.
As far as we know, it is the first time a stochastic model accounts
for the complex post-transcriptional control, modeling the splicing and
polyadenylation sites regulation, and connect this latter to the transcrip-
tional control layer mediated by the promoters activities in order to ex-
plore complex patterns that can arise only from the modeling and the
interconnection of different control layers.
9.1.2 NOVEL HPV MODEL
In this thesis we have developed a novel stochastic and deterministic
mathematical model of HPV gene regulatory network, in collaboration
with the Elston Lab at Chapel Hill, University of North Carolina (UNC),
and with the Department of Molecular Medicine (DMM) at University of
Padova.
HPV offers a case of study of great interest in molecular systems bi-
ology and clinical studies. It involves a number of relevant regulatory
mechanisms (e.g. transcription, translation, promoter modulation, polyadeny-
lation regulation, splicing,) connected together to form a complex net-
work, albeit its genome is relatively simple, thus suitable for an accurate
deterministic and even stochastic modeling. Modeling its promoters ac-
tivities and its post-transcriptional regulation gave use the possibility to
investigate complex patterns formation that on the one hand have a gen-
eral validity in dynamically explain the behavior of gene expression in its
entireness and on the other allowed us to explore interesting qualitative
behavior of the HPV gene network. In particular, a stochastic modeling
gave us the perspective to understand how the intrinsic noise can affect
and modify the behavior of each single modules and how it can gener-
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ate complex patterns due to the interconnection of different modules and
that cannot be predicted by a deterministic formulation.
As regards the biological/clinical aspects, we have developed a new
synthesis of the HPV molecular biology with especial regard to gather/infer
from literature the parameters useful for designing a dynamical model,
and to shed light in what is still lacking in the biological literature, to
complete and optimize a model of HPV gene regulatory network. In par-
ticular, it was done an effort in trying to get together the poor knowledge
about the late promoter regulation, in order to present the minimal pre-
requisites necessary to design a dynamical model of this still elusive but
of great importance in the context of the viral life cycle, upon differentia-
tion.
The model shows a good agreement with the current biological knowl-
edge and, as far as we know, there is no model of HPV gene regulation
available in literature, apart a first heuristic/deterministic model on the
early promoter regulation we have developed (Giaretta et al. (2015)).
The model is also able to predict complex patterns by connecting to-
gether the promoter activity regulation and the post-transcriptional reg-
ulation. These complex patterns were also very interesting in a biological
perspective in finding out novel control mechanisms the virus could ex-
hibit, such as an efficient and pulsatile control of viral replication or cell
cycle restoration. Among these patterns it was possible to discover the
capability of the developed model to predict the qualitative behavior of
HPV integration and making the model structure interesting in a clinical
perspective.
9.2 EXPERIMENTAL DESIGN AND MODEL VALIDATION
Validation is integral to the overall modeling process. It needs to be per-
formed both during model building, and upon completion of the model.
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9.2.1 VALIDATION DURING MODEL FORMULATION
Model validation involves assessing the model in order to check that is
well-founded and fulfils the purpose for which it was intended. Valida-
tion needs to be considered all the way through the modeling process. It
begins when specifying the modeling activity and continues right on to
the completed model.
The building of a model normally proceeds by postulating a concep-
tual model and then proceeding to a mathematical realization of this
conceptual form. In putting up a conceptual framework, care needs to
be taken to ensure that all the relevant physical and chemical concepts
are properly described. This is important when it comes to producing
the mathematical realization.
So far we followed and accomplished all these tasks throughout the the
HPV model development process. We have stated the main purpose of
the model was to reproduce the HPV gene regulatory network dynamics
and we built the model structure consistently with the known molecular
biology gathering/inferring all the available parameters from literature.
During the building of the model we took care in reproducing the avail-
able knowledge and data we had available. In fact we were able to fit the
experimental data about the early promoter activity and to qualitatively
reproduce the dynamical evolution of E1 and E2 transcripts produced by
the late promoter during differentiation.
9.2.2 VALIDATION OF THE COMPLETED MODEL
The validation process is dependent on the model purpose. In other
words, the task is problems-specific. Validity is a general concept reflect-
ing model purpose, current theories, and experimental data relating to
the particular biological system of interest. Thus, as new theories are de-
veloped and new data become available, the requirements for a model
to be deemed valid can change although its validity is still assessed in
terms of the same criteria. A model to be valid needs to satisfy one or
more of the criteria of: theoretical, empirical, pragmatic and heuristic va-
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lidity (Cobelli Claudio (2008)).
Theoretical validity is concerned with ensuring that the model is con-
sistent with accepted biological theories; Empirical validity is assessed by
examining how well the model corresponds to available data; Pragmatic
validity is used in supporting clinical decision making and heuristic va-
lidity is important when a model is to be used to test biological hypothe-
sis.
So far we have theoretically validated the model being its structure
has been designed by translating the major regulatory mechanisms be-
hind its gene regulatory networks. Moreover it was developed by using
a stochastic formalism representing the most accurate to describe molec-
ular systems.
We have also in part accomplished the empirical validation being able
to fit the early promoter activity and to qualitatively reproduce theE1 and
E2 mRNAs pattern generated by the late promoter during differentiation.
Obviously this part is still under development and we need new and
complete data to completely and accurately accomplish this validation.
9.2.3 EXPERIMENTAL DESIGN
The model allowed us to properly design an experiment in order to get
time courses of the viral transcripts during the viral life cycle. The model
was useful to select the proper chemical species to measure, in what con-
ditions and to set up an appropriate sample times grid.
The experiment will start in the next months and will take account for
the analysis of HPV transcriptome and host gene expression during ker-
atinocyte differentiation. The analysis will be performed at different time
points after induction of keratinocyte differentiation (mediated by Ca2+)
thickening the sampling grid at the beginning of the infection to account
for the splicing regulation modulating the oncogenes, then it will be re-
duced in the middle of the experiment and will be thickened again to
account for the possible delayed production of E1, E2, E4, L1 and L2 mR-
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NAs. The analysis will be carried out for HPV16 genome by means of
quantitative real-time PCR in order to obtain time series of all the viral
transcripts (both early and late) and of the splicing factor SRSF1 and the
transcription factors p63 and C/EBPβ. This will be the first time that all
the viral transcripts will be evaluated in time series together with tem-
poral series of the major splicing factor and the two major late promoter
regulators during the whole HPV life cycle.
The experimental data will then be useful to empirically validate the
whole model.
9.3 HPV MODEL USAGES
Definitely this model will help in achieving a deep understanding of HPV
gene expression in order to shed light into both the early and late pro-
moter regulation but also in the post-transcriptional and post-translational
modifications to reach a better comprehension of the viral life cycle and
the delayed expression of the viral transcripts and proteins, especially
upon differentiation. Moreover it will be useful to investigate the dy-
namical properties of post-transcriptional regulation and its dynamical
cross-talk with the promoter regulation.
Once empirically validated, the model will represent an in silico simu-
lator able to predict the HPV gene expression in different biological con-
ditions. Updating the model with new experimental evidences even on
the clinical side could be of potential usage in predict the evolution of
pre-cancerous and cancerous stages.
Another very interesting and actual problem is regarding the develop-
ment of antiviral therapies. In literature there are several antiviral ther-
apy proposals but every of them tends to analyze just a single molecular
actor at a time, speculating on new therapies proposals. Nevertheless,
nowadays there isn’t any working antiviral therapy. The problem could
precisely reside in not keeping a holistic perspective, we have repeatedly
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stressed during this entire discussion. Most likely, the winner approach
could be to consider the system in its entireness by analyzing it at differ-
ent functioning levels (e.g. transcriptional and post-transcriptional reg-
ulation). The model, once empirically validated, would be of great help
in deigning and/or optimizing an antiviral therapy. Actually, antiviral
therapy is none other than imposing control to the viral system. In other
terms it can be viewed as a modification of the HPV model structure. If
the HPV model has been validated than it can be used in order to test
some hypothesis and predict its modified behavior after its modification
with the antiviral proposal therapy. In this way we could understand
by means of in silico experiments if the antiviral proposal can be valid,
before carrying out an experiment to verify the goodness of the idea. Sub-
sequently we can use the model to test proper hypothesis in order to de-
sign a good an functioning antiviral therapy. In this way we will be able
to accomplish an heuristic validation of the model, too.
9.4 FUTURE DEVELOPMENT
• We will empirically validate the deterministic model (RT-PCR mea-
surements are good to identify a deterministic model but not a stochas-
tic one) by using the experimental measurements soon available. At
first we will tune the parameters of the model in order to fit the ex-
perimental data, with the constraint to keep the parameters within
acceptable biological values. Secondly we will seek to make the
model identifiable, univocally identifying the parameters or com-
binations of them by means of standard identification algorithms
such as weighted least squares (Cobelli Claudio (2008)).
Even if these data will not suitable for validating the stochastic
model, by identifying the deterministic version we will get a more
robust set of parameters to subsequently better investigate the stochas-
tic behavior of the model
• Once we will be sure the model is able to reproduce the experimen-
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tal results we will perform an analysis of the statistical moments
(mean, variance,...) of the chemical species.
• After the validation of the deterministic model we will design a
single cell experiment in order to validate the stochastic formal-
ism. This will be interesting in order to evaluate the strength of the
stochastic sources inside the system, such as transcription, degrada-
tion, translation, promoter regulation, ... and find out what are the
principal parameters constraints behind the noise strength modula-
tion. Another interesting application could reside in the parameters
identification of the stochastic system by identifying the determin-
istic system of its statistical moments (El Samad et al. (2005)).
We will make use of the stochastic simulations, by fixing the param-
eters identified in the deterministic validation of the model, to ana-
lyze the probability distributions of the state variables. This will be
useful to the best statistical moments order to stop in order to main-
tain a good statistical information. The statistical moments will be
described by means of a system of ordinary differential equations,
derived by the ME. One way to perform such analysis, given the
complex structure of the syste, could be to approximate the whole
master equation of the system in terms of its diffusion limit Fokker-
Planck Equation (for each state combination of the control markov
chains) (Gardiner (2009), VanKampen (2007), Scott (2013)), subse-
quently deriving the statistical moments by applying their defini-
tion to the FPE and the closure of moments to make the system
closed (moments system won’t be closed because of the model non-
linearities) (Pirone and Elston (2004)).
• In this thesis we have performed the stochastic simulations numer-
ically solving the Master Equation by means of the Gillespie Algo-
rithm. This is because on the one hand the computational effort in
simulating the model was acceptable with the fixed parameters we
inferred form literature and with the upper bound of copy number
estimated. For this reason we preferred to investigate the stochastic
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model predictions in terms of the exact numerical solutions we can
achieve by using the Gillespie’s algorithm.
However, we will approximate the model in terms of stochastic dif-
ferential equations (SDE) that are much more computationally ef-
ficient. This will be performed by following a hybrid scheme to
the stochastic simulation. This is necessary in order to maintain
the jump control processes intrinsically associated to the promot-
ers, splicing sites and polyadenylation sites that are essential to ex-
plain strong stochastic events such as bursts in gene expression. The
stochastic variables accounting for the control logic of the system
(i.e., promoters, splicing and polyadenylation state variables) will
be maintained discrete and simulated by means of an efficient ver-
sion of Gillespie’s algorithm. For the remaining chemical species a
FPE will be derived by applying the diffusion limit of the Master
Equation. Subsequently, the FPE will be converted into a system of
stochastic differential equations (SDE) by applying the Ito’s Lemma
(Øksendal (2013), Gardiner (2009), Adalsteinsson et al. (2004)).
• The model will be extended in terms of a spatial diffusion formula-
tion in order to describe the distribution of the viral proteins through-
out the epithelium during cellular differentiation.
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